name	nt_name	aa_name	multi_aa_name	multiaa_mutation_split_names	start	vcf_gene	chrom_region	mutation_type	dp	obs_sample_size	variant_pop_size	ps_filter	ps_exc	mat_pep_id	mat_pep_desc	mat_pep_acc	ro	ao_by_var_seq	ao	variant_seq	reference_seq	function_category	citation	citation_url	comb_mutation	function_description	heterozygosity	viral_lineages	clade_defining_status	status	voi_designation_date	voc_designation_date	vum_designation_date
c.-12_-11insAACA	c.-12_-11insAACA				28262	N	intergenic		11385	172.0	11387						11	GAACA=11374	11374	GAACA	G						False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
c.C-25T	c.C-25T				241	orf1ab	5' UTR		11387	172.0	11387						0	T=11387	11387	T	C						False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
c.C-36T	c.C-36T				27858	ORF8	intergenic		2	2.0	11387						0	T=2	2	T	C						False	P.1.12.1	P.1.12.1=True	VOC		11-Jan-2021	
c.G-132T	c.G-132T				27762	ORF8	intergenic		26	26.0	11387						22	T=4	4	T	G						False	P.1.17	P.1.17=False	VOC		11-Jan-2021	
c.G29764A	c.G*4380A				29764	intergenic	Stem-loop,3' UTR		133	133.0	11387						118	A=15	15	A	G						False	P.1	P.1=False	VOC		11-Jan-2021	
p.3676del	c.11023_11031delTCTGGTTTT	p.S3675_F3677del	S3675_F3677del	'S3675del', 'F3677del'	11287	orf1ab	ORF1ab		11389	344.0	11387			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab	YP_009725302.1	0	G=11389	11389	G	GTCTGGTTTT						False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.A3143V	c.C9428T	p.A3143V			9693	orf1ab	ORF1ab	MISSENSE	2	2.0	11387			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab	YP_009725300.1	1	T=1	1	T	C						False	P.1.7	P.1.7=False	VOC		11-Jan-2021	
p.A35A	c.G105T	p.A35A			28378	N	N	SILENT	137	137.0	11387						106	T=31	31	T	G						False	P.1.12, P.1	P.1=False, P.1.12=False	VOC		11-Jan-2021	
p.A3648T	c.G10942A	p.A3648T			11207	orf1ab	ORF1ab	MISSENSE	4	4.0	11387			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab	YP_009725302.1	3	A=1	1	A	G						False	P.1.12	P.1.12=False	VOC		11-Jan-2021	
p.A4285V	c.C12854T	p.A4285V			13119	orf1ab	ORF1ab	MISSENSE	26	26.0	11387			nsp10	nsp10_CysHis, formerly known as growth-factor-like protein (GFL), produced by both pp1a and pp1ab	YP_009725306.1	9	T=17	17	T	C						False	P.1.17	P.1.17=False	VOC		11-Jan-2021	
p.A4835A	c.T14505G	p.A4835A			14769	orf1ab	ORF1ab	SILENT	2	2.0	11387			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only	YP_009725307.1	0	G=2	2	G	T						False	P.1.12.1	P.1.12.1=True	VOC		11-Jan-2021	
p.A735V	c.C2204T	p.A735V			2469	orf1ab	ORF1ab	MISSENSE	26	26.0	11387			nsp2	produced by both pp1a and pp1ab	YP_009725298.1	23	T=3	3	T	C						False	P.1.17	P.1.17=False	VOC		11-Jan-2021	
p.A859V	c.C2576T	p.A859V			2841	orf1ab	ORF1ab	MISSENSE	4	4.0	11387			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	1	T=3	3	T	C						False	P.1.10	P.1.10=False	VOC		11-Jan-2021	
p.A879S	c.G2635T	p.A879S			24197	S	S	MISSENSE	4	4.0	11387						3	T=1	1	T	G						False	P.1.10	P.1.10=False	VOC		11-Jan-2021	
p.C37F	c.G110T	p.C37F			28003	ORF8	ORF8	MISSENSE	4	4.0	11387						3	T=1	1	T	G						False	P.1.12	P.1.12=False	VOC		11-Jan-2021	
p.C5343C	c.C16029T	p.C5343C			16293	orf1ab	ORF1ab	SILENT	2	2.0	11387			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only	YP_009725308.1	0	T=2	2	T	C						False	P.1.7	P.1.7=True	VOC		11-Jan-2021	
p.C657Y	c.G1970A	p.C657Y			2235	orf1ab	ORF1ab	MISSENSE	2	2.0	11387			nsp2	produced by both pp1a and pp1ab	YP_009725298.1	0	A=2	2	A	G						False	P.1.12.1	P.1.12.1=True	VOC		11-Jan-2021	
p.D138Y	c.G412T	p.D138Y			21974	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	G	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.32x increase in binding (KD) relative to D614G.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D138Y	c.G412T	p.D138Y			21974	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	G	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G', 'L18F', 'T20N', 'P26S', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing P.1 aka Gamma)  showed a 4.24x increase in binding (KD) relative to D614G.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D138Y	c.G412T	p.D138Y			21974	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	G	anthropozoonotic events	Montagutelli et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.18.436013v1	'L18F', 'T20N', 'P26S', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	Unlike wild type or B.1.1.7, P.1 lineage virus was able to infect and replicate in common lab mouse strains, with high titer.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D138Y	c.G412T	p.D138Y			21974	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	G	antibody epitope effects	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 	'L18F', 'T20N', 'P26S', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	B.1.1.248 variant constellation ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07. B.1.1.248 variant constellation ablates Class 3 N-terminal domain targeting antibody COV2-2676.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D138Y	c.G412T	p.D138Y			21974	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	G	antibody epitope effects	Dejnirattisai et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.055	'L18F', 'T20N', 'P26S', 'R190S'	"The neutralization titer of NTD-binding mAb159 was 133-fold reduced on P.1 compared to Victoria (~wild type), with only 64% neutralization at 10 μg/mL.  Residues 20, 18, and 138 form a cluster underlying the 245–259 loop, which inserts into a groove between the light and heavy chains of Fab 159. In addition, the N-terminal residues preceding residue 18 interact with the antibody and may be perturbed.  Given that there is likely a single supersite (""i"") for potent NTD-binding antibodies, the binding of many of these are likely affected. Using 20 potent (primaruly anti-RBD) antibodies, neutralization was measured by a focus reduction neutralization test (FRNT) and compared with  neutralization of Victoria (~wild type) and variants B.1.1.7 and B.1.351. Compared to Victoria neutralization by the mAbs was significantly impacted by P.1,  with 12/20 showing > 10-fold reduction in FRNT50 titer and a number showing complete knockout of activity. The results with P.1 showed a  greater impact compared to B.1.1.7 but were, as expected, similar to those with B.1.351."	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D138Y	c.G412T	p.D138Y			21974	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	G	antibody epitope effects	Wang et al. (2021)	https://dx.doi.org/10.1101%2F2021.03.01.433466	'L18F', 'T20N', 'P26S', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y'	Amongst RBD-targeting Emergency Use Authorized monoclonal antibody treatments CB6, LY-CoV555 and REGN10933 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1, but REGN10987 activity remains strong. RBD-targeting monoclonal antibodies 2-15 and C121 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1. N terminal domain targeting monoclonal antibodies 5-7, 4-8, 4-18 and 2-17 have abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D138Y	c.G412T	p.D138Y			21974	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	G	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.56x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D138Y	c.G412T	p.D138Y			21974	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	G	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G', 'L18F', 'T20N', 'P26S', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	This variant combination (representing P.1 aka Gamma)  showed a 1.3x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D138Y	c.G412T	p.D138Y			21974	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	G	convalescent plasma escape	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 	'L18F', 'T20N', 'P26S', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	B.1.1.248 variant constellation in 10 convalescent human sera ~1mo post infection had mild to moderate resistence against most samples, P	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D138Y	c.G412T	p.D138Y			21974	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	G	convalescent plasma escape	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 	'L18F', 'T20N', 'P26S', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	B.1.1.7 variant constellation two-tailed Wilcoxon matched-pairs signed-rank test against 10 convalescent sera P	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D138Y	c.G412T	p.D138Y			21974	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	G	convalescent plasma escape	Hoffman et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.036	'L18F', 'T20N', 'P26S', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	VSV pseudotype P.1 showed 4.8-fold decrease in NT50 vs wild type in sera from 9 ICU patients undergoing treatment in Germany (pre-variant infections).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D138Y	c.G412T	p.D138Y			21974	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	G	convalescent plasma escape	Luftig et al. (2021)	https://doi.org/10.1056/nejmc2104036	'L18F', 'T20N', 'P26S', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	In sera from six patients collected 1 to 12 weeks post-infection with B.1, antibody titer in a microneutralization assay was on average 71.46 for P.1 virus. Compare to much stronger neutralization titers for B.1.1.7 (256) and wild type (456.1) in the same sera. 	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D138Y	c.G412T	p.D138Y			21974	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	G	convalescent plasma escape	McCallum et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1	'L18F', 'T20N', 'P26S', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	In 13 plasma collected ~1mo after B.1.1.7 infection (nursing home in Ticino, Switzerland), neutralization  reduced to undetectable levels in many plasma for P.1 pseudotyped virus, as well as WT and other VOCs.  [paper does not detail the P.1 variants used, using the most popular as a stand in]	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D138Y	c.G412T	p.D138Y			21974	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	G	convalescent plasma escape	Mendes-Correa et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.05.11.21256908v1	'L18F', 'T20N', 'P26S', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	Neutralizing antibodies that were generated following a mild infection with SARS-CoV-2 B.1.128 were effective in vitro,  and likely protective, against the SARS-CoV-2 P.1. variant in the majority of individuals based on 60 convalescent sera tested.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D138Y	c.G412T	p.D138Y			21974	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	G	convalescent plasma escape	Tang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.19.436183v1	'L18F', 'T20N', 'P26S', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	Loss of neutralizing activity (PsVNA50 assay) using 6 hyperimmune immunoglobulin preparations from convalescent plasma was seen against P.1 (3.5-fold). Neutralization against 10 convalescent plasma was slightly poorer (3.9-fold).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D138Y	c.G412T	p.D138Y			21974	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	G	convalescent plasma escape	Wang et al. (2021)	https://dx.doi.org/10.1101%2F2021.03.01.433466	'L18F', 'T20N', 'P26S', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y'	In convalescent sera one month or more post-infection in Spring 2020, an average 6.5x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.4x decrease against the full P.1 type vs WA-1 was observed, with  better full P.1 ID50 reciprocal value compared to the 10-mutation model.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D138Y	c.G412T	p.D138Y			21974	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	G	pharmaceutical effectiveness	Hoffman et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.036	'L18F', 'T20N', 'P26S', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	VSV pseudotype P.1 entry mediated by the S proteins of the P.1 variant was completely resistant to blocking by REGN10989 and Bamlanivimab. Cell fusion proficiency was slight impaired. Entry driven by the S proteins of the B.1.351 was partially resistant against Casirivimab.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D138Y	c.G412T	p.D138Y			21974	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	G	reinfection	Malta Romano et al. (2021)	https://doi.org/10.1590/s1678-9946202163036	'L18F', 'T20N', 'P26S', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I'	After a 128 day interval, a patient in Sao Paulo State, Brazil reinfected with P.1 (first episode likely predates P.1 emergence). Both cases were fairly mild (difficulty breathing, tiredness, dizziness and fatigue).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D138Y	c.G412T	p.D138Y			21974	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	G	trafficking	Esclera et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.05.455290v1	'L18F', 'T20N', 'P26S', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I'	~6x cleavage of S2 relative to WA1 (D614G) wildtype by Gamma variant as measured by mass spectrometry of Vero-TMPRSS culture  [no mutations directly at furin cleavage site, but H655Y is upstream] Compare to 4.5x or less for variants of concern with  direct furin clevage site mutations.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D138Y	c.G412T	p.D138Y			21974	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	G	trafficking	Hoffman et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.036	'L18F', 'T20N', 'P26S', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	VSV pseudotype P.1 showed slight decrease in cell entry relative to wild type in 262T and 263T-ACE2 (kidney) cell lines. Cell fusion proficiency was slight impaired.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D138Y	c.G412T	p.D138Y			21974	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	G	transmissibility	Stefanelli et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.04.06.21254923v1	'L18F', 'T20N', 'P26S', 'R190S', 'E484K', 'N501Y', 'D614G', 'H655Y'	The relative transmissibility of P.1 estimated at the national level (Italy) varied according to the assumed  degree of cross-protection granted by infection with other lineages and ranged from 1.12 (95%CI 1.03-1.23) in the  case of complete immune evasion by P.1 to 1.39 (95%CI 1.26-1.56) in the case of complete cross-protection. PG: variant list has been abbreviated due to mixed K417 bases in this lineage, potential miscalls of deletions	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D138Y	c.G412T	p.D138Y			21974	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	G	vaccine neutralization efficacy	Alenquer et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1	'L18F', 'T20N', 'P26S', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	Using P.1 defining mutations for Spike, observed 4x average decrease in neutralization efficiency  (but still relevant titres) for sera from 10 BNT162b2 vaccinees 12 days after second dose, but only one  relevant titre 12 days after first dose. Compares unfavorably to wild type or B.1.1.7 titres.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D138Y	c.G412T	p.D138Y			21974	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	G	vaccine neutralization efficacy	Andrade et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.14.439719v1	'L18F', 'T20N', 'P26S', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	In human sera 8 weeks post-vaccination with INO-4800, a ~2-fold reduction in P.1 neutralization was observed.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D138Y	c.G412T	p.D138Y			21974	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	G	vaccine neutralization efficacy	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 	'L18F', 'T20N', 'P26S', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	The neutralizing activity of vaccine was slightly lower against B.1.1.248 variant constellation in sera tested from most of the 15 patients with  the BNT162b2 mRNA vaccine. (Fig. 4)	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D138Y	c.G412T	p.D138Y			21974	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	G	vaccine neutralization efficacy	Choi et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1	'L18F', 'T20N', 'P26S', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	Neutralization efficiency (ID50) against P.1 reduced 3.2x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D138Y	c.G412T	p.D138Y			21974	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	G	vaccine neutralization efficacy	Gallagher et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.03.442455v1	'L18F', 'T20N', 'P26S', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	ELISpot assays show T cell neutralization reduced by 16.6% in this B.1.1.248 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose, with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D138Y	c.G412T	p.D138Y			21974	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	G	vaccine neutralization efficacy	Garcia-Beltran et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.013	'L18F', 'T20N', 'P26S', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	Pseudotyped P.1 virus has reduced neutralization activity vs wild type: 6.7x (30 sera Pfizer median 9 days post 2nd dose)  and 4.5x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D138Y	c.G412T	p.D138Y			21974	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	G	vaccine neutralization efficacy	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'L18F', 'T20N', 'P26S', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	1.15x *increase* in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees)	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D138Y	c.G412T	p.D138Y			21974	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	G	vaccine neutralization efficacy	Hitchlings et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.04.07.21255081v1	'L18F', 'T20N', 'P26S', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	Among 46,884 HCWs in Manaus, Brazil vaccinated with at least one dose of CoronaVac, a 0.50-fold reduction (adjusted vaccine  effectiveness, 49.6%: 95% CI, 11.3 - 71.4) in the odds of  symptomatic SARS-CoV-2 infection was observed during the period 14 days or more after receiving the first dose. Estimated vaccine effectiveness of at least one dose against any SARS-CoV-2 infection was 35.1% (95% CI, −6.6 - 60.5) in the same time period.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D138Y	c.G412T	p.D138Y			21974	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	G	vaccine neutralization efficacy	Hoffman et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.036	'L18F', 'T20N', 'P26S', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	VSV pseudotype P.1 showed 5.12-fold reduction in neutralization efficiency vs wild type in 15 Pfizer BNT162b2 vaccinee sera 13-15 days post second dose. Cell fusion proficiency was slight impaired.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D138Y	c.G412T	p.D138Y			21974	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	G	vaccine neutralization efficacy	Leier et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.04.25.21256049v1	'L18F', 'T20N', 'P26S', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	Neutralizing antibody titers increased in previously infected vaccinees relative to uninfected vaccinees  4.3-fold against P.1 (contrast with 3.4 fold against original SARS-CoV-2).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D138Y	c.G412T	p.D138Y			21974	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	G	vaccine neutralization efficacy	Tarke et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.27.433180v1	'L18F', 'T20N', 'P26S', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	PBMCs of Pfizer/BioNTech BNT162b2 (n	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D138Y	c.G412T	p.D138Y			21974	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	G	vaccine neutralization efficacy	Wang et al. (2021)	https://dx.doi.org/10.1101%2F2021.03.01.433466	'L18F', 'T20N', 'P26S', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y'	In 12 Moderna vaccinee sera 15 days post second dose (43 days since first vaccination), an average 2.8x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 4.8x decrease against the full P.1 type vs WA-1 was observed, though overall with  a higher ID50 reciprocal value. In 10 Pfizer vaccinee sera 7 days or more post second dose (28 days or more since first vaccination), an average 2.2x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.8x decrease against the full P.1 type vs WA-1 was observed, with  similar variant ID50 reciprocal value.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D138Y	c.G412T	p.D138Y			21974	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	G	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.37x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.56x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D138Y	c.G412T	p.D138Y			21974	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	G	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G', 'L18F', 'T20N', 'P26S', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	This variant combination (representing P.1 aka Gamma)  showed a 1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.27x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D138Y	c.G412T	p.D138Y			21974	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	G	virion structure	Spratt et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1		Estimated free energy change (ddG) for this variant is 0.43 kcal/mol (i.e. stabilizing relative to wild type) 	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D138Y	c.G412T	p.D138Y			21974	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	G	virion structure	Wang et al. (2021)	https://dx.doi.org/10.1101%2F2021.03.01.433466	'L18F', 'T20N', 'P26S', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y'	CryoEM reveals the P.1 trimer to adopt exclusively a conformation in which one of the receptor-binding domains is in the “up” position.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D156D	c.T468C	p.D156D			733	orf1ab	ORF1ab	SILENT	11386	172.0	11387			leader protein	nsp1, produced by both pp1a and pp1ab	YP_009725297.1	22	C=11364	11364	C	T						False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D225D	c.C675T	p.D225D			28948	N	N	SILENT	2	2.0	11387						1	T=1	1	T	C						False	P.1.7	P.1.7=False	VOC		11-Jan-2021	
p.D22Y	c.G64T	p.D22Y			25456	ORF3a	ORF3a	MISSENSE	4	4.0	11387						3	T=1	1	T	G						False	P.1.10	P.1.10=False	VOC		11-Jan-2021	
p.D4532D	c.C13596T	p.D4532D			13860	orf1ab	ORF1ab	SILENT	11384	172.0	11387			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only	YP_009725307.1	1	T=11383	11383	T	C						False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D5955D	c.C17865T	p.D5955D			18129	orf1ab	ORF1ab	SILENT	1	1.0	11387			3'-to-5' exonuclease	nsp14A2_ExoN and nsp14B_NMT, produced by pp1ab only	YP_009725309.1	0	T=1	1	T	C						False	P.1.15	P.1.15=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	11383	172.0	11387						0	G=11383	11383	G	A	ACE2 receptor binding affinity	Dejnirattisai et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.055	'K417T', 'E484K', 'N501Y'	The KD for the pseudotyped P.1-ACE2 interaction is 4.8 nM, showing that binding to P.1 is essentially indistinguishable from B.1.351 (4.0 nM), which binds with ~19x greater affinity that wild type.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	11383	172.0	11387						0	G=11383	11383	G	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D138Y'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.32x increase in binding (KD) relative to D614G.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	11383	172.0	11387						0	G=11383	11383	G	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'E484K'	This variant appears twice in the experiments, with slightly different affinities (both ~1.2x decrease in binding relative to D614G)  using flow cytometry and ACE2 ectodomains-Fc portion IgG complex.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	11383	172.0	11387						0	G=11383	11383	G	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'H655Y'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.21x increase in binding (KD) relative to D614G.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	11383	172.0	11387						0	G=11383	11383	G	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'K417T'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.28x increase in binding (KD) relative to D614G.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	11383	172.0	11387						0	G=11383	11383	G	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'L18F'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.07x decrease in binding (KD) relative to D614G. Compare to increased binding in full Spike variant complements for major lineages containing this variant subset: 3.56x (B.1.351 aka Beta), 4.24x (P.1 aka Gamma).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	11383	172.0	11387						0	G=11383	11383	G	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing P.1 aka Gamma)  showed a 4.24x increase in binding (KD) relative to D614G.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	2	2.0	11387						0	G=2	2	G	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'L5F'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.1x decrease in binding (KD) relative to D614G.	False	P.1.7	P.1.7=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	11383	172.0	11387						0	G=11383	11383	G	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'N501Y'	"Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.52x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis). Compare to full Spike variant complements for major lineages containing this variant subset: 5.43x (B.1.1.7 aka Alpha), 3.56x (B.1.351 aka Beta), 4.24x (P.1 aka Gamma)."	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	11383	172.0	11387						0	G=11383	11383	G	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'P26S'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.58x increase in binding (KD) relative to D614G.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	2	2.0	11387						0	G=2	2	G	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'P681H'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.23x decrease in binding (KD) relative to D614G.	False	P.1.7	P.1.7=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	11383	172.0	11387						0	G=11383	11383	G	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'R190S'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.82x increase in binding (KD) relative to D614G.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	11383	172.0	11387						0	G=11383	11383	G	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'T1027I'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.69x decrease in binding (KD) relative to D614G.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	11383	172.0	11387						0	G=11383	11383	G	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'T20N'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.96x increase in binding (KD) relative to D614G.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	11383	172.0	11387						0	G=11383	11383	G	A	ACE2 receptor binding affinity	Li et al. (2020)	https://doi.org/10.1016/j.cell.2020.07.012		In four cell lines (including 293T-hACE2 cells), this mutation combination increases infectivity vs D614G alone	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	11383	172.0	11387						0	G=11383	11383	G	A	anthropozoonotic events	Montagutelli et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.18.436013v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	Unlike wild type or B.1.1.7, P.1 lineage virus was able to infect and replicate in common lab mouse strains, with high titer.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	11383	172.0	11387						0	G=11383	11383	G	A	antibody epitope effects	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	B.1.1.248 variant constellation ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07. B.1.1.248 variant constellation ablates Class 3 N-terminal domain targeting antibody COV2-2676.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	11383	172.0	11387						0	G=11383	11383	G	A	antibody epitope effects	Wang et al. (2021)	https://dx.doi.org/10.1101%2F2021.03.01.433466	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y'	Amongst RBD-targeting Emergency Use Authorized monoclonal antibody treatments CB6, LY-CoV555 and REGN10933 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1, but REGN10987 activity remains strong. RBD-targeting monoclonal antibodies 2-15 and C121 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1. N terminal domain targeting monoclonal antibodies 5-7, 4-8, 4-18 and 2-17 have abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	11383	172.0	11387						0	G=11383	11383	G	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D138Y'	1.56x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	11383	172.0	11387						0	G=11383	11383	G	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'E484K'	1.42x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	11383	172.0	11387						0	G=11383	11383	G	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'H655Y'	1.48x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	11383	172.0	11387						0	G=11383	11383	G	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'K417T'	1.65x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	11383	172.0	11387						0	G=11383	11383	G	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'L18F'	1.66x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset. Compare to decreased binding in full Spike variant complements for major lineages containing this variant subset: 0.96x (B.1.351 aka Beta), 0.77x (P.1 aka Gamma).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	11383	172.0	11387						0	G=11383	11383	G	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	This variant combination (representing P.1 aka Gamma)  showed a 1.3x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	2	2.0	11387						0	G=2	2	G	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'L5F'	No change in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	P.1.7	P.1.7=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	11383	172.0	11387						0	G=11383	11383	G	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'N501Y'	1.65x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	11383	172.0	11387						0	G=11383	11383	G	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'P26S'	1.08x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	2	2.0	11387						0	G=2	2	G	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'P681H'	1.26x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	P.1.7	P.1.7=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	11383	172.0	11387						0	G=11383	11383	G	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'R190S'	1.09x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	11383	172.0	11387						0	G=11383	11383	G	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'T1027I'	1.56x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	11383	172.0	11387						0	G=11383	11383	G	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'T20N'	1.65x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	11383	172.0	11387						0	G=11383	11383	G	A	convalescent plasma escape	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	B.1.1.248 variant constellation in 10 convalescent human sera ~1mo post infection had mild to moderate resistence against most samples, P	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	11383	172.0	11387						0	G=11383	11383	G	A	convalescent plasma escape	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	B.1.1.7 variant constellation two-tailed Wilcoxon matched-pairs signed-rank test against 10 convalescent sera P	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	11383	172.0	11387						0	G=11383	11383	G	A	convalescent plasma escape	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1	'E484K'	Pseudotyped viruses for B.1.618 was 2.5-fold resistant to neutralization by convalescent sera compared to wild type - a finding that was similar to that of the 3-fold resistance of the South Africa B.1.351 variant using the same assay. The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618. [details on the convalescent patient sera collection are not abundantly clear in the preprint]	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	11383	172.0	11387						0	G=11383	11383	G	A	convalescent plasma escape	Wang et al. (2021)	https://dx.doi.org/10.1101%2F2021.03.01.433466	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y'	In convalescent sera one month or more post-infection in Spring 2020, an average 6.5x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.4x decrease against the full P.1 type vs WA-1 was observed, with  better full P.1 ID50 reciprocal value compared to the 10-mutation model.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	11383	172.0	11387						0	G=11383	11383	G	A	immunosuppression variant emergence	Landis et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.05.08.21256775v1		Studying 94 COVID-19 extended infection cases with genomics April 1 to October 17, 2020, one case developed 23 mutations in a 19 day period, including this combination in Spike.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	11383	172.0	11387						0	G=11383	11383	G	A	reinfection	Malta Romano et al. (2021)	https://doi.org/10.1590/s1678-9946202163036	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	After a 128 day interval, a patient in Sao Paulo State, Brazil reinfected with P.1 (first episode likely predates P.1 emergence). Both cases were fairly mild (difficulty breathing, tiredness, dizziness and fatigue).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	11383	172.0	11387						0	G=11383	11383	G	A	syncytium formation	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633		Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	11383	172.0	11387						0	G=11383	11383	G	A	syncytium formation	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633	'E484K', 'N501Y'	~50% Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, signficantly higher than D614G.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	11383	172.0	11387						0	G=11383	11383	G	A	syncytium formation	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633	'N501Y'	Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, no change relative to D614G.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	11383	172.0	11387						0	G=11383	11383	G	A	tissue specific neutralization	Planas et al. (2021)	https://www.nature.com/articles/s41591-021-01318-5		The nasal mucosa of Pfizer vaccinees with time course collection was evaluated against VSV pseudotypes: results (only one nasal  swab from different previously infected vacinee neutralizing at weeks 3 and 6 against B.1.1.7 and D614G) suggest that vaccinees probably  do not elicit an early humoral response detectable at mucosal surfaces even though sera neutralization was observed. They strengthen the hypothesis that some vaccines may not protect against  viral acquisition and infection of the oral–nasal region, but may prevent severe disease associated with viral dissemination in the lower respiratory tract. 	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	11383	172.0	11387						0	G=11383	11383	G	A	trafficking	Barrett et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.24.428007v1		Circulating variant shown in vitro to not have major defects or enhancement of cell surface protein trafficking (i.e. Spike cleavage or fusion required for cell entry)	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	11383	172.0	11387						0	G=11383	11383	G	A	trafficking	Daniloski et al. (2021)	https://doi.org/10.7554/elife.65365		The increased transduction with Spike D614G ranged from 1.3- to 2.4-fold in Caco-2 and Calu-3 cells expressing  endogenous ACE2 and from 1.5- to 7.7-fold in A549ACE2 and Huh7.5ACE2 overexpressing ACE2.  Although there is minimal difference in ACE2 receptor binding between the D614 and G614 Spike variants,  the G614 variant is more resistant to proteolytic cleavage, suggesting a possible mechanism for the increased transduction.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	11383	172.0	11387						0	G=11383	11383	G	A	trafficking	Esclera et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.05.455290v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	~6x cleavage of S2 relative to WA1 (D614G) wildtype by Gamma variant as measured by mass spectrometry of Vero-TMPRSS culture  [no mutations directly at furin cleavage site, but H655Y is upstream] Compare to 4.5x or less for variants of concern with  direct furin clevage site mutations.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	11383	172.0	11387						0	G=11383	11383	G	A	trafficking	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633		No change in infectivity (24h) relative to D614G alone in Caco-2 cells, Vero or Calu-3.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	11383	172.0	11387						0	G=11383	11383	G	A	trafficking	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633		~4x more efficient S2 domain cleavage compared to wild type in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	11383	172.0	11387						0	G=11383	11383	G	A	trafficking	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633	'E484K', 'N501Y'	More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~11x, Vero ~10x, and Calu-3 ~11x. Compare to wild type at ~5x across cell types.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	11383	172.0	11387						0	G=11383	11383	G	A	trafficking	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633	'E484K', 'N501Y'	~6x more efficient S2 domain cleavage compared to wild type, compared to 4x by D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3). [N501Y+D614G does not show an increase in cleavage, therefore a synergistic effect of the trio is implied]	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	11383	172.0	11387						0	G=11383	11383	G	A	trafficking	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633	'N501Y'	More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~9x, Vero ~8x, and Calu-3 ~8x. Compare to wild type at ~5x across cell types.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	11383	172.0	11387						0	G=11383	11383	G	A	trafficking	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633	'N501Y'	~4x more efficient S2 domain cleavage compared to wild type, no change relative to D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	11383	172.0	11387						0	G=11383	11383	G	A	trafficking	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'E484K'	~2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	11383	172.0	11387						0	G=11383	11383	G	A	trafficking	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'E484K', 'N501Y'	~12x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (~additive effects of 501 and 484).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	11387	344.0	11387						0	G=11387	11387	G	A	trafficking	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'N501Y'	9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	11383	172.0	11387						0	G=11383	11383	G	A	trafficking	Ozono et al. (2020)	https://www.nature.com/articles/s41467-021-21118-2		Among S variants tested, the D614G mutant shows the highest cell entry (~3.5x wild type), as supported by  structural and binding analyses. 	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	11383	172.0	11387						0	G=11383	11383	G	A	trafficking	Zhang et l. (2020)	https://www.nature.com/articles/s41467-020-19808-4		We report here pseudoviruses carrying SG614 enter ACE2-expressing cells more efficiently than wild type (~9-fold).  This increased entry correlates with less S1-domain shedding and higher S-protein incorporation into the virion.  D614G does not alter S-protein binding to ACE2 or neutralization sensitivity of pseudoviruses. Thus, D614G may  increase infectivity by assembling more functional S protein into the virion.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	11383	172.0	11387						0	G=11383	11383	G	A	transmissibility	Stefanelli et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.04.06.21254923v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'E484K', 'N501Y', 'H655Y'	The relative transmissibility of P.1 estimated at the national level (Italy) varied according to the assumed  degree of cross-protection granted by infection with other lineages and ranged from 1.12 (95%CI 1.03-1.23) in the  case of complete immune evasion by P.1 to 1.39 (95%CI 1.26-1.56) in the case of complete cross-protection. PG: variant list has been abbreviated due to mixed K417 bases in this lineage, potential miscalls of deletions	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	11383	172.0	11387						0	G=11383	11383	G	A	vaccine neutralization efficacy	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	The neutralizing activity of vaccine was slightly lower against B.1.1.248 variant constellation in sera tested from most of the 15 patients with  the BNT162b2 mRNA vaccine. (Fig. 4)	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	11383	172.0	11387						0	G=11383	11383	G	A	vaccine neutralization efficacy	Gallagher et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.03.442455v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	ELISpot assays show T cell neutralization reduced by 16.6% in this B.1.1.248 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose, with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	11383	172.0	11387						0	G=11383	11383	G	A	vaccine neutralization efficacy	Garcia-Beltran et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.013		Pseudotyped D614G virus has reduced neutralization activity vs wild type: 1.2x (37 sera Pfizer median 9  days post 2nd dose, 37 sera Moderna median 18 days post 2nd dose). This was NOT significant by ANOVA.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	11383	172.0	11387						0	G=11383	11383	G	A	vaccine neutralization efficacy	Garcia-Beltran et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.013	'E484K', 'V1176F'	Pseudotyped P.2 virus has reduced neutralization activity vs wild type: 5.8x (30 sera Pfizer median 9 days post 2nd dose)  and 2.9x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	11383	172.0	11387						0	G=11383	11383	G	A	vaccine neutralization efficacy	Garcia-Beltran et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.013	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	Pseudotyped P.1 virus has reduced neutralization activity vs wild type: 6.7x (30 sera Pfizer median 9 days post 2nd dose)  and 4.5x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	11383	172.0	11387						0	G=11383	11383	G	A	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008		Using a lentivirus virus pseudotyped with D614G Spike, sera from vaccinated individuals who received the second dose (9–11 days post-second dose of Pfizer) exhibited a robust  neutralizing potential, with a mean NT50 value of 99,000. This was an average of a 2-fold increase, relative to sera drawn from the  individuals who received one dose of vaccination—mean NT50 dilution of 51,300. Importantly, a 6-fold increase in mean NT50 dilution was  obtained when sera from the first vaccination dose was compared to convalescent sera from cohort with severe disease (NT50 51,000 vs 8,700)  21 to 63 days post-onset. 	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	11383	172.0	11387						0	G=11383	11383	G	A	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'E484K'	This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	11383	172.0	11387						0	G=11383	11383	G	A	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'E484K', 'N501Y'	This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n 	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	11383	172.0	11387						0	G=11383	11383	G	A	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'N501Y'	This variant showed no change in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	11383	172.0	11387						0	G=11383	11383	G	A	vaccine neutralization efficacy	Leier et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.04.25.21256049v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	Neutralizing antibody titers increased in previously infected vaccinees relative to uninfected vaccinees  4.3-fold against P.1 (contrast with 3.4 fold against original SARS-CoV-2).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	11383	172.0	11387						0	G=11383	11383	G	A	vaccine neutralization efficacy	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1	'E484K'	Pseudotyped viruses for B.1.618 was 2.7-fold resistant to neutralization by 6 BNT162b2 vaccine sera 28 days post-booster compared to wild type - a finding that was similar to that of the 3.4-fold resistance of the South Africa B.1.351 variant using the same assay. Neutralization by 3 Moderna vaccine sera 28 days post-booster was 3-fold resistant (vs. 2.2-fold for B.1.351). The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	11383	172.0	11387						0	G=11383	11383	G	A	vaccine neutralization efficacy	Wang et al. (2021)	https://dx.doi.org/10.1101%2F2021.03.01.433466	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y'	In 12 Moderna vaccinee sera 15 days post second dose (43 days since first vaccination), an average 2.8x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 4.8x decrease against the full P.1 type vs WA-1 was observed, though overall with  a higher ID50 reciprocal value. In 10 Pfizer vaccinee sera 7 days or more post second dose (28 days or more since first vaccination), an average 2.2x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.8x decrease against the full P.1 type vs WA-1 was observed, with  similar variant ID50 reciprocal value.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	2	2.0	11387						0	G=2	2	G	A	vaccine neutralization efficacy	Zuckerman et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.03.25.21253908v1	'P681H'	No significant change in virus neutralzation by 18 Pfizer two dose vaccinee sera compared to B.1.1.7. [results without including the used mutation A27S likely generalizable, as this is not a lineage defining mutation]	False	P.1.7	P.1.7=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	11383	172.0	11387						0	G=11383	11383	G	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D138Y'	1.37x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.56x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	11383	172.0	11387						0	G=11383	11383	G	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'E484K'	1.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.06x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	11383	172.0	11387						0	G=11383	11383	G	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'H655Y'	1.04x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	11383	172.0	11387						0	G=11383	11383	G	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'K417T'	1.04x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.1x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	11383	172.0	11387						0	G=11383	11383	G	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'L18F'	1.30x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  Compare to varied binding in full Spike variant complements for major lineages containing this variant subset: 1.28x increase (B.1.351 aka Beta), and 1.14x decrease (P.1 aka Gamma). 1.47x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees. Compare to varied binding in full Spike variant complements for major lineages containing this variant subset: 1.17x increase (B.1.351 aka Beta), and 1.47x decrease (P.1 aka Gamma).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	11383	172.0	11387						0	G=11383	11383	G	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	This variant combination (representing P.1 aka Gamma)  showed a 1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.27x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	2	2.0	11387						0	G=2	2	G	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'L5F'	1.23x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.1x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	P.1.7	P.1.7=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	11383	172.0	11387						0	G=11383	11383	G	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'N501Y'	1.17x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	11383	172.0	11387						0	G=11383	11383	G	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'P26S'	1.23x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.37x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	2	2.0	11387						0	G=2	2	G	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'P681H'	1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.11x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	P.1.7	P.1.7=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	11383	172.0	11387						0	G=11383	11383	G	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'R190S'	1.19x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.59x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	11383	172.0	11387						0	G=11383	11383	G	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'T1027I'	1.32x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.22x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	11383	172.0	11387						0	G=11383	11383	G	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'T20N'	1.29x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.39x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	11383	172.0	11387						0	G=11383	11383	G	A	viral load	Plante et al. (2020)	https://www.nature.com/articles/s41586-020-2895-3		Hamsters infected with SARS-CoV-2 expressing spike(D614G) (G614 virus) produced higher infectious titres in nasal washes and the trachea, but not in the lungs,  supporting clinical evidence showing that the mutation enhances viral loads in the upper respiratory tract of COVID-19 patients and may increase transmission.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	11383	172.0	11387						0	G=11383	11383	G	A	virion structure	Spratt et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1		Estimated free energy change (ddG) for this variant is 2.5 kcal/mol (i.e. stabilizing relative to wild type) 	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	11383	172.0	11387						0	G=11383	11383	G	A	virion structure	Wang et al. (2021)	https://dx.doi.org/10.1101%2F2021.03.01.433466	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y'	CryoEM reveals the P.1 trimer to adopt exclusively a conformation in which one of the receptor-binding domains is in the “up” position.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	11383	172.0	11387						0	G=11383	11383	G	A	virion structure	Weissman et al. (2020)	https://www.medrxiv.org/content/10.1101/2020.07.22.20159905v2		"Negative stain EM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2."	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	11383	172.0	11387						0	G=11383	11383	G	A	virion structure	Yurkovetskiy et al. (2020)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492024/		"CryoEM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2."	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	11383	172.0	11387						0	G=11383	11383	G	A	virion structure	Zhang et al. (2020)	https://www.nature.com/articles/s41467-020-19808-4		Based on pseudotyped virus experiments, D614G may increase infectivity by assembling more functional S protein into the virion.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.D828D	c.C2484T	p.D828D			2749	orf1ab	ORF1ab	SILENT	11387	172.0	11387			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	0	T=11387	11387	T	C						False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E246A	c.A737C	p.E246A			1002	orf1ab	ORF1ab	MISSENSE	4	4.0	11387			nsp2	produced by both pp1a and pp1ab	YP_009725298.1	3	C=1	1	C	A						False	P.1.12	P.1.12=False	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	ACE2 receptor binding affinity	Barton et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1	'K417T', 'N501Y'	The affinity of the P.1 RBD variants for ACE2 increased by 5.3 fold as measured by surface plasmon resonance relative to wild  type RBD by increasing the k(on) and decreasing the k(off) rate constants. 	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	ACE2 receptor binding affinity	Barton et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1	'N501Y'	In the case of VOC B.1.1.7+E484K, the addition of the E484K mutation to N501Y further increased the affinity, to ~15 fold higher than WT RBD (KD ~5 nM), by further increasing the k(on) as measured by surface plasmon resonance. Because the higher k(on) could result in mass transfer limiting binding, we confirmed that the kinetic measurement for this variant was not substantially affected by varying levels of immobilization.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	ACE2 receptor binding affinity	Collier et al. (2021)	https://www.nature.com/articles/s41586-021-03412-7		This combination showed ~3x increase binding to ACE2 vs wild type, about half that of the B.1.1.7 lineage, suggesting that the K417N mutation is slightly detrimental to ACE2 binding, probably as a result of disrupting the salt bridge formed with ACE2 residue D30	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	ACE2 receptor binding affinity	Dejnirattisai et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.055	'K417T', 'N501Y', 'D614G'	The KD for the pseudotyped P.1-ACE2 interaction is 4.8 nM, showing that binding to P.1 is essentially indistinguishable from B.1.351 (4.0 nM), which binds with ~19x greater affinity that wild type.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	This variant appears twice in the experiments, with slightly different affinities (both ~1.2x decrease in binding relative to D614G)  using flow cytometry and ACE2 ectodomains-Fc portion IgG complex.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G', 'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'N501Y', 'H655Y', 'T1027I'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing P.1 aka Gamma)  showed a 4.24x increase in binding (KD) relative to D614G.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	ACE2 receptor binding affinity	Laffeber et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.22.432357v1		RBD containing the N501Y mutation results in 9-fold stronger binding to the hACE2 receptor than  wild type RBD. The E484K mutation does not significantly influence the affinity for the receptor,  while K417N attenuates affinity. As a result, RBD from B.1.351 containing all three mutations binds  3-fold stronger to hACE2 than wild type RBD but 3-fold weaker than N501Y.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	ACE2 receptor binding affinity	Liu et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1		Studying the key covariants in lineage of concern 501Y.V2,  observed about 2-fold increase in ACE2 binding vs wildtype, but greatly decreased mAb binding, suggesting evolutionary optimum tension between  immune evasion and ACE2 binding affinity as the N501Y variant alone has 10x increase in affinity but no effect on tested mAb binding.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	ACE2 receptor binding affinity	Ramanathan et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.22.432359v1		Using Mircoscale Thermopheresis, the B.1.351 variant harboring three mutations, binds ACE2 at nearly  five-fold greater affinity than the original SARS-COV-2 RBD (Kd 87.6, vs 402.5 nM).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	ACE2 receptor binding affinity	Starr et al. (2020)	https://doi.org/10.1016/j.cell.2020.08.012		Experimentally, ACE2 binding affinity increased 0.06 fold	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	ACE2 receptor binding affinity	Tian et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2		Reported moderate increase in affinity compared to wild-type RBD on the cell surface (Kd 	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	ACE2 receptor binding affinity	Tian et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2		Reported slight increase in affinity compared to wild-type RBD on the cell surface (Kd 	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	ACE2 receptor binding affinity	Vogel et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.04.433887v1		The affinity of ACE2 for this mutation combination was twice as high as for wild type. Having in mind that the affinity of SARS-CoV-2 for ACE2 is only 4-fold higher compared to SARS-CoV-1, this factor of 2 is expected to be biologically significant.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	ACE2 receptor binding affinity	Zahradnik et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.06.425392		Among the first selected variants in an in vitro evolution experiment for ACE2 binding.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	T cell evasion	Reynolds et al. (2021)	https://science.sciencemag.org/content/early/2021/04/29/science.abh1282		Analyzing responses to the E484K mutation seen in B.1.351 and P.1 variants, we noted that it did  not fall in a region predicted to bind the HLAII alleles tested (table S4). The mutation appeared  to have no substantial or differential impact on T cell responses.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	anthropozoonotic events	Montagutelli et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.18.436013v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	Unlike wild type or B.1.1.7, P.1 lineage virus was able to infect and replicate in common lab mouse strains, with high titer.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	antibody epitope effects	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w		Ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07, COVOX-384 and S2H58.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	antibody epitope effects	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	B.1.1.248 variant constellation ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07. B.1.1.248 variant constellation ablates Class 3 N-terminal domain targeting antibody COV2-2676.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	antibody epitope effects	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 	'N501Y'	Ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07, COVOX-384, and S2H58. Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	antibody epitope effects	Collier et al. (2021)	https://www.nature.com/articles/s41586-021-03412-7		Of 50 mAbs tested, major loss of neutralization observed for S2N28, S2X615, S2N12, S2X192, S2H7, S2X16, S2X58, S2H70, S2X613, S2D19, S2N22, S2D32, S2H58, S2M11, S2D106, S2X30.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	antibody epitope effects	Gaebler et al. (2021)	https://www.biorxiv.org/content/10.1101/2020.11.03.367391v2		Ablates binding by class 2 mAbs such as C144 that directly interfere with ACE2 binding,  but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  show pronounced increase in binding to the variant. 	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	antibody epitope effects	Li et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.19.440481v1		Monoclonal antibodies 13G9 and 58G6 maintain fairly high neutralization potency, compared to others interfacing with E484K.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	antibody epitope effects	Liu et al. (2020)	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2		Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows high resistence to 4 antibodies,  and broad low level resistence against much of the rest of the panel.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	antibody epitope effects	Rappazzo et al. (2021)	https://science.sciencemag.org/content/371/6531/823		Massive reduction in binding efficiency vs wild type for mAb LY-CoV555.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	antibody epitope effects	Sun et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.22.436481v1		Complete loss of binding in ELISA by the variant against monoclonal antibody VH-Fc ab8	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	antibody epitope effects	Wang et al. (2021)	https://www.nature.com/articles/s41586-021-03398-2		Pseudotyped virus model ablates neutralization by RBD-directed mAbs 4-20, 2-4, 2-43, 2-30, 2-15, LY-Cov555, C121. Pseudotyped virus model impairs neutralization by RBD-directed mAb COV2-2196 (somewhat more than fully pseudotyped B.1.351 or live virus)	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	antibody epitope effects	Wang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2		Resistent to all seven class 2 (Spike 'up' or 'down' conformation, RBD targeting) antibodies tested, with 10-fold  or greater reduction in neutralization (plus notable reudction in two unclassfied mAbs).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	antibody epitope effects	Wang et al. (2021)	https://dx.doi.org/10.1101%2F2021.03.01.433466	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'N501Y', 'D614G', 'H655Y'	Amongst RBD-targeting Emergency Use Authorized monoclonal antibody treatments CB6, LY-CoV555 and REGN10933 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1, but REGN10987 activity remains strong. RBD-targeting monoclonal antibodies 2-15 and C121 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1. N terminal domain targeting monoclonal antibodies 5-7, 4-8, 4-18 and 2-17 have abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.42x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G', 'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'N501Y', 'H655Y', 'T1027I'	This variant combination (representing P.1 aka Gamma)  showed a 1.3x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	convalescent plasma escape	Alenquer et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1		Average ~5-fold reduction in neutralization efficacy in convalescent sera of 16 health workers infected in Spring 2020.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	convalescent plasma escape	Andreano et al. (2020)	https://www.biorxiv.org/content/10.1101/2020.12.28.424451		This mutation occurred in 100% of sequenced virions after 12 passages and led to a 4-fold decrease in convalescent plasma neutralization activity	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	convalescent plasma escape	Cele et al. (2021)	https://www.krisp.org.za/manuscripts/MEDRXIV-2021-250224v1-Sigal.pdf		The 501Y.V2 to first wave IC50 ratio ranged from 6 to 200-fold. Averaging across all 7 participant convalescent sera highlighted the dramatic decrease in sensitivity to neutralization of authentic 501Y.V2 variants. PG: I'm purposefully ignoring D614G and A701V as contributors	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	convalescent plasma escape	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	B.1.1.248 variant constellation in 10 convalescent human sera ~1mo post infection had mild to moderate resistence against most samples, P	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	convalescent plasma escape	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	B.1.1.7 variant constellation two-tailed Wilcoxon matched-pairs signed-rank test against 10 convalescent sera P	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	convalescent plasma escape	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 	'N501Y'	In 19 convalescent human sera ~1mo post infection had mild to moderate resistence against all samples. 	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	convalescent plasma escape	Hoffman et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.036	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	VSV pseudotype P.1 showed 4.8-fold decrease in NT50 vs wild type in sera from 9 ICU patients undergoing treatment in Germany (pre-variant infections).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	convalescent plasma escape	Liu et al. (2021)	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2		Remarkably, several of the E484 escape mutants were resistant to neutralization at the highest concentration (1:80 initial dilution) of all 4 convalescent sera tested (triplicate experiments). Against a wider panel of 16 convalescent plasma (no replicates), all but one show major resistance.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	convalescent plasma escape	Luftig et al. (2021)	https://doi.org/10.1056/nejmc2104036	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	In sera from six patients collected 1 to 12 weeks post-infection with B.1, antibody titer in a microneutralization assay was on average 71.46 for P.1 virus. Compare to much stronger neutralization titers for B.1.1.7 (256) and wild type (456.1) in the same sera. 	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	convalescent plasma escape	McCallum et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	In 13 plasma collected ~1mo after B.1.1.7 infection (nursing home in Ticino, Switzerland), neutralization  reduced to undetectable levels in many plasma for P.1 pseudotyped virus, as well as WT and other VOCs.  [paper does not detail the P.1 variants used, using the most popular as a stand in]	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	convalescent plasma escape	Mendes-Correa et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.05.11.21256908v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	Neutralizing antibodies that were generated following a mild infection with SARS-CoV-2 B.1.128 were effective in vitro,  and likely protective, against the SARS-CoV-2 P.1. variant in the majority of individuals based on 60 convalescent sera tested.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	convalescent plasma escape	Schmidt et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1		Escape mutant found after in passage in plasma pool of 26 convalescents mean 1.5 post symptom onset.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	convalescent plasma escape	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1		The only mutation in the B.1.351 lineage that appears to contribute to neutralization reduction (~1.7x across 10 convalescent sera from April 2020 infectees)	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	convalescent plasma escape	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1	'D614G'	Pseudotyped viruses for B.1.618 was 2.5-fold resistant to neutralization by convalescent sera compared to wild type - a finding that was similar to that of the 3-fold resistance of the South Africa B.1.351 variant using the same assay. The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618. [details on the convalescent patient sera collection are not abundantly clear in the preprint]	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	convalescent plasma escape	Tang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.19.436183v1		As measured by surface plasmon resonance, RBD with the E484K mutation alone showed a mean 19.1x decrease in binding affinity for  six batches of hyperimmune immunoglobulin (hCoV-2IG) preparations generated from SARS-CoV-2 convalescent plasma.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	convalescent plasma escape	Tang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.19.436183v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	Loss of neutralizing activity (PsVNA50 assay) using 6 hyperimmune immunoglobulin preparations from convalescent plasma was seen against P.1 (3.5-fold). Neutralization against 10 convalescent plasma was slightly poorer (3.9-fold).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	convalescent plasma escape	Wang et al. (2021)	https://www.nature.com/articles/s41586-021-03398-2		The neutralizing activity of 15/20 convalescent sera was significantly lower against this pseudotyped virus model	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	convalescent plasma escape	Wang et al. (2021)	https://dx.doi.org/10.1101%2F2021.03.01.433466	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'N501Y', 'D614G', 'H655Y'	In convalescent sera one month or more post-infection in Spring 2020, an average 6.5x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.4x decrease against the full P.1 type vs WA-1 was observed, with  better full P.1 ID50 reciprocal value compared to the 10-mutation model.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	convalescent plasma escape	Wibmer et al. (2021)	https://doi.org/10.1101/2021.01.18.427166		"27% of 44 early pandemic exposure convalescent plasma/sera lose all activity against a RBD triple mutant pseudovirus (RBD mutatants of the 501Y.V2 ""South African"" lineage), while only 23% retained high titres "	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	convalescent plasma escape	Wibmer et al. (2021)	https://doi.org/10.1101/2021.01.18.427166		"Nearly half (21 of 44, 48%) of early pandemic exposure convalescent plasma/sera failed to neutralize the 501Y.V2 (""South African"") lineage pseudovirus construct Only 3 of 44 convascent sera (those with the highest titer, which correlated direectly with initial infection severity) had high neutralization against this 501Y.V2  PG: note that lineage variant R246I was excluded from the text in reference to these sera assays, not sure if that was an oversight."	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	convalescent plasma escape	Zhou et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.24.436620v1		"Subtype of the B.1.526 ""New York"" lineage, lentivirus pseudotyped with this mutation combination in showed 3.3x reduction in  IC50 serum dilution concentration for 6 convalescent sera."	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	monoclonal antibody serial passage escape	Barnes et al. (2020)	https://www.nature.com/articles/s41586-020-2852-1_reference.pdf?origin		The engineered mutation cause 10-fold or more increase in the disassociation constant with many monoclonal antibodies (C144/C002/C121/C104/C110).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	monoclonal antibody serial passage escape	Baum et al. (2020)	http://dx.doi.org/10.1126/science.abd0831		Escape variant 100% appearance in 2 passages against Regeneron monoclonal antibody REGN10989 @ 50ug/mL (99% after one passage)	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	monoclonal antibody serial passage escape	Greaney et al. (2020)	https://doi.org/10.1016/j.chom.2020.11.007		Mildly effective mutant against this position in the RBD for highly neutralizing COV2-2479 monoclonal antibody Effective mutant against this position in the RBD for highly neutralizing COV2-2050 monoclonal antibody	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	monoclonal antibody serial passage escape	Starr et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1		Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	monoclonal antibody serial passage escape	Wang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2		Class 2 antibodies C627, C602, C671, C643, and class 2/3 antibody C603 selected for the emergence of the E484K mutation in vitro.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	monoclonal antibody serial passage escape	Weisblum et al. (2020)	https://www.biorxiv.org/content/10.1101/2020.07.21.214759v1.full.pdf		Strong positive selection (up to 50% of supernatant sequences) after C121 monoclonal antibody assay, decreasing in subsequent passages Strong positive selection (up to 44% of supernatant sequences) after after one round of C144 monoclonal antibody passage, then waning on subsequent passages	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	outcome hazard ratio	Funk et al. (2021)	https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2021.26.16.2100348	'L18F', 'K417T', 'N501Y', 'H655Y'	On average across 7 European countries studied, using P.1 defining mutations: Significant shift to infection in those without pre-existing conditions (27.8% vs 89% for non-VOC cases). Significant increase in hospitalization rate (20% vs 7.5% for non-VOC cases). Significant increase in ICU rate (2.1% vs 0.6% for non-VOC cases). Significant increase in health care worker rate (19.8% vs 8.0% for non-VOC cases).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	outcome hazard ratio	Ribas Freitas et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.04.13.21255281v1	'L18F', 'K417T', 'N501Y', 'H655Y'	In the Southern Brazilian stats of Rio Grande do Sul, comparing pre-P.1 and post-P.1 waves:  The increase in Case Fatality Rate occurred in a greatest intensity in the population between 20 and 59 years old and among patients without pre-existing risk conditions. Female 20 to 39 years old, with no pre-existing risk conditions, were at risk of death 5.65 times higher in February (95%CI 	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	outcome hazard ratio	Santos de Oliviera et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.03.24.21254046v1	'L18F', 'K417T', 'N501Y', 'H655Y'	In the Parana state of Brazil, patients aged 20-29 years experienced a tripling of their case fatality rate (CFR), from 0.04% to 0.13%, while those aged  30-39, 40-49, 50-59 experienced approximate CFR doubling comparing February to January in 2021. Notably,  the observed CFR increase coincided with the second consecutive month of declining number of diagnosed SARS-CoV-2 cases.  Taken together, these preliminary findings suggest significant increases in CFR in young and middle-aged adults after  identification of a novel SARS-CoV-2 strain circulating in Brazil.  [this is somewhat indirect evidence that assume greatly increasing proportion of P.1 cases in March (70%) compared to  February, but the first official ID of P.1 in Parana state (Feb 16th) may be due to testing procedures rather than actual prevalence]	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	pharmaceutical effectiveness	Engelhart et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1		Bamlanivimab (LY-CoV555) lost ~16x binding against this isolated mutation. Casirivimab lost ~16x binding against this isolated mutation.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	pharmaceutical effectiveness	Engelhart et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1		Tixagevimab, Regdanvimab and COR-101 display reduced binding affinity to virus pseudotyped as RBD from B.1.351.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	pharmaceutical effectiveness	Engelhart et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1	'K417T', 'N501Y'	Tixagevimab, Regdanvimab and COR-101 display reduced binding affinity to virus pseudotyped as RBD from P.1.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	pharmaceutical effectiveness	Engelhart et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1	'N501Y'	Bamlanivimab (LY-CoV555) lost ~64x binding against this double mutation. COR-101 lost ~50x binding against this double mutation. Casirivimab lost ~250x binding against this double mutation. Estesevimab lost ~16x binding against this double mutation. Regdanvimab lost ~32x binding against this double mutation. Tixagevimab lost ~10x binding against this double mutation.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	pharmaceutical effectiveness	Hoffman et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.036	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	VSV pseudotype P.1 entry mediated by the S proteins of the P.1 variant was completely resistant to blocking by REGN10989 and Bamlanivimab. Cell fusion proficiency was slight impaired. Entry driven by the S proteins of the B.1.351 was partially resistant against Casirivimab.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	pharmaceutical effectiveness	Liu et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1		This mutated version of RBD completely abolishes the binding to a therapeutic antibody, Bamlanivimab, in vitro.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	reinfection	Malta Romano et al. (2021)	https://doi.org/10.1590/s1678-9946202163036	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'N501Y', 'D614G', 'H655Y', 'T1027I'	After a 128 day interval, a patient in Sao Paulo State, Brazil reinfected with P.1 (first episode likely predates P.1 emergence). Both cases were fairly mild (difficulty breathing, tiredness, dizziness and fatigue).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	syncytium formation	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633	'N501Y', 'D614G'	~50% Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, signficantly higher than D614G.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	trafficking	Esclera et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.05.455290v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'N501Y', 'D614G', 'H655Y', 'T1027I'	~6x cleavage of S2 relative to WA1 (D614G) wildtype by Gamma variant as measured by mass spectrometry of Vero-TMPRSS culture  [no mutations directly at furin cleavage site, but H655Y is upstream] Compare to 4.5x or less for variants of concern with  direct furin clevage site mutations.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	trafficking	Ferriera et al (2021)	https://www.biorxiv.org/content/10.1101/2021.05.08.443253v1		This variant alone shows a ~5x decrease in cell entry efficiency (RLU measurement in 293T cells) compared to D614G. 	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	trafficking	Hoffman et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.036	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	VSV pseudotype P.1 showed slight decrease in cell entry relative to wild type in 262T and 263T-ACE2 (kidney) cell lines. Cell fusion proficiency was slight impaired.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	trafficking	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633	'N501Y', 'D614G'	More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~11x, Vero ~10x, and Calu-3 ~11x. Compare to wild type at ~5x across cell types.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	trafficking	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633	'N501Y', 'D614G'	~6x more efficient S2 domain cleavage compared to wild type, compared to 4x by D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3). [N501Y+D614G does not show an increase in cleavage, therefore a synergistic effect of the trio is implied]	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	trafficking	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'D614G'	~2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	trafficking	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'N501Y', 'D614G'	~12x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (~additive effects of 501 and 484).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	trafficking	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1		Lentiviral pseudotyped with this individual mutation from B.1.351 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing no change in infection rate amongst the cells.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	transmissibility	Stefanelli et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.04.06.21254923v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'N501Y', 'D614G', 'H655Y'	The relative transmissibility of P.1 estimated at the national level (Italy) varied according to the assumed  degree of cross-protection granted by infection with other lineages and ranged from 1.12 (95%CI 1.03-1.23) in the  case of complete immune evasion by P.1 to 1.39 (95%CI 1.26-1.56) in the case of complete cross-protection. PG: variant list has been abbreviated due to mixed K417 bases in this lineage, potential miscalls of deletions	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	vaccine neutralization efficacy	Alenquer et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'N501Y', 'H655Y', 'T1027I'	Using P.1 defining mutations for Spike, observed 4x average decrease in neutralization efficiency  (but still relevant titres) for sera from 10 BNT162b2 vaccinees 12 days after second dose, but only one  relevant titre 12 days after first dose. Compares unfavorably to wild type or B.1.1.7 titres.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	vaccine neutralization efficacy	Andrade et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.14.439719v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'N501Y', 'H655Y', 'T1027I'	In human sera 8 weeks post-vaccination with INO-4800, a ~2-fold reduction in P.1 neutralization was observed.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	vaccine neutralization efficacy	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	The neutralizing activity of vaccine was slightly lower against B.1.1.248 variant constellation in sera tested from most of the 15 patients with  the BNT162b2 mRNA vaccine. (Fig. 4)	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	vaccine neutralization efficacy	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w	'N501Y'	The neutralizing activity of vaccine was slightly to significantly lower against this variant combination in sera from all 24 patients with  the BNT162b2 mRNA vaccine. (Fig. 4) [In stark contrast to this combination plus K417N, which had no effect (P<0.0001 vs. P	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	vaccine neutralization efficacy	Choi et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	Neutralization efficiency (ID50) against P.1 reduced 3.2x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	vaccine neutralization efficacy	Ferreira et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.08.443253v1		Nine stored sera from Pfizer BNT162b2 vaccinees were tested against a range of spike mutation bearing PV. E484K conferred a ten-fold reduction in neutralisation by vaccine sera.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	vaccine neutralization efficacy	Gallagher et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.03.442455v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	ELISpot assays show T cell neutralization reduced by 16.6% in this B.1.1.248 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose, with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	vaccine neutralization efficacy	Garcia-Beltran et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.013	'D614G', 'V1176F'	Pseudotyped P.2 virus has reduced neutralization activity vs wild type: 5.8x (30 sera Pfizer median 9 days post 2nd dose)  and 2.9x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	vaccine neutralization efficacy	Garcia-Beltran et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.013	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	Pseudotyped P.1 virus has reduced neutralization activity vs wild type: 6.7x (30 sera Pfizer median 9 days post 2nd dose)  and 4.5x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	vaccine neutralization efficacy	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	1.15x *increase* in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees)	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	vaccine neutralization efficacy	Hitchlings et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.04.07.21255081v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'N501Y', 'H655Y', 'T1027I'	Among 46,884 HCWs in Manaus, Brazil vaccinated with at least one dose of CoronaVac, a 0.50-fold reduction (adjusted vaccine  effectiveness, 49.6%: 95% CI, 11.3 - 71.4) in the odds of  symptomatic SARS-CoV-2 infection was observed during the period 14 days or more after receiving the first dose. Estimated vaccine effectiveness of at least one dose against any SARS-CoV-2 infection was 35.1% (95% CI, −6.6 - 60.5) in the same time period.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	vaccine neutralization efficacy	Hoffman et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.036	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	VSV pseudotype P.1 showed 5.12-fold reduction in neutralization efficiency vs wild type in 15 Pfizer BNT162b2 vaccinee sera 13-15 days post second dose. Cell fusion proficiency was slight impaired.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	vaccine neutralization efficacy	Ikegame et al. (2021)	https://dx.doi.org/10.21203%2Frs.3.rs-400230%2Fv1		E484K pseudotyped VSV was tested for neutralization in a clonal HEK-293T ACE2 TMPRSS2 cell line optimized for highly efficient  S-mediated infection. A cohort of 12 Argentinian recipients of the Gamaleya Sputnik V Ad26 / Ad5 vaccine  showed a mean 2.8x decrease in neutralization effiacacy.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	vaccine neutralization efficacy	Jangra et al. (2021)	https://doi.org/10.1016/S2666-5247(21		Human sera from 5 two-dose Pfizer vaccinated individuals (47-68 days post 1st-dose) neutralized this variant 3.4x less relative to reference  USA-WA1/2020 strain. 8 convalescent plasma with weak IgG ELISA titre neutralized this variant 2.4x less relative to reference  USA-WA1/2020 strain. One plasma failed to neutralize at all. 11 convalescent plasma with moderate IgG ELISA titre neutralized this variant 4.2x less relative to reference  USA-WA1/2020 strain.  11 convalescent plasma with high IgG ELISA titre neutralized this variant 2.6x less relative to reference  USA-WA1/2020 strain. 	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'D614G'	This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'N501Y', 'D614G'	This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n 	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	vaccine neutralization efficacy	Leier et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.04.25.21256049v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	Neutralizing antibody titers increased in previously infected vaccinees relative to uninfected vaccinees  4.3-fold against P.1 (contrast with 3.4 fold against original SARS-CoV-2).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	vaccine neutralization efficacy	Solfrosi et al. (2021)	https://doi.org/10.1084/jem.20202756		Neutralizing antibody titers of non-human primate sera after one or two doses of Ad26.COV2.S (Jannsen vaccine)  against the variants containing the E484K substitution in the RBD were present but reduced  (fold reduction between 3.35–7.78, 95% confidence interval all above twofold difference, one-sample t test). 	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	vaccine neutralization efficacy	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1	'D614G'	Pseudotyped viruses for B.1.618 was 2.7-fold resistant to neutralization by 6 BNT162b2 vaccine sera 28 days post-booster compared to wild type - a finding that was similar to that of the 3.4-fold resistance of the South Africa B.1.351 variant using the same assay. Neutralization by 3 Moderna vaccine sera 28 days post-booster was 3-fold resistant (vs. 2.2-fold for B.1.351). The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	vaccine neutralization efficacy	Tarke et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.27.433180v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	PBMCs of Pfizer/BioNTech BNT162b2 (n	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	vaccine neutralization efficacy	Wang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2		In a cohort of 20 patients 8+ weeks after second vaccine dose of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines,  ELISA tests show 10x reduced efficacy of a majority of isolated antibodies, but only a modest decrease for vaccine plasma overall.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	vaccine neutralization efficacy	Wang et al. (2021)	https://dx.doi.org/10.1101%2F2021.03.01.433466	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'N501Y', 'D614G', 'H655Y'	In 12 Moderna vaccinee sera 15 days post second dose (43 days since first vaccination), an average 2.8x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 4.8x decrease against the full P.1 type vs WA-1 was observed, though overall with  a higher ID50 reciprocal value. In 10 Pfizer vaccinee sera 7 days or more post second dose (28 days or more since first vaccination), an average 2.2x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.8x decrease against the full P.1 type vs WA-1 was observed, with  similar variant ID50 reciprocal value.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	vaccine neutralization efficacy	Xie et al. (2021)	https://www.nature.com/articles/s41591-021-01270-4	'N501Y'	In 20 sera from BNT162b2 mRNA vaccine inoculated participants, 6 displayed mild (2x) reductions in neutralization. This variant combination showed the highest reduction, but the magnitude of the differences was small  compared to the >4x differences in HA-inhibition titers that have been used to signal potential need for a strain change in influenza vaccines.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.06x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G', 'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'N501Y', 'H655Y', 'T1027I'	This variant combination (representing P.1 aka Gamma)  showed a 1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.27x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	virion structure	Spratt et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1		Estimated free energy change (ddG) for this variant is -0.6 kcal/mol (i.e. destabilizing relative to wild type) 	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	11382	172.0	11387						0	A=11382	11382	A	G	virion structure	Wang et al. (2021)	https://dx.doi.org/10.1101%2F2021.03.01.433466	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'N501Y', 'D614G', 'H655Y'	CryoEM reveals the P.1 trimer to adopt exclusively a conformation in which one of the receptor-binding domains is in the “up” position.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E5665D	c.G16995T	p.E5665D			17259	orf1ab	ORF1ab	MISSENSE	11387	172.0	11387			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only	YP_009725308.1	0	T=11387	11387	T	G						False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.E92K	c.G274A	p.E92K			28167	ORF8	ORF8	MISSENSE	11384	172.0	11387						0	A=11384	11384	A	G						False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.F110F	c.C330T	p.F110F			28603	N	N	SILENT	26	26.0	11387						0	T=26	26	T	C						False	P.1.17	P.1.17=True	VOC		11-Jan-2021	
p.F120V	c.TTC358_360GTT	p.F120V			28251	ORF8	ORF8		6	6.0	11387						3	GTT=3	3	GTT	TTC						False	P.1.12.1, P.1.12	P.1.12=False, P.1.12.1=True	VOC		11-Jan-2021	
p.F3100F	c.C9300T	p.F3100F			9565	orf1ab	ORF1ab	SILENT	4	4.0	11387			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab	YP_009725300.1	3	T=1	1	T	C						False	P.1.10	P.1.10=False	VOC		11-Jan-2021	
p.F3677del	c.11023_11031delTCTGGTTTT	p.S3675_F3677del	S3675_F3677del	'S3675del', '3676del'	11287	orf1ab	ORF1ab		11385	172.0	11387			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab	YP_009725302.1	0	G=11385	11385	G	GTCTGGTTTT						False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.F4440F	c.C13320T	p.F4440F			13584	orf1ab	ORF1ab	SILENT	4	4.0	11387			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only	YP_009725307.1	3	T=1	1	T	C						False	P.1.10	P.1.10=False	VOC		11-Jan-2021	
p.F924F	c.C2772T	p.F924F			3037	orf1ab	ORF1ab	SILENT	11387	172.0	11387			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	0	T=11387	11387	T	C						False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.G2814S	c.G8440A	p.G2814S			8705	orf1ab	ORF1ab	MISSENSE	4	4.0	11387			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab	YP_009725300.1	3	A=1	1	A	G						False	P.1.10	P.1.10=False	VOC		11-Jan-2021	
p.H388Y	c.C1162T	p.H388Y			1427	orf1ab	ORF1ab	MISSENSE	4	4.0	11387			nsp2	produced by both pp1a and pp1ab	YP_009725298.1	0	T=4	4	T	C						False	P.1.10	P.1.10=True	VOC		11-Jan-2021	
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	11368	172.0	11387						39	T=11329	11329	T	C	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.21x increase in binding (KD) relative to D614G.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	11368	172.0	11387						39	T=11329	11329	T	C	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G', 'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'T1027I'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing P.1 aka Gamma)  showed a 4.24x increase in binding (KD) relative to D614G.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	11368	172.0	11387						39	T=11329	11329	T	C	anthropozoonotic events	Esclera et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.05.455290v1		Six minks were intranasally infected with WA1 isolate, all developed this mutation during infection.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	11368	172.0	11387						39	T=11329	11329	T	C	anthropozoonotic events	Montagutelli et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.18.436013v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'T1027I', 'V1176F'	Unlike wild type or B.1.1.7, P.1 lineage virus was able to infect and replicate in common lab mouse strains, with high titer.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	11368	172.0	11387						39	T=11329	11329	T	C	antibody epitope effects	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'T1027I', 'V1176F'	B.1.1.248 variant constellation ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07. B.1.1.248 variant constellation ablates Class 3 N-terminal domain targeting antibody COV2-2676.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	11368	172.0	11387						39	T=11329	11329	T	C	antibody epitope effects	Wang et al. (2021)	https://dx.doi.org/10.1101%2F2021.03.01.433466	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G'	Amongst RBD-targeting Emergency Use Authorized monoclonal antibody treatments CB6, LY-CoV555 and REGN10933 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1, but REGN10987 activity remains strong. RBD-targeting monoclonal antibodies 2-15 and C121 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1. N terminal domain targeting monoclonal antibodies 5-7, 4-8, 4-18 and 2-17 have abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	11368	172.0	11387						39	T=11329	11329	T	C	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.48x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	11368	172.0	11387						39	T=11329	11329	T	C	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G', 'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'T1027I'	This variant combination (representing P.1 aka Gamma)  showed a 1.3x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	11368	172.0	11387						39	T=11329	11329	T	C	convalescent plasma escape	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'T1027I', 'V1176F'	B.1.1.248 variant constellation in 10 convalescent human sera ~1mo post infection had mild to moderate resistence against most samples, P	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	11368	172.0	11387						39	T=11329	11329	T	C	convalescent plasma escape	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'T1027I', 'V1176F'	B.1.1.7 variant constellation two-tailed Wilcoxon matched-pairs signed-rank test against 10 convalescent sera P	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	11368	172.0	11387						39	T=11329	11329	T	C	convalescent plasma escape	Hoffman et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.036	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'T1027I', 'V1176F'	VSV pseudotype P.1 showed 4.8-fold decrease in NT50 vs wild type in sera from 9 ICU patients undergoing treatment in Germany (pre-variant infections).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	11368	172.0	11387						39	T=11329	11329	T	C	convalescent plasma escape	Luftig et al. (2021)	https://doi.org/10.1056/nejmc2104036	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'T1027I', 'V1176F'	In sera from six patients collected 1 to 12 weeks post-infection with B.1, antibody titer in a microneutralization assay was on average 71.46 for P.1 virus. Compare to much stronger neutralization titers for B.1.1.7 (256) and wild type (456.1) in the same sera. 	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	11368	172.0	11387						39	T=11329	11329	T	C	convalescent plasma escape	McCallum et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'T1027I', 'V1176F'	In 13 plasma collected ~1mo after B.1.1.7 infection (nursing home in Ticino, Switzerland), neutralization  reduced to undetectable levels in many plasma for P.1 pseudotyped virus, as well as WT and other VOCs.  [paper does not detail the P.1 variants used, using the most popular as a stand in]	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	11368	172.0	11387						39	T=11329	11329	T	C	convalescent plasma escape	Mendes-Correa et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.05.11.21256908v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'T1027I', 'V1176F'	Neutralizing antibodies that were generated following a mild infection with SARS-CoV-2 B.1.128 were effective in vitro,  and likely protective, against the SARS-CoV-2 P.1. variant in the majority of individuals based on 60 convalescent sera tested.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	11368	172.0	11387						39	T=11329	11329	T	C	convalescent plasma escape	Tang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.19.436183v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'T1027I', 'V1176F'	Loss of neutralizing activity (PsVNA50 assay) using 6 hyperimmune immunoglobulin preparations from convalescent plasma was seen against P.1 (3.5-fold). Neutralization against 10 convalescent plasma was slightly poorer (3.9-fold).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	11368	172.0	11387						39	T=11329	11329	T	C	convalescent plasma escape	Wang et al. (2021)	https://dx.doi.org/10.1101%2F2021.03.01.433466	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G'	In convalescent sera one month or more post-infection in Spring 2020, an average 6.5x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.4x decrease against the full P.1 type vs WA-1 was observed, with  better full P.1 ID50 reciprocal value compared to the 10-mutation model.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	11368	172.0	11387						39	T=11329	11329	T	C	homoplasy	Borges et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.19.444774v1		In experimental models of SARS-CoV-2 mutational evolution (without immune pressure), this mutation in the N terminal domain appears convergent. 	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	11368	172.0	11387						39	T=11329	11329	T	C	outcome hazard ratio	Funk et al. (2021)	https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2021.26.16.2100348	'L18F', 'K417T', 'E484K', 'N501Y'	On average across 7 European countries studied, using P.1 defining mutations: Significant shift to infection in those without pre-existing conditions (27.8% vs 89% for non-VOC cases). Significant increase in hospitalization rate (20% vs 7.5% for non-VOC cases). Significant increase in ICU rate (2.1% vs 0.6% for non-VOC cases). Significant increase in health care worker rate (19.8% vs 8.0% for non-VOC cases).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	11368	172.0	11387						39	T=11329	11329	T	C	outcome hazard ratio	Ribas Freitas et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.04.13.21255281v1	'L18F', 'K417T', 'E484K', 'N501Y'	In the Southern Brazilian stats of Rio Grande do Sul, comparing pre-P.1 and post-P.1 waves:  The increase in Case Fatality Rate occurred in a greatest intensity in the population between 20 and 59 years old and among patients without pre-existing risk conditions. Female 20 to 39 years old, with no pre-existing risk conditions, were at risk of death 5.65 times higher in February (95%CI 	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	11368	172.0	11387						39	T=11329	11329	T	C	outcome hazard ratio	Santos de Oliviera et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.03.24.21254046v1	'L18F', 'K417T', 'E484K', 'N501Y'	In the Parana state of Brazil, patients aged 20-29 years experienced a tripling of their case fatality rate (CFR), from 0.04% to 0.13%, while those aged  30-39, 40-49, 50-59 experienced approximate CFR doubling comparing February to January in 2021. Notably,  the observed CFR increase coincided with the second consecutive month of declining number of diagnosed SARS-CoV-2 cases.  Taken together, these preliminary findings suggest significant increases in CFR in young and middle-aged adults after  identification of a novel SARS-CoV-2 strain circulating in Brazil.  [this is somewhat indirect evidence that assume greatly increasing proportion of P.1 cases in March (70%) compared to  February, but the first official ID of P.1 in Parana state (Feb 16th) may be due to testing procedures rather than actual prevalence]	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	11368	172.0	11387						39	T=11329	11329	T	C	pharmaceutical effectiveness	Hoffman et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.036	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'T1027I', 'V1176F'	VSV pseudotype P.1 entry mediated by the S proteins of the P.1 variant was completely resistant to blocking by REGN10989 and Bamlanivimab. Cell fusion proficiency was slight impaired. Entry driven by the S proteins of the B.1.351 was partially resistant against Casirivimab.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	11368	172.0	11387						39	T=11329	11329	T	C	reinfection	Malta Romano et al. (2021)	https://doi.org/10.1590/s1678-9946202163036	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'T1027I'	After a 128 day interval, a patient in Sao Paulo State, Brazil reinfected with P.1 (first episode likely predates P.1 emergence). Both cases were fairly mild (difficulty breathing, tiredness, dizziness and fatigue).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	11368	172.0	11387						39	T=11329	11329	T	C	trafficking	Esclera et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.05.455290v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'T1027I'	~6x cleavage of S2 relative to WA1 (D614G) wildtype by Gamma variant as measured by mass spectrometry of Vero-TMPRSS culture  [no mutations directly at furin cleavage site, but H655Y is upstream] Compare to 4.5x or less for variants of concern with  direct furin clevage site mutations.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	11368	172.0	11387						39	T=11329	11329	T	C	trafficking	Hoffman et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.036	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'T1027I', 'V1176F'	VSV pseudotype P.1 showed slight decrease in cell entry relative to wild type in 262T and 263T-ACE2 (kidney) cell lines. Cell fusion proficiency was slight impaired.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	11368	172.0	11387						39	T=11329	11329	T	C	transmissibility	Stefanelli et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.04.06.21254923v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'E484K', 'N501Y', 'D614G'	The relative transmissibility of P.1 estimated at the national level (Italy) varied according to the assumed  degree of cross-protection granted by infection with other lineages and ranged from 1.12 (95%CI 1.03-1.23) in the  case of complete immune evasion by P.1 to 1.39 (95%CI 1.26-1.56) in the case of complete cross-protection. PG: variant list has been abbreviated due to mixed K417 bases in this lineage, potential miscalls of deletions	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	11368	172.0	11387						39	T=11329	11329	T	C	vaccine neutralization efficacy	Alenquer et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'T1027I'	Using P.1 defining mutations for Spike, observed 4x average decrease in neutralization efficiency  (but still relevant titres) for sera from 10 BNT162b2 vaccinees 12 days after second dose, but only one  relevant titre 12 days after first dose. Compares unfavorably to wild type or B.1.1.7 titres.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	11368	172.0	11387						39	T=11329	11329	T	C	vaccine neutralization efficacy	Andrade et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.14.439719v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'T1027I'	In human sera 8 weeks post-vaccination with INO-4800, a ~2-fold reduction in P.1 neutralization was observed.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	11368	172.0	11387						39	T=11329	11329	T	C	vaccine neutralization efficacy	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'T1027I', 'V1176F'	The neutralizing activity of vaccine was slightly lower against B.1.1.248 variant constellation in sera tested from most of the 15 patients with  the BNT162b2 mRNA vaccine. (Fig. 4)	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	11368	172.0	11387						39	T=11329	11329	T	C	vaccine neutralization efficacy	Choi et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'T1027I', 'V1176F'	Neutralization efficiency (ID50) against P.1 reduced 3.2x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	11368	172.0	11387						39	T=11329	11329	T	C	vaccine neutralization efficacy	Gallagher et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.03.442455v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'T1027I', 'V1176F'	ELISpot assays show T cell neutralization reduced by 16.6% in this B.1.1.248 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose, with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	11368	172.0	11387						39	T=11329	11329	T	C	vaccine neutralization efficacy	Garcia-Beltran et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.013	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'T1027I', 'V1176F'	Pseudotyped P.1 virus has reduced neutralization activity vs wild type: 6.7x (30 sera Pfizer median 9 days post 2nd dose)  and 4.5x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	11368	172.0	11387						39	T=11329	11329	T	C	vaccine neutralization efficacy	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'T1027I', 'V1176F'	1.15x *increase* in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees)	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	11368	172.0	11387						39	T=11329	11329	T	C	vaccine neutralization efficacy	Hitchlings et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.04.07.21255081v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'T1027I'	Among 46,884 HCWs in Manaus, Brazil vaccinated with at least one dose of CoronaVac, a 0.50-fold reduction (adjusted vaccine  effectiveness, 49.6%: 95% CI, 11.3 - 71.4) in the odds of  symptomatic SARS-CoV-2 infection was observed during the period 14 days or more after receiving the first dose. Estimated vaccine effectiveness of at least one dose against any SARS-CoV-2 infection was 35.1% (95% CI, −6.6 - 60.5) in the same time period.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	11368	172.0	11387						39	T=11329	11329	T	C	vaccine neutralization efficacy	Hoffman et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.036	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'T1027I', 'V1176F'	VSV pseudotype P.1 showed 5.12-fold reduction in neutralization efficiency vs wild type in 15 Pfizer BNT162b2 vaccinee sera 13-15 days post second dose. Cell fusion proficiency was slight impaired.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	11368	172.0	11387						39	T=11329	11329	T	C	vaccine neutralization efficacy	Leier et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.04.25.21256049v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'T1027I', 'V1176F'	Neutralizing antibody titers increased in previously infected vaccinees relative to uninfected vaccinees  4.3-fold against P.1 (contrast with 3.4 fold against original SARS-CoV-2).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	11368	172.0	11387						39	T=11329	11329	T	C	vaccine neutralization efficacy	Tarke et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.27.433180v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'T1027I', 'V1176F'	PBMCs of Pfizer/BioNTech BNT162b2 (n	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	11368	172.0	11387						39	T=11329	11329	T	C	vaccine neutralization efficacy	Wang et al. (2021)	https://dx.doi.org/10.1101%2F2021.03.01.433466	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G'	In 12 Moderna vaccinee sera 15 days post second dose (43 days since first vaccination), an average 2.8x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 4.8x decrease against the full P.1 type vs WA-1 was observed, though overall with  a higher ID50 reciprocal value. In 10 Pfizer vaccinee sera 7 days or more post second dose (28 days or more since first vaccination), an average 2.2x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.8x decrease against the full P.1 type vs WA-1 was observed, with  similar variant ID50 reciprocal value.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	11368	172.0	11387						39	T=11329	11329	T	C	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.04x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	11368	172.0	11387						39	T=11329	11329	T	C	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G', 'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'T1027I'	This variant combination (representing P.1 aka Gamma)  showed a 1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.27x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	11368	172.0	11387						39	T=11329	11329	T	C	virion structure	Spratt et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1		Estimated free energy change (ddG) for this variant is 0.87 kcal/mol (i.e. stabilizing relative to wild type) 	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	11368	172.0	11387						39	T=11329	11329	T	C	virion structure	Wang et al. (2021)	https://dx.doi.org/10.1101%2F2021.03.01.433466	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G'	CryoEM reveals the P.1 trimer to adopt exclusively a conformation in which one of the receptor-binding domains is in the “up” position.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.I2346T	c.T7037C	p.I2346T			7302	orf1ab	ORF1ab	MISSENSE	4	4.0	11387			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	3	C=1	1	C	T						False	P.1.12	P.1.12=False	VOC		11-Jan-2021	
p.I285I	c.T855C	p.I285I			22417	S	S	SILENT	1	1.0	11387						0	C=1	1	C	T						False	P.1.15	P.1.15=True	VOC		11-Jan-2021	
p.K1795Q	c.A5383C	p.K1795Q			5648	orf1ab	ORF1ab	MISSENSE	11387	172.0	11387			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	0	C=11387	11387	C	A						False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	11372	172.0	11387						0	C=11372	11372	C	A	ACE2 receptor binding affinity	Barton et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1		The K417T mutation decreased the affinity ~2 fold, mainly by decreasing the k(on) but also by increasing the k(off) as measured by surface plasmon resonance.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	11372	172.0	11387						0	C=11372	11372	C	A	ACE2 receptor binding affinity	Barton et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1	'E484K', 'N501Y'	The affinity of the P.1 RBD variants for ACE2 increased by 5.3 fold as measured by surface plasmon resonance relative to wild  type RBD by increasing the k(on) and decreasing the k(off) rate constants. 	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	11372	172.0	11387						0	C=11372	11372	C	A	ACE2 receptor binding affinity	Dejnirattisai et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.055	'E484K', 'N501Y', 'D614G'	The KD for the pseudotyped P.1-ACE2 interaction is 4.8 nM, showing that binding to P.1 is essentially indistinguishable from B.1.351 (4.0 nM), which binds with ~19x greater affinity that wild type.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	11372	172.0	11387						0	C=11372	11372	C	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.28x increase in binding (KD) relative to D614G.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	11372	172.0	11387						0	C=11372	11372	C	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G', 'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'E484K', 'N501Y', 'H655Y', 'T1027I'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing P.1 aka Gamma)  showed a 4.24x increase in binding (KD) relative to D614G.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	11372	172.0	11387						0	C=11372	11372	C	A	anthropozoonotic events	Montagutelli et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.18.436013v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	Unlike wild type or B.1.1.7, P.1 lineage virus was able to infect and replicate in common lab mouse strains, with high titer.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	11372	172.0	11387						0	C=11372	11372	C	A	antibody epitope effects	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	B.1.1.248 variant constellation ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07. B.1.1.248 variant constellation ablates Class 3 N-terminal domain targeting antibody COV2-2676.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	11372	172.0	11387						0	C=11372	11372	C	A	antibody epitope effects	Wang et al. (2021)	https://dx.doi.org/10.1101%2F2021.03.01.433466	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'E484K', 'N501Y', 'D614G', 'H655Y'	Amongst RBD-targeting Emergency Use Authorized monoclonal antibody treatments CB6, LY-CoV555 and REGN10933 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1, but REGN10987 activity remains strong. RBD-targeting monoclonal antibodies 2-15 and C121 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1. N terminal domain targeting monoclonal antibodies 5-7, 4-8, 4-18 and 2-17 have abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	11372	172.0	11387						0	C=11372	11372	C	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.65x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	11372	172.0	11387						0	C=11372	11372	C	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G', 'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'E484K', 'N501Y', 'H655Y', 'T1027I'	This variant combination (representing P.1 aka Gamma)  showed a 1.3x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	11372	172.0	11387						0	C=11372	11372	C	A	convalescent plasma escape	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	B.1.1.248 variant constellation in 10 convalescent human sera ~1mo post infection had mild to moderate resistence against most samples, P	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	11372	172.0	11387						0	C=11372	11372	C	A	convalescent plasma escape	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	B.1.1.7 variant constellation two-tailed Wilcoxon matched-pairs signed-rank test against 10 convalescent sera P	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	11372	172.0	11387						0	C=11372	11372	C	A	convalescent plasma escape	Hoffman et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.036	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	VSV pseudotype P.1 showed 4.8-fold decrease in NT50 vs wild type in sera from 9 ICU patients undergoing treatment in Germany (pre-variant infections).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	11372	172.0	11387						0	C=11372	11372	C	A	convalescent plasma escape	Luftig et al. (2021)	https://doi.org/10.1056/nejmc2104036	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	In sera from six patients collected 1 to 12 weeks post-infection with B.1, antibody titer in a microneutralization assay was on average 71.46 for P.1 virus. Compare to much stronger neutralization titers for B.1.1.7 (256) and wild type (456.1) in the same sera. 	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	11372	172.0	11387						0	C=11372	11372	C	A	convalescent plasma escape	McCallum et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	In 13 plasma collected ~1mo after B.1.1.7 infection (nursing home in Ticino, Switzerland), neutralization  reduced to undetectable levels in many plasma for P.1 pseudotyped virus, as well as WT and other VOCs.  [paper does not detail the P.1 variants used, using the most popular as a stand in]	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	11372	172.0	11387						0	C=11372	11372	C	A	convalescent plasma escape	Mendes-Correa et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.05.11.21256908v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	Neutralizing antibodies that were generated following a mild infection with SARS-CoV-2 B.1.128 were effective in vitro,  and likely protective, against the SARS-CoV-2 P.1. variant in the majority of individuals based on 60 convalescent sera tested.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	11372	172.0	11387						0	C=11372	11372	C	A	convalescent plasma escape	Tang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.19.436183v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	Loss of neutralizing activity (PsVNA50 assay) using 6 hyperimmune immunoglobulin preparations from convalescent plasma was seen against P.1 (3.5-fold). Neutralization against 10 convalescent plasma was slightly poorer (3.9-fold).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	11372	172.0	11387						0	C=11372	11372	C	A	convalescent plasma escape	Wang et al. (2021)	https://dx.doi.org/10.1101%2F2021.03.01.433466	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'E484K', 'N501Y', 'D614G', 'H655Y'	In convalescent sera one month or more post-infection in Spring 2020, an average 6.5x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.4x decrease against the full P.1 type vs WA-1 was observed, with  better full P.1 ID50 reciprocal value compared to the 10-mutation model.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	11372	172.0	11387						0	C=11372	11372	C	A	gene expression increase	Starr et al. (2020)	https://doi.org/10.1016/j.cell.2020.08.012		Experimentally, Spike gene expression increased 0.25 fold	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	11372	172.0	11387						0	C=11372	11372	C	A	monoclonal antibody serial passage escape	Starr et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1		Escape mutation against monoclonal antibody LY-CoV016	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	11372	172.0	11387						0	C=11372	11372	C	A	monoclonal antibody serial passage escape	Wang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2		In vitro selection against class 1 antibody C682	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	11372	172.0	11387						0	C=11372	11372	C	A	outcome hazard ratio	Funk et al. (2021)	https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2021.26.16.2100348	'L18F', 'E484K', 'N501Y', 'H655Y'	On average across 7 European countries studied, using P.1 defining mutations: Significant shift to infection in those without pre-existing conditions (27.8% vs 89% for non-VOC cases). Significant increase in hospitalization rate (20% vs 7.5% for non-VOC cases). Significant increase in ICU rate (2.1% vs 0.6% for non-VOC cases). Significant increase in health care worker rate (19.8% vs 8.0% for non-VOC cases).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	11372	172.0	11387						0	C=11372	11372	C	A	outcome hazard ratio	Ribas Freitas et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.04.13.21255281v1	'L18F', 'E484K', 'N501Y', 'H655Y'	In the Southern Brazilian stats of Rio Grande do Sul, comparing pre-P.1 and post-P.1 waves:  The increase in Case Fatality Rate occurred in a greatest intensity in the population between 20 and 59 years old and among patients without pre-existing risk conditions. Female 20 to 39 years old, with no pre-existing risk conditions, were at risk of death 5.65 times higher in February (95%CI 	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	11372	172.0	11387						0	C=11372	11372	C	A	outcome hazard ratio	Santos de Oliviera et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.03.24.21254046v1	'L18F', 'E484K', 'N501Y', 'H655Y'	In the Parana state of Brazil, patients aged 20-29 years experienced a tripling of their case fatality rate (CFR), from 0.04% to 0.13%, while those aged  30-39, 40-49, 50-59 experienced approximate CFR doubling comparing February to January in 2021. Notably,  the observed CFR increase coincided with the second consecutive month of declining number of diagnosed SARS-CoV-2 cases.  Taken together, these preliminary findings suggest significant increases in CFR in young and middle-aged adults after  identification of a novel SARS-CoV-2 strain circulating in Brazil.  [this is somewhat indirect evidence that assume greatly increasing proportion of P.1 cases in March (70%) compared to  February, but the first official ID of P.1 in Parana state (Feb 16th) may be due to testing procedures rather than actual prevalence]	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	11372	172.0	11387						0	C=11372	11372	C	A	pharmaceutical effectiveness	Engelhart et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1		COR-101 lost ~16x binding against this isolated mutation. Estesevimab lost ~16x binding against this isolated mutation. m396 lost ~8x binding against this isolated mutation.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	11372	172.0	11387						0	C=11372	11372	C	A	pharmaceutical effectiveness	Engelhart et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1	'E484K', 'N501Y'	Tixagevimab, Regdanvimab and COR-101 display reduced binding affinity to virus pseudotyped as RBD from P.1.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	11372	172.0	11387						0	C=11372	11372	C	A	pharmaceutical effectiveness	Hoffman et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.036	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	VSV pseudotype P.1 entry mediated by the S proteins of the P.1 variant was completely resistant to blocking by REGN10989 and Bamlanivimab. Cell fusion proficiency was slight impaired. Entry driven by the S proteins of the B.1.351 was partially resistant against Casirivimab.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	11372	172.0	11387						0	C=11372	11372	C	A	reinfection	Malta Romano et al. (2021)	https://doi.org/10.1590/s1678-9946202163036	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I'	After a 128 day interval, a patient in Sao Paulo State, Brazil reinfected with P.1 (first episode likely predates P.1 emergence). Both cases were fairly mild (difficulty breathing, tiredness, dizziness and fatigue).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	11372	172.0	11387						0	C=11372	11372	C	A	trafficking	Esclera et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.05.455290v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I'	~6x cleavage of S2 relative to WA1 (D614G) wildtype by Gamma variant as measured by mass spectrometry of Vero-TMPRSS culture  [no mutations directly at furin cleavage site, but H655Y is upstream] Compare to 4.5x or less for variants of concern with  direct furin clevage site mutations.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	11372	172.0	11387						0	C=11372	11372	C	A	trafficking	Hoffman et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.036	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	VSV pseudotype P.1 showed slight decrease in cell entry relative to wild type in 262T and 263T-ACE2 (kidney) cell lines. Cell fusion proficiency was slight impaired.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	11372	172.0	11387						0	C=11372	11372	C	A	vaccine neutralization efficacy	Alenquer et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'E484K', 'N501Y', 'H655Y', 'T1027I'	Using P.1 defining mutations for Spike, observed 4x average decrease in neutralization efficiency  (but still relevant titres) for sera from 10 BNT162b2 vaccinees 12 days after second dose, but only one  relevant titre 12 days after first dose. Compares unfavorably to wild type or B.1.1.7 titres.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	11372	172.0	11387						0	C=11372	11372	C	A	vaccine neutralization efficacy	Andrade et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.14.439719v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'E484K', 'N501Y', 'H655Y', 'T1027I'	In human sera 8 weeks post-vaccination with INO-4800, a ~2-fold reduction in P.1 neutralization was observed.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	11372	172.0	11387						0	C=11372	11372	C	A	vaccine neutralization efficacy	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	The neutralizing activity of vaccine was slightly lower against B.1.1.248 variant constellation in sera tested from most of the 15 patients with  the BNT162b2 mRNA vaccine. (Fig. 4)	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	11372	172.0	11387						0	C=11372	11372	C	A	vaccine neutralization efficacy	Choi et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	Neutralization efficiency (ID50) against P.1 reduced 3.2x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	11372	172.0	11387						0	C=11372	11372	C	A	vaccine neutralization efficacy	Gallagher et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.03.442455v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	ELISpot assays show T cell neutralization reduced by 16.6% in this B.1.1.248 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose, with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	11372	172.0	11387						0	C=11372	11372	C	A	vaccine neutralization efficacy	Garcia-Beltran et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.013	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	Pseudotyped P.1 virus has reduced neutralization activity vs wild type: 6.7x (30 sera Pfizer median 9 days post 2nd dose)  and 4.5x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	11372	172.0	11387						0	C=11372	11372	C	A	vaccine neutralization efficacy	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	1.15x *increase* in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees)	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	11372	172.0	11387						0	C=11372	11372	C	A	vaccine neutralization efficacy	Hitchlings et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.04.07.21255081v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'E484K', 'N501Y', 'H655Y', 'T1027I'	Among 46,884 HCWs in Manaus, Brazil vaccinated with at least one dose of CoronaVac, a 0.50-fold reduction (adjusted vaccine  effectiveness, 49.6%: 95% CI, 11.3 - 71.4) in the odds of  symptomatic SARS-CoV-2 infection was observed during the period 14 days or more after receiving the first dose. Estimated vaccine effectiveness of at least one dose against any SARS-CoV-2 infection was 35.1% (95% CI, −6.6 - 60.5) in the same time period.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	11372	172.0	11387						0	C=11372	11372	C	A	vaccine neutralization efficacy	Hoffman et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.036	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	VSV pseudotype P.1 showed 5.12-fold reduction in neutralization efficiency vs wild type in 15 Pfizer BNT162b2 vaccinee sera 13-15 days post second dose. Cell fusion proficiency was slight impaired.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	11372	172.0	11387						0	C=11372	11372	C	A	vaccine neutralization efficacy	Leier et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.04.25.21256049v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	Neutralizing antibody titers increased in previously infected vaccinees relative to uninfected vaccinees  4.3-fold against P.1 (contrast with 3.4 fold against original SARS-CoV-2).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	11372	172.0	11387						0	C=11372	11372	C	A	vaccine neutralization efficacy	Tarke et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.27.433180v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	PBMCs of Pfizer/BioNTech BNT162b2 (n	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	11372	172.0	11387						0	C=11372	11372	C	A	vaccine neutralization efficacy	Wang et al. (2021)	https://dx.doi.org/10.1101%2F2021.03.01.433466	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'E484K', 'N501Y', 'D614G', 'H655Y'	In 12 Moderna vaccinee sera 15 days post second dose (43 days since first vaccination), an average 2.8x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 4.8x decrease against the full P.1 type vs WA-1 was observed, though overall with  a higher ID50 reciprocal value. In 10 Pfizer vaccinee sera 7 days or more post second dose (28 days or more since first vaccination), an average 2.2x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.8x decrease against the full P.1 type vs WA-1 was observed, with  similar variant ID50 reciprocal value.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	11372	172.0	11387						0	C=11372	11372	C	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.04x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.1x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	11372	172.0	11387						0	C=11372	11372	C	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G', 'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'E484K', 'N501Y', 'H655Y', 'T1027I'	This variant combination (representing P.1 aka Gamma)  showed a 1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.27x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	11372	172.0	11387						0	C=11372	11372	C	A	virion structure	Spratt et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1		Estimated free energy change (ddG) for this variant is -0.64 kcal/mol (i.e. destabilizing relative to wild type) 	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.K417T	c.A1250C	p.K417T			22812	S	S	MISSENSE	11372	172.0	11387						0	C=11372	11372	C	A	virion structure	Wang et al. (2021)	https://dx.doi.org/10.1101%2F2021.03.01.433466	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'E484K', 'N501Y', 'D614G', 'H655Y'	CryoEM reveals the P.1 trimer to adopt exclusively a conformation in which one of the receptor-binding domains is in the “up” position.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.K4783R	c.A14348G	p.K4783R			14612	orf1ab	ORF1ab	MISSENSE	4	4.0	11387			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only	YP_009725307.1	3	G=1	1	G	A						False	P.1.10	P.1.10=False	VOC		11-Jan-2021	
p.L1621L	c.T4861C	p.L1621L			5126	orf1ab	ORF1ab	SILENT	26	26.0	11387			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	6	C=20	20	C	T						False	P.1.17	P.1.17=True	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	C	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.07x decrease in binding (KD) relative to D614G. Compare to increased binding in full Spike variant complements for major lineages containing this variant subset: 3.56x (B.1.351 aka Beta), 4.24x (P.1 aka Gamma).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	C	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing P.1 aka Gamma)  showed a 4.24x increase in binding (KD) relative to D614G.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	C	anthropozoonotic events	Montagutelli et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.18.436013v1	'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	Unlike wild type or B.1.1.7, P.1 lineage virus was able to infect and replicate in common lab mouse strains, with high titer.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	C	antibody epitope effects	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 	'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	B.1.1.248 variant constellation ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07. B.1.1.248 variant constellation ablates Class 3 N-terminal domain targeting antibody COV2-2676.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	C	antibody epitope effects	Dejnirattisai et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.055	'T20N', 'P26S', 'D138Y', 'R190S'	"The neutralization titer of NTD-binding mAb159 was 133-fold reduced on P.1 compared to Victoria (~wild type), with only 64% neutralization at 10 μg/mL.  Residues 20, 18, and 138 form a cluster underlying the 245–259 loop, which inserts into a groove between the light and heavy chains of Fab 159. In addition, the N-terminal residues preceding residue 18 interact with the antibody and may be perturbed.  Given that there is likely a single supersite (""i"") for potent NTD-binding antibodies, the binding of many of these are likely affected. Using 20 potent (primaruly anti-RBD) antibodies, neutralization was measured by a focus reduction neutralization test (FRNT) and compared with  neutralization of Victoria (~wild type) and variants B.1.1.7 and B.1.351. Compared to Victoria neutralization by the mAbs was significantly impacted by P.1,  with 12/20 showing > 10-fold reduction in FRNT50 titer and a number showing complete knockout of activity. The results with P.1 showed a  greater impact compared to B.1.1.7 but were, as expected, similar to those with B.1.351."	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	C	antibody epitope effects	McCallum et al. (2021)	https://doi.org/10.1101/2021.01.14.426475		"Massive reduction in S2L28 monoclonal antibody EC50 (i.e. ablated recognition), within antigenic supersite ""i"", but no effect on other mAbs within that supersite"	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	C	antibody epitope effects	Wang et al. (2021)	https://www.nature.com/articles/s41586-021-03398-2		Ablates neutralization by N-terminal-domain-targeting mAbs 4-19. Impairs neutralization by N-terminal-domain-targeting mAbs 4A8 and 2-17.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	C	antibody epitope effects	Wang et al. (2021)	https://dx.doi.org/10.1101%2F2021.03.01.433466	'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y'	Amongst RBD-targeting Emergency Use Authorized monoclonal antibody treatments CB6, LY-CoV555 and REGN10933 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1, but REGN10987 activity remains strong. RBD-targeting monoclonal antibodies 2-15 and C121 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1. N terminal domain targeting monoclonal antibodies 5-7, 4-8, 4-18 and 2-17 have abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	C	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.66x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset. Compare to decreased binding in full Spike variant complements for major lineages containing this variant subset: 0.96x (B.1.351 aka Beta), 0.77x (P.1 aka Gamma).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	C	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	This variant combination (representing P.1 aka Gamma)  showed a 1.3x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	C	convalescent plasma escape	Cele et al. (2021)	https://www.krisp.org.za/manuscripts/MEDRXIV-2021-250224v1-Sigal.pdf		The 501Y.V2 to first wave IC50 ratio ranged from 6 to 200-fold. Averaging across all 7 participant convalescent sera highlighted the dramatic decrease in sensitivity to neutralization of authentic 501Y.V2 variants. PG: I'm purposefully ignoring D614G and A701V as contributors	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	C	convalescent plasma escape	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 	'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	B.1.1.248 variant constellation in 10 convalescent human sera ~1mo post infection had mild to moderate resistence against most samples, P	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	C	convalescent plasma escape	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 	'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	B.1.1.7 variant constellation two-tailed Wilcoxon matched-pairs signed-rank test against 10 convalescent sera P	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	C	convalescent plasma escape	Hoffman et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.036	'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	VSV pseudotype P.1 showed 4.8-fold decrease in NT50 vs wild type in sera from 9 ICU patients undergoing treatment in Germany (pre-variant infections).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	C	convalescent plasma escape	Luftig et al. (2021)	https://doi.org/10.1056/nejmc2104036	'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	In sera from six patients collected 1 to 12 weeks post-infection with B.1, antibody titer in a microneutralization assay was on average 71.46 for P.1 virus. Compare to much stronger neutralization titers for B.1.1.7 (256) and wild type (456.1) in the same sera. 	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	C	convalescent plasma escape	McCallum et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1	'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	In 13 plasma collected ~1mo after B.1.1.7 infection (nursing home in Ticino, Switzerland), neutralization  reduced to undetectable levels in many plasma for P.1 pseudotyped virus, as well as WT and other VOCs.  [paper does not detail the P.1 variants used, using the most popular as a stand in]	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	C	convalescent plasma escape	Mendes-Correa et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.05.11.21256908v1	'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	Neutralizing antibodies that were generated following a mild infection with SARS-CoV-2 B.1.128 were effective in vitro,  and likely protective, against the SARS-CoV-2 P.1. variant in the majority of individuals based on 60 convalescent sera tested.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	C	convalescent plasma escape	Tang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.19.436183v1	'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	Loss of neutralizing activity (PsVNA50 assay) using 6 hyperimmune immunoglobulin preparations from convalescent plasma was seen against P.1 (3.5-fold). Neutralization against 10 convalescent plasma was slightly poorer (3.9-fold).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	C	convalescent plasma escape	Wang et al. (2021)	https://dx.doi.org/10.1101%2F2021.03.01.433466	'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y'	In convalescent sera one month or more post-infection in Spring 2020, an average 6.5x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.4x decrease against the full P.1 type vs WA-1 was observed, with  better full P.1 ID50 reciprocal value compared to the 10-mutation model.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	C	convalescent plasma escape	Wibmer et al. (2021)	https://doi.org/10.1101/2021.01.18.427166		"Nearly half (21 of 44, 48%) of early pandemic exposure convalescent plasma/sera failed to neutralize the 501Y.V2 (""South African"") lineage pseudovirus construct Only 3 of 44 convascent sera (those with the highest titer, which correlated direectly with initial infection severity) had high neutralization against this 501Y.V2  PG: note that lineage variant R246I was excluded from the text in reference to these sera assays, not sure if that was an oversight."	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	C	outcome hazard ratio	Funk et al. (2021)	https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2021.26.16.2100348	'K417T', 'E484K', 'N501Y', 'H655Y'	On average across 7 European countries studied, using P.1 defining mutations: Significant shift to infection in those without pre-existing conditions (27.8% vs 89% for non-VOC cases). Significant increase in hospitalization rate (20% vs 7.5% for non-VOC cases). Significant increase in ICU rate (2.1% vs 0.6% for non-VOC cases). Significant increase in health care worker rate (19.8% vs 8.0% for non-VOC cases).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	C	outcome hazard ratio	Ribas Freitas et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.04.13.21255281v1	'K417T', 'E484K', 'N501Y', 'H655Y'	In the Southern Brazilian stats of Rio Grande do Sul, comparing pre-P.1 and post-P.1 waves:  The increase in Case Fatality Rate occurred in a greatest intensity in the population between 20 and 59 years old and among patients without pre-existing risk conditions. Female 20 to 39 years old, with no pre-existing risk conditions, were at risk of death 5.65 times higher in February (95%CI 	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	C	outcome hazard ratio	Santos de Oliviera et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.03.24.21254046v1	'K417T', 'E484K', 'N501Y', 'H655Y'	In the Parana state of Brazil, patients aged 20-29 years experienced a tripling of their case fatality rate (CFR), from 0.04% to 0.13%, while those aged  30-39, 40-49, 50-59 experienced approximate CFR doubling comparing February to January in 2021. Notably,  the observed CFR increase coincided with the second consecutive month of declining number of diagnosed SARS-CoV-2 cases.  Taken together, these preliminary findings suggest significant increases in CFR in young and middle-aged adults after  identification of a novel SARS-CoV-2 strain circulating in Brazil.  [this is somewhat indirect evidence that assume greatly increasing proportion of P.1 cases in March (70%) compared to  February, but the first official ID of P.1 in Parana state (Feb 16th) may be due to testing procedures rather than actual prevalence]	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	C	pharmaceutical effectiveness	Hoffman et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.036	'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	VSV pseudotype P.1 entry mediated by the S proteins of the P.1 variant was completely resistant to blocking by REGN10989 and Bamlanivimab. Cell fusion proficiency was slight impaired. Entry driven by the S proteins of the B.1.351 was partially resistant against Casirivimab.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	C	reinfection	Malta Romano et al. (2021)	https://doi.org/10.1590/s1678-9946202163036	'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I'	After a 128 day interval, a patient in Sao Paulo State, Brazil reinfected with P.1 (first episode likely predates P.1 emergence). Both cases were fairly mild (difficulty breathing, tiredness, dizziness and fatigue).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	C	trafficking	Esclera et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.05.455290v1	'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I'	~6x cleavage of S2 relative to WA1 (D614G) wildtype by Gamma variant as measured by mass spectrometry of Vero-TMPRSS culture  [no mutations directly at furin cleavage site, but H655Y is upstream] Compare to 4.5x or less for variants of concern with  direct furin clevage site mutations.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	C	trafficking	Hoffman et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.036	'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	VSV pseudotype P.1 showed slight decrease in cell entry relative to wild type in 262T and 263T-ACE2 (kidney) cell lines. Cell fusion proficiency was slight impaired.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	C	trafficking	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1		Lentiviral pseudotyped with this individual mutation from B.1.351 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing mild decrease in infection rate amongst the cells, suggetsing that this  mutation does not contributing to cell entry fitness.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	C	transmissibility	Stefanelli et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.04.06.21254923v1	'T20N', 'P26S', 'D138Y', 'R190S', 'E484K', 'N501Y', 'D614G', 'H655Y'	The relative transmissibility of P.1 estimated at the national level (Italy) varied according to the assumed  degree of cross-protection granted by infection with other lineages and ranged from 1.12 (95%CI 1.03-1.23) in the  case of complete immune evasion by P.1 to 1.39 (95%CI 1.26-1.56) in the case of complete cross-protection. PG: variant list has been abbreviated due to mixed K417 bases in this lineage, potential miscalls of deletions	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	C	vaccine neutralization efficacy	Alenquer et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1	'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	Using P.1 defining mutations for Spike, observed 4x average decrease in neutralization efficiency  (but still relevant titres) for sera from 10 BNT162b2 vaccinees 12 days after second dose, but only one  relevant titre 12 days after first dose. Compares unfavorably to wild type or B.1.1.7 titres.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	C	vaccine neutralization efficacy	Andrade et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.14.439719v1	'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	In human sera 8 weeks post-vaccination with INO-4800, a ~2-fold reduction in P.1 neutralization was observed.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	C	vaccine neutralization efficacy	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 	'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	The neutralizing activity of vaccine was slightly lower against B.1.1.248 variant constellation in sera tested from most of the 15 patients with  the BNT162b2 mRNA vaccine. (Fig. 4)	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	C	vaccine neutralization efficacy	Choi et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1	'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	Neutralization efficiency (ID50) against P.1 reduced 3.2x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	C	vaccine neutralization efficacy	Gallagher et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.03.442455v1	'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	ELISpot assays show T cell neutralization reduced by 16.6% in this B.1.1.248 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose, with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	C	vaccine neutralization efficacy	Garcia-Beltran et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.013	'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	Pseudotyped P.1 virus has reduced neutralization activity vs wild type: 6.7x (30 sera Pfizer median 9 days post 2nd dose)  and 4.5x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	C	vaccine neutralization efficacy	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	1.15x *increase* in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees)	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	C	vaccine neutralization efficacy	Hitchlings et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.04.07.21255081v1	'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	Among 46,884 HCWs in Manaus, Brazil vaccinated with at least one dose of CoronaVac, a 0.50-fold reduction (adjusted vaccine  effectiveness, 49.6%: 95% CI, 11.3 - 71.4) in the odds of  symptomatic SARS-CoV-2 infection was observed during the period 14 days or more after receiving the first dose. Estimated vaccine effectiveness of at least one dose against any SARS-CoV-2 infection was 35.1% (95% CI, −6.6 - 60.5) in the same time period.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	C	vaccine neutralization efficacy	Hoffman et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.036	'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	VSV pseudotype P.1 showed 5.12-fold reduction in neutralization efficiency vs wild type in 15 Pfizer BNT162b2 vaccinee sera 13-15 days post second dose. Cell fusion proficiency was slight impaired.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	C	vaccine neutralization efficacy	Leier et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.04.25.21256049v1	'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	Neutralizing antibody titers increased in previously infected vaccinees relative to uninfected vaccinees  4.3-fold against P.1 (contrast with 3.4 fold against original SARS-CoV-2).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	C	vaccine neutralization efficacy	Tarke et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.27.433180v1	'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	PBMCs of Pfizer/BioNTech BNT162b2 (n	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	C	vaccine neutralization efficacy	Wang et al. (2021)	https://dx.doi.org/10.1101%2F2021.03.01.433466	'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y'	In 12 Moderna vaccinee sera 15 days post second dose (43 days since first vaccination), an average 2.8x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 4.8x decrease against the full P.1 type vs WA-1 was observed, though overall with  a higher ID50 reciprocal value. In 10 Pfizer vaccinee sera 7 days or more post second dose (28 days or more since first vaccination), an average 2.2x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.8x decrease against the full P.1 type vs WA-1 was observed, with  similar variant ID50 reciprocal value.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	C	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.30x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  Compare to varied binding in full Spike variant complements for major lineages containing this variant subset: 1.28x increase (B.1.351 aka Beta), and 1.14x decrease (P.1 aka Gamma). 1.47x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees. Compare to varied binding in full Spike variant complements for major lineages containing this variant subset: 1.17x increase (B.1.351 aka Beta), and 1.47x decrease (P.1 aka Gamma).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	C	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	This variant combination (representing P.1 aka Gamma)  showed a 1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.27x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	C	virion structure	Wang et al. (2021)	https://dx.doi.org/10.1101%2F2021.03.01.433466	'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y'	CryoEM reveals the P.1 trimer to adopt exclusively a conformation in which one of the receptor-binding domains is in the “up” position.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.L27L	c.C81T	p.L27L			346	orf1ab	ORF1ab	SILENT	26	26.0	11387			leader protein	nsp1, produced by both pp1a and pp1ab	YP_009725297.1	0	T=26	26	T	C						False	P.1.17	P.1.17=True	VOC		11-Jan-2021	
p.L3776L	c.T11328A	p.L3776L			11593	orf1ab	ORF1ab	SILENT	8	8.0	11387			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab	YP_009725302.1	6	A=2	2	A	T						False	P.1.10	P.1.10=False	VOC		11-Jan-2021	
p.L3786L	c.T11356C	p.L3786L			11621	orf1ab	ORF1ab	SILENT	2	2.0	11387			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab	YP_009725302.1	1	C=1	1	C	T						False	P.1.7	P.1.7=False	VOC		11-Jan-2021	
p.L5F	c.C13T	p.L5F			21575	S	S	MISSENSE	2	2.0	11387	mask	highly_homoplasic				1	T=1	1	T	C	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.1x decrease in binding (KD) relative to D614G.	False	P.1.7	P.1.7=False	VOC		11-Jan-2021	
p.L5F	c.C13T	p.L5F			21575	S	S	MISSENSE	2	2.0	11387	mask	highly_homoplasic				1	T=1	1	T	C	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	No change in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	P.1.7	P.1.7=False	VOC		11-Jan-2021	
p.L5F	c.C13T	p.L5F			21575	S	S	MISSENSE	2	2.0	11387	mask	highly_homoplasic				1	T=1	1	T	C	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.23x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.1x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	P.1.7	P.1.7=False	VOC		11-Jan-2021	
p.L6887L	c.G20661A	p.L6887L			20925	orf1ab	ORF1ab	SILENT	6	6.0	11387			2'-O-ribose methyltransferase	nsp16_OMT, 2'-o-MT, produced by pp1ab only	YP_009725311.1	3	A=3	3	A	G						False	P.1.12.1, P.1.12	P.1.12=False, P.1.12.1=True	VOC		11-Jan-2021	
p.L7042L	c.T21124C	p.L7042L			21388	orf1ab	ORF1ab	SILENT	2	2.0	11387			2'-O-ribose methyltransferase	nsp16_OMT, 2'-o-MT, produced by pp1ab only	YP_009725311.1	1	C=1	1	C	T						False	P.1.7	P.1.7=False	VOC		11-Jan-2021	
p.N1109N	c.T3327C	p.N1109N			3592	orf1ab	ORF1ab	SILENT	3	6.0	11387			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	0	C=3	3	C	T						False	P.1.12.1, P.1.12	P.1.12=True, P.1.12.1=True	VOC		11-Jan-2021	
p.N2523N	c.C7569T	p.N2523N			7834	orf1ab	ORF1ab	SILENT	4	4.0	11387			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	3	T=1	1	T	C						False	P.1.10	P.1.10=False	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	ACE2 receptor binding affinity	Barton et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1		The N501Y mutation had the biggest effect on ACE2 affinity of any VOC mutation tested, increasing the affinity ~10 fold to KD ~7 nM, by increasing the k(on) ~1.8 fold and decreasing the k(off) by ~ 7 fold as measured by surface plasmon resonance. 	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	ACE2 receptor binding affinity	Barton et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1	'E484K'	In the case of VOC B.1.1.7+E484K, the addition of the E484K mutation to N501Y further increased the affinity, to ~15 fold higher than WT RBD (KD ~5 nM), by further increasing the k(on) as measured by surface plasmon resonance. Because the higher k(on) could result in mass transfer limiting binding, we confirmed that the kinetic measurement for this variant was not substantially affected by varying levels of immobilization.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	ACE2 receptor binding affinity	Barton et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1	'K417T', 'E484K'	The affinity of the P.1 RBD variants for ACE2 increased by 5.3 fold as measured by surface plasmon resonance relative to wild  type RBD by increasing the k(on) and decreasing the k(off) rate constants. 	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	ACE2 receptor binding affinity	Collier et al. (2021)	https://www.nature.com/articles/s41586-021-03412-7		This combination showed ~3x increase binding to ACE2 vs wild type, about half that of the B.1.1.7 lineage, suggesting that the K417N mutation is slightly detrimental to ACE2 binding, probably as a result of disrupting the salt bridge formed with ACE2 residue D30	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	ACE2 receptor binding affinity	Dejnirattisai et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.055	'K417T', 'E484K', 'D614G'	The KD for the pseudotyped P.1-ACE2 interaction is 4.8 nM, showing that binding to P.1 is essentially indistinguishable from B.1.351 (4.0 nM), which binds with ~19x greater affinity that wild type.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	ACE2 receptor binding affinity	Gamez et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.09.439154v1		The most frequent RBM mutation N501Y (165,519 instances) makes defective the atypical N-glycosylation  sequon NGV 501-503, becoming a key RBM position for the interaction with hACE2-binding hotspot 353.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	"Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.52x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis). Compare to full Spike variant complements for major lineages containing this variant subset: 5.43x (B.1.1.7 aka Alpha), 3.56x (B.1.351 aka Beta), 4.24x (P.1 aka Gamma)."	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G', 'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'H655Y', 'T1027I'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing P.1 aka Gamma)  showed a 4.24x increase in binding (KD) relative to D614G.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	ACE2 receptor binding affinity	Laffeber et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.22.432357v1		RBD containing the N501Y mutation results in 9-fold stronger binding to the hACE2 receptor than  wild type RBD. The E484K mutation does not significantly influence the affinity for the receptor,  while K417N attenuates affinity. As a result, RBD from B.1.351 containing all three mutations binds  3-fold stronger to hACE2 than wild type RBD but 3-fold weaker than N501Y.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	ACE2 receptor binding affinity	Liu et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.02.428884v1		Reported 10-fold increase in ACE2 binding vs wildtype (Kd 	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	ACE2 receptor binding affinity	Liu et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1		Studying the key covariants in lineage of concern 501Y.V2,  observed about 2-fold increase in ACE2 binding vs wildtype, but greatly decreased mAb binding, suggesting evolutionary optimum tension between  immune evasion and ACE2 binding affinity as the N501Y variant alone has 10x increase in affinity but no effect on tested mAb binding.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	ACE2 receptor binding affinity	Motozono et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.02.438288v1		~4-fold increase in binding affinity vs wild type.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	ACE2 receptor binding affinity	Ramanathan et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.22.432359v1		Using Microscale Thermopheresis, this variant binds ACE2 at nearly  two-fold greater affinity than the original SARS-COV-2 RBD (203.7 nM vs 402.5 nM).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	ACE2 receptor binding affinity	Ramanathan et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.22.432359v1		Using Mircoscale Thermopheresis, the B.1.351 variant harboring three mutations, binds ACE2 at nearly  five-fold greater affinity than the original SARS-COV-2 RBD (Kd 87.6, vs 402.5 nM).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	ACE2 receptor binding affinity	Santos and Passos (2021)	https://www.biorxiv.org/content/10.1101/2020.12.29.424708v1		In silico methods (PyMOL and PDBePISA) involving mutagenesis (N501Y mutation) and interface analysis focusing on the Spike  RDB-ACE2 interaction showed that the SARS-CoV-2 N501Y mutant (lineage B.1.1.7) establishes a more significant number of  interactions relating to the mutant residue Y501 (Spike RDB) with residues Y41 and K353 (ACE2). This finding shows that the  increased infectivity of SARS-CoV-2 lineage B.1.1.7 is associated with the interaction force between the Spike RBD Y501  mutant residue with the ACE2 receptor, which in this strain is increased.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	ACE2 receptor binding affinity	Starr et al. (2020)	https://doi.org/10.1016/j.cell.2020.08.012		Experimentally, ACE2 binding affinity increased 0.24 fold	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	ACE2 receptor binding affinity	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1		This single mutation causes major increase in binding affinity vs. wild type as measured by IC50 vs pseudotyped lentivirus,  but combined with the complete set of B.1.1.7   lineage variants no major change vs wild type affnity is observed. 	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	ACE2 receptor binding affinity	Tian et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2		Reported 4-fold increase in affinity compared to wild-type RBD on the cell surface (Kd 	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	ACE2 receptor binding affinity	Tian et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2		Reported slight increase in affinity compared to wild-type RBD on the cell surface (Kd 	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	ACE2 receptor binding affinity	Vogel et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.04.433887v1		The affinity of ACE2 for this mutation combination was twice as high as for wild type. Having in mind that the affinity of SARS-CoV-2 for ACE2 is only 4-fold higher compared to SARS-CoV-1, this factor of 2 is expected to be biologically significant.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	ACE2 receptor binding affinity	Zahradnik et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.06.425392		Among the first selected and fixed variants in an in vitro evolution experiment for ACE2 binding. Calculated disassociation constant for this variant is nearly four fold lower than wild type (Kd 	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	ACE2 receptor binding affinity	Zhu et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.11.426269v2		N501Y residue inserts into a cavity at the binding interface near Y41 of ACE2.  The additional interactions result in increased affinity of ACE2 for the N501Y mutant,  accounting for its increased infectivity.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	T cell evasion	Reynolds et al. (2021)	https://science.sciencemag.org/content/early/2021/04/29/science.abh1282		Vaccinated, but not post-infection sera, show decreased average T cell response to an N501Y peptide. When we primed transgenic mice expressing human HLA-DRB1*0401 with the Wuhan Hu-1 peptide pool,  T cell responses to the B.1.1.7 variant peptide pool were significantly reduced (p 	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	anthropozoonotic events	Montagutelli et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.18.436013v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'D614G', 'H655Y', 'T1027I', 'V1176F'	Unlike wild type or B.1.1.7, P.1 lineage virus was able to infect and replicate in common lab mouse strains, with high titer.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	antibody epitope effects	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 		Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	antibody epitope effects	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 	'E484K'	Ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07, COVOX-384, and S2H58. Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	antibody epitope effects	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'D614G', 'H655Y', 'T1027I', 'V1176F'	B.1.1.248 variant constellation ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07. B.1.1.248 variant constellation ablates Class 3 N-terminal domain targeting antibody COV2-2676.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	antibody epitope effects	Collier et al. (2021)	https://www.nature.com/articles/s41586-021-03412-7		Of 50 mAbs tested, major loss of neutralization observed for S2X128, S2D8, S2X192, S2D19, S2H14, S2H19.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	antibody epitope effects	Haynes et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.01.06.20248960v1		Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 3% to 1.2% (poorer immune recognition) Together with other B1.1.7 lineage mutational changes (Spike: Y144del, A570D, P681H, Nucleoprotein: D3L, S235F) resulted in only 2 or 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	antibody epitope effects	Klegerman et al. (2021)	https://doi.org/10.1101/2021.04.26.441517		Contrary to other reports on N501Y containing lineages (i.e. with additional mutations), N501Y alone may have an even greater affinity for a human monoclonal antibody specific for wild type. These results suggest that the individual N501Y mutation does not contribute to altered viral properties by itself, but may contribute to a collective conformational shift produced by multiple mutations.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	antibody epitope effects	Rees-Spear et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.15.426849v1		Lowered the neutralization potency of mAb COVA1-12 to the limit of the assay. Decrease in potency was observed against the N501Y pseudotype for the cluster IX mAb COVA2-17.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	antibody epitope effects	Shen et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.27.428516v2		Reduction in neutralization by mAbs COVA1-18 (~4x), COVA2-15 (~9x), S309 (~3x)	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	antibody epitope effects	Wang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2		4 antibodies tested were less potent against K417N by ten-fold or more, in both mAb classes 1 and 3	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	antibody epitope effects	Wang et al. (2021)	https://dx.doi.org/10.1101%2F2021.03.01.433466	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'D614G', 'H655Y'	Amongst RBD-targeting Emergency Use Authorized monoclonal antibody treatments CB6, LY-CoV555 and REGN10933 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1, but REGN10987 activity remains strong. RBD-targeting monoclonal antibodies 2-15 and C121 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1. N terminal domain targeting monoclonal antibodies 5-7, 4-8, 4-18 and 2-17 have abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.65x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G', 'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'H655Y', 'T1027I'	This variant combination (representing P.1 aka Gamma)  showed a 1.3x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	convalescent plasma escape	Cele et al. (2021)	https://www.krisp.org.za/manuscripts/MEDRXIV-2021-250224v1-Sigal.pdf		The 501Y.V2 to first wave IC50 ratio ranged from 6 to 200-fold. Averaging across all 7 participant convalescent sera highlighted the dramatic decrease in sensitivity to neutralization of authentic 501Y.V2 variants. PG: I'm purposefully ignoring D614G and A701V as contributors	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	convalescent plasma escape	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 	'E484K'	In 19 convalescent human sera ~1mo post infection had mild to moderate resistence against all samples. 	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	convalescent plasma escape	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'D614G', 'H655Y', 'T1027I', 'V1176F'	B.1.1.248 variant constellation in 10 convalescent human sera ~1mo post infection had mild to moderate resistence against most samples, P	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	convalescent plasma escape	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'D614G', 'H655Y', 'T1027I', 'V1176F'	B.1.1.7 variant constellation two-tailed Wilcoxon matched-pairs signed-rank test against 10 convalescent sera P	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	convalescent plasma escape	Hoffman et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.036	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'H655Y', 'T1027I', 'V1176F'	VSV pseudotype P.1 showed 4.8-fold decrease in NT50 vs wild type in sera from 9 ICU patients undergoing treatment in Germany (pre-variant infections).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	convalescent plasma escape	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008		0.7x reduction in neutralization by key variant in several variants of concern in sera collected from cohort of 10 with severe  disease 21 to 63 days post-onset. 	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	convalescent plasma escape	Luftig et al. (2021)	https://doi.org/10.1056/nejmc2104036	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'H655Y', 'T1027I', 'V1176F'	In sera from six patients collected 1 to 12 weeks post-infection with B.1, antibody titer in a microneutralization assay was on average 71.46 for P.1 virus. Compare to much stronger neutralization titers for B.1.1.7 (256) and wild type (456.1) in the same sera. 	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	convalescent plasma escape	McCallum et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'H655Y', 'T1027I', 'V1176F'	In 13 plasma collected ~1mo after B.1.1.7 infection (nursing home in Ticino, Switzerland), neutralization  reduced to undetectable levels in many plasma for P.1 pseudotyped virus, as well as WT and other VOCs.  [paper does not detail the P.1 variants used, using the most popular as a stand in]	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	convalescent plasma escape	Mendes-Correa et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.05.11.21256908v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'H655Y', 'T1027I', 'V1176F'	Neutralizing antibodies that were generated following a mild infection with SARS-CoV-2 B.1.128 were effective in vitro,  and likely protective, against the SARS-CoV-2 P.1. variant in the majority of individuals based on 60 convalescent sera tested.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	convalescent plasma escape	Rathnasinghe et al. (2021)	https://dx.doi.org/10.1101%2F2021.01.19.21249592		In 30 samples collected 111 to 260 days post onset of symptoms, the covalescent plasma can neutralize both  the reference USA-WA1/2020 strain and the mouse adapted strain that contains the N501Y spike mutation with similar efficiency.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	convalescent plasma escape	Shen et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.27.428516v2		Neutralization activity of convalescent sera tested decreased ~2x with this B.1.1.7 pseudotyped virus.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	convalescent plasma escape	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1		Viruses containing the point mutations of B.1.1.7 showed that the single point mutations (Δ69-70 and N501Y) were neutralized as efficiently as D614G across 10 convalescent sera from April 2020 infectees.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	convalescent plasma escape	Tang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.19.436183v1		As measured by surface plasmon resonance, RBD with the N501Y mutation alone showed a mean 2.1x decrease in binding affinity for  six batches of hyperimmune immunoglobulin (hCoV-2IG) preparations generated from SARS-CoV-2 convalescent plasma.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	convalescent plasma escape	Tang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.19.436183v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'H655Y', 'T1027I', 'V1176F'	Loss of neutralizing activity (PsVNA50 assay) using 6 hyperimmune immunoglobulin preparations from convalescent plasma was seen against P.1 (3.5-fold). Neutralization against 10 convalescent plasma was slightly poorer (3.9-fold).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	convalescent plasma escape	Wang et al. (2021)	https://dx.doi.org/10.1101%2F2021.03.01.433466	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'D614G', 'H655Y'	In convalescent sera one month or more post-infection in Spring 2020, an average 6.5x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.4x decrease against the full P.1 type vs WA-1 was observed, with  better full P.1 ID50 reciprocal value compared to the 10-mutation model.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	convalescent plasma escape	Wibmer et al. (2021)	https://doi.org/10.1101/2021.01.18.427166		"27% of 44 early pandemic exposure convalescent plasma/sera lose all activity against a RBD triple mutant pseudovirus (RBD mutatants of the 501Y.V2 ""South African"" lineage), while only 23% retained high titres "	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	convalescent plasma escape	Wibmer et al. (2021)	https://doi.org/10.1101/2021.01.18.427166		"Nearly half (21 of 44, 48%) of early pandemic exposure convalescent plasma/sera failed to neutralize the 501Y.V2 (""South African"") lineage pseudovirus construct Only 3 of 44 convascent sera (those with the highest titer, which correlated direectly with initial infection severity) had high neutralization against this 501Y.V2  PG: note that lineage variant R246I was excluded from the text in reference to these sera assays, not sure if that was an oversight."	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	environmental condition stability	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1		Relative to D614G, this mutation demonstrated significant increase in infectivity (i.e. heat stability) after incubation at 50C after 30 minutes or 1 hour	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	homoplasy	Flores-Alanis et al. (2021)	https://www.mdpi.com/2076-0817/10/2/184/htm		Variant within the six key residues in the receptor binding domain (RBD). Independently reported in UK, Australia  (same origin as UK), and South Africa (independent origin).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	immunosuppression variant emergence	Choi et al. (2020)	https://www.nejm.org/doi/full/10.1056/NEJMc2031364		Appeared (day 128) and persisted in chronic (152 day) SARS-CoV-2 infection of immunocompromised patient with severe antiphospholipid syndrome	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	monoclonal antibody serial passage escape	Wang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2		In vitro selection against class 1 (Spike 'up' conformation) monoclonal antibody C663, and to a lesser extent C613.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	outcome hazard ratio	Funk et al. (2021)	https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2021.26.16.2100348	'L18F', 'K417T', 'E484K', 'H655Y'	On average across 7 European countries studied, using P.1 defining mutations: Significant shift to infection in those without pre-existing conditions (27.8% vs 89% for non-VOC cases). Significant increase in hospitalization rate (20% vs 7.5% for non-VOC cases). Significant increase in ICU rate (2.1% vs 0.6% for non-VOC cases). Significant increase in health care worker rate (19.8% vs 8.0% for non-VOC cases).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	outcome hazard ratio	Ribas Freitas et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.04.13.21255281v1	'L18F', 'K417T', 'E484K', 'H655Y'	In the Southern Brazilian stats of Rio Grande do Sul, comparing pre-P.1 and post-P.1 waves:  The increase in Case Fatality Rate occurred in a greatest intensity in the population between 20 and 59 years old and among patients without pre-existing risk conditions. Female 20 to 39 years old, with no pre-existing risk conditions, were at risk of death 5.65 times higher in February (95%CI 	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	outcome hazard ratio	Santos de Oliviera et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.03.24.21254046v1	'L18F', 'K417T', 'E484K', 'H655Y'	In the Parana state of Brazil, patients aged 20-29 years experienced a tripling of their case fatality rate (CFR), from 0.04% to 0.13%, while those aged  30-39, 40-49, 50-59 experienced approximate CFR doubling comparing February to January in 2021. Notably,  the observed CFR increase coincided with the second consecutive month of declining number of diagnosed SARS-CoV-2 cases.  Taken together, these preliminary findings suggest significant increases in CFR in young and middle-aged adults after  identification of a novel SARS-CoV-2 strain circulating in Brazil.  [this is somewhat indirect evidence that assume greatly increasing proportion of P.1 cases in March (70%) compared to  February, but the first official ID of P.1 in Parana state (Feb 16th) may be due to testing procedures rather than actual prevalence]	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	pharmaceutical effectiveness	Engelhart et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1		COR-101 lost ~8x binding against this isolated mutation. Regdanvimab lost ~6x binding against this isolated mutation.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	pharmaceutical effectiveness	Engelhart et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1		Tixagevimab, Regdanvimab and COR-101 display reduced binding affinity to virus pseudotyped as RBD from B.1.351.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	pharmaceutical effectiveness	Engelhart et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1	'E484K'	Bamlanivimab (LY-CoV555) lost ~64x binding against this double mutation. COR-101 lost ~50x binding against this double mutation. Casirivimab lost ~250x binding against this double mutation. Estesevimab lost ~16x binding against this double mutation. Regdanvimab lost ~32x binding against this double mutation. Tixagevimab lost ~10x binding against this double mutation.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	pharmaceutical effectiveness	Engelhart et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1	'K417T', 'E484K'	Tixagevimab, Regdanvimab and COR-101 display reduced binding affinity to virus pseudotyped as RBD from P.1.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	pharmaceutical effectiveness	Hoffman et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.036	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'H655Y', 'T1027I', 'V1176F'	VSV pseudotype P.1 entry mediated by the S proteins of the P.1 variant was completely resistant to blocking by REGN10989 and Bamlanivimab. Cell fusion proficiency was slight impaired. Entry driven by the S proteins of the B.1.351 was partially resistant against Casirivimab.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	pharmaceutical effectiveness	Liu et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1		This mutated version of RBD completely abolishes the binding to a therapeutic antibody, Bamlanivimab, in vitro.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	reinfection	Malta Romano et al. (2021)	https://doi.org/10.1590/s1678-9946202163036	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'D614G', 'H655Y', 'T1027I'	After a 128 day interval, a patient in Sao Paulo State, Brazil reinfected with P.1 (first episode likely predates P.1 emergence). Both cases were fairly mild (difficulty breathing, tiredness, dizziness and fatigue).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	syncytium formation	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633	'D614G'	Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, no change relative to D614G.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	syncytium formation	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633	'E484K', 'D614G'	~50% Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, signficantly higher than D614G.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	trafficking	Esclera et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.05.455290v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'D614G', 'H655Y', 'T1027I'	~6x cleavage of S2 relative to WA1 (D614G) wildtype by Gamma variant as measured by mass spectrometry of Vero-TMPRSS culture  [no mutations directly at furin cleavage site, but H655Y is upstream] Compare to 4.5x or less for variants of concern with  direct furin clevage site mutations.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	trafficking	Hoffman et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.036	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'H655Y', 'T1027I', 'V1176F'	VSV pseudotype P.1 showed slight decrease in cell entry relative to wild type in 262T and 263T-ACE2 (kidney) cell lines. Cell fusion proficiency was slight impaired.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	trafficking	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633	'D614G'	More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~9x, Vero ~8x, and Calu-3 ~8x. Compare to wild type at ~5x across cell types.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	trafficking	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633	'D614G'	~4x more efficient S2 domain cleavage compared to wild type, no change relative to D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	trafficking	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633	'E484K', 'D614G'	More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~11x, Vero ~10x, and Calu-3 ~11x. Compare to wild type at ~5x across cell types.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	trafficking	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633	'E484K', 'D614G'	~6x more efficient S2 domain cleavage compared to wild type, compared to 4x by D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3). [N501Y+D614G does not show an increase in cleavage, therefore a synergistic effect of the trio is implied]	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11378	344.0	11387						0	T=11373	11373	T	A	trafficking	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'D614G'	9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	trafficking	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'E484K', 'D614G'	~12x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (~additive effects of 501 and 484).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	trafficking	Motozono et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.02.438288v1		Decreased stability of RBD expression in yeast, suggesting decreased Spike protein stability.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	trafficking	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1		Lentiviral pseudotyped with this individual mutation from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing slightly increased infection rate amongst the cells.  [in what is essentially a replicate experiment in the same paper, because  each B.1.351 lineage variant was independetly evaluated and N501 is in both lineages,  a significant decrease was observed, therefore the error bars described in this paper should be interpreted carefully]	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	transmissibility	Stefanelli et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.04.06.21254923v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'E484K', 'D614G', 'H655Y'	The relative transmissibility of P.1 estimated at the national level (Italy) varied according to the assumed  degree of cross-protection granted by infection with other lineages and ranged from 1.12 (95%CI 1.03-1.23) in the  case of complete immune evasion by P.1 to 1.39 (95%CI 1.26-1.56) in the case of complete cross-protection. PG: variant list has been abbreviated due to mixed K417 bases in this lineage, potential miscalls of deletions	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	vaccine neutralization efficacy	Alenquer et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'H655Y', 'T1027I'	Using P.1 defining mutations for Spike, observed 4x average decrease in neutralization efficiency  (but still relevant titres) for sera from 10 BNT162b2 vaccinees 12 days after second dose, but only one  relevant titre 12 days after first dose. Compares unfavorably to wild type or B.1.1.7 titres.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	vaccine neutralization efficacy	Andrade et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.14.439719v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'H655Y', 'T1027I'	In human sera 8 weeks post-vaccination with INO-4800, a ~2-fold reduction in P.1 neutralization was observed.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	vaccine neutralization efficacy	Bates et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.04.04.21254881v1		Observed 1.3-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose)  against pseudotype B.1.1.7 key variant lentivirus. Compare to 2.6-fold reduction against cultured B.1.1.7 virus.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	vaccine neutralization efficacy	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w	'E484K'	The neutralizing activity of vaccine was slightly to significantly lower against this variant combination in sera from all 24 patients with  the BNT162b2 mRNA vaccine. (Fig. 4) [In stark contrast to this combination plus K417N, which had no effect (P<0.0001 vs. P	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	vaccine neutralization efficacy	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'D614G', 'H655Y', 'T1027I', 'V1176F'	The neutralizing activity of vaccine was slightly lower against B.1.1.248 variant constellation in sera tested from most of the 15 patients with  the BNT162b2 mRNA vaccine. (Fig. 4)	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	vaccine neutralization efficacy	Choi et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'H655Y', 'T1027I', 'V1176F'	Neutralization efficiency (ID50) against P.1 reduced 3.2x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	vaccine neutralization efficacy	Edara et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.02.02.21250799v1		1.2x drop in neutralization using sera collected from 14 healthy adult participants that received two injections of the mRNA-1273 (Moderna) vaccine  at a dose of 100 µg (18-55 years: day 1 and day 14 post-2nd dose) against a recombinant single variant virus (modified replicating WA-1 cDNA clone)  relative to contemporary circulating D614G variant (USA/GA-EHC-083E/2020) using a live-virus Focus Reduction Neutralization Test (FRNT) assay. 	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	vaccine neutralization efficacy	Gallagher et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.03.442455v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'D614G', 'H655Y', 'T1027I', 'V1176F'	ELISpot assays show T cell neutralization reduced by 16.6% in this B.1.1.248 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose, with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	vaccine neutralization efficacy	Garcia-Beltran et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.013	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'D614G', 'H655Y', 'T1027I', 'V1176F'	Pseudotyped P.1 virus has reduced neutralization activity vs wild type: 6.7x (30 sera Pfizer median 9 days post 2nd dose)  and 4.5x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	vaccine neutralization efficacy	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'H655Y', 'T1027I', 'V1176F'	1.15x *increase* in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees)	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	vaccine neutralization efficacy	Hitchlings et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.04.07.21255081v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'H655Y', 'T1027I'	Among 46,884 HCWs in Manaus, Brazil vaccinated with at least one dose of CoronaVac, a 0.50-fold reduction (adjusted vaccine  effectiveness, 49.6%: 95% CI, 11.3 - 71.4) in the odds of  symptomatic SARS-CoV-2 infection was observed during the period 14 days or more after receiving the first dose. Estimated vaccine effectiveness of at least one dose against any SARS-CoV-2 infection was 35.1% (95% CI, −6.6 - 60.5) in the same time period.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	vaccine neutralization efficacy	Hoffman et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.036	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'H655Y', 'T1027I', 'V1176F'	VSV pseudotype P.1 showed 5.12-fold reduction in neutralization efficiency vs wild type in 15 Pfizer BNT162b2 vaccinee sera 13-15 days post second dose. Cell fusion proficiency was slight impaired.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	vaccine neutralization efficacy	Jacobson et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.04.14.21255431v2		The presence of this variant in 189 post-mRNA-vaccination COVID-19 cases was proportionally in line with lineage prevalence in Northen California during the study period, suggesting no effect of these variants on immune escape.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'D614G'	This variant showed no change in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'E484K', 'D614G'	This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n 	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	vaccine neutralization efficacy	Leier et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.04.25.21256049v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'D614G', 'H655Y', 'T1027I', 'V1176F'	Neutralizing antibody titers increased in previously infected vaccinees relative to uninfected vaccinees  4.3-fold against P.1 (contrast with 3.4 fold against original SARS-CoV-2).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	vaccine neutralization efficacy	Rathnasinghe et al. (2021)	https://dx.doi.org/10.1101%2F2021.01.19.21249592		Human sera from 6 two-dose Pfizer vaccinated individuals (47-68 days post 1st-dose) can neutralize both the reference  USA-WA1/2020 strain and the mouse adapted SARS-CoV-2 strain that contains the N501Y spike mutation with similar efficiency.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	vaccine neutralization efficacy	Tarke et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.27.433180v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'H655Y', 'T1027I', 'V1176F'	PBMCs of Pfizer/BioNTech BNT162b2 (n	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	vaccine neutralization efficacy	Wang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2		In a cohort of 20 patients 8+ weeks after second vaccine dose of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines,  a modest decrease in neutralization by vaccine plasma was observed.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	vaccine neutralization efficacy	Wang et al. (2021)	https://dx.doi.org/10.1101%2F2021.03.01.433466	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'D614G', 'H655Y'	In 12 Moderna vaccinee sera 15 days post second dose (43 days since first vaccination), an average 2.8x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 4.8x decrease against the full P.1 type vs WA-1 was observed, though overall with  a higher ID50 reciprocal value. In 10 Pfizer vaccinee sera 7 days or more post second dose (28 days or more since first vaccination), an average 2.2x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.8x decrease against the full P.1 type vs WA-1 was observed, with  similar variant ID50 reciprocal value.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	vaccine neutralization efficacy	Xie et al. (2021)	https://www.nature.com/articles/s41591-021-01270-4	'E484K'	In 20 sera from BNT162b2 mRNA vaccine inoculated participants, 6 displayed mild (2x) reductions in neutralization. This variant combination showed the highest reduction, but the magnitude of the differences was small  compared to the >4x differences in HA-inhibition titers that have been used to signal potential need for a strain change in influenza vaccines.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.17x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G', 'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'H655Y', 'T1027I'	This variant combination (representing P.1 aka Gamma)  showed a 1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.27x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	virion structure	Spratt et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1		Estimated free energy change (ddG) for this variant is 0.69 kcal/mol (i.e. stabilizing relative to wild type) 	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	11374	172.0	11387						0	T=11369	11369	T	A	virion structure	Wang et al. (2021)	https://dx.doi.org/10.1101%2F2021.03.01.433466	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'D614G', 'H655Y'	CryoEM reveals the P.1 trimer to adopt exclusively a conformation in which one of the receptor-binding domains is in the “up” position.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.N5813N	c.C17439T	p.N5813N			17703	orf1ab	ORF1ab	SILENT	2	2.0	11387			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only	YP_009725308.1	0	T=2	2	T	C						False	P.1.12.1	P.1.12.1=True	VOC		11-Jan-2021	
p.N606N	c.C1818T	p.N606N			23380	S	S	SILENT	11204	0.0	11387						0	T=11204	11204	T	C						False	P.1.14	P.1.14=True	VOC		11-Jan-2021	
p.N615N	c.C1845T	p.N615N			2110	orf1ab	ORF1ab	SILENT	4	4.0	11387			nsp2	produced by both pp1a and pp1ab	YP_009725298.1	2	T=2	2	T	C						False	P.1.10	P.1.10=False	VOC		11-Jan-2021	
p.N679K	c.T2037A	p.N679K			23599	S	S	MISSENSE	6	6.0	11387						2	A=4	4	A	T						False	P.1.12.1, P.1.12	P.1.12=False, P.1.12.1=True	VOC		11-Jan-2021	
p.P1862L	c.C5585T	p.P1862L			5850	orf1ab	ORF1ab	MISSENSE	4	4.0	11387			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	3	T=1	1	T	C						False	P.1.10	P.1.10=False	VOC		11-Jan-2021	
p.P2018P	c.A6054G	p.P2018P			6319	orf1ab	ORF1ab	SILENT	11322	171.0	11387			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	16	G=11305	11305	G	A						False	P.1.12.1, P.1.17, P.1.14, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.14=True	VOC		11-Jan-2021	
p.P2018S	c.CCA6052_6054TCG	p.P2018S			6317	orf1ab	ORF1ab		1	1.0	11387			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	0	TCG=1	1	TCG	CCA						False	P.1.15	P.1.15=True	VOC		11-Jan-2021	
p.P26S	c.C76T	p.P26S			21638	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	C	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.58x increase in binding (KD) relative to D614G.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.P26S	c.C76T	p.P26S			21638	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	C	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G', 'L18F', 'T20N', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing P.1 aka Gamma)  showed a 4.24x increase in binding (KD) relative to D614G.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.P26S	c.C76T	p.P26S			21638	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	C	anthropozoonotic events	Montagutelli et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.18.436013v1	'L18F', 'T20N', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	Unlike wild type or B.1.1.7, P.1 lineage virus was able to infect and replicate in common lab mouse strains, with high titer.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.P26S	c.C76T	p.P26S			21638	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	C	antibody epitope effects	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 	'L18F', 'T20N', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	B.1.1.248 variant constellation ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07. B.1.1.248 variant constellation ablates Class 3 N-terminal domain targeting antibody COV2-2676.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.P26S	c.C76T	p.P26S			21638	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	C	antibody epitope effects	Dejnirattisai et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.055	'L18F', 'T20N', 'D138Y', 'R190S'	"The neutralization titer of NTD-binding mAb159 was 133-fold reduced on P.1 compared to Victoria (~wild type), with only 64% neutralization at 10 μg/mL.  Residues 20, 18, and 138 form a cluster underlying the 245–259 loop, which inserts into a groove between the light and heavy chains of Fab 159. In addition, the N-terminal residues preceding residue 18 interact with the antibody and may be perturbed.  Given that there is likely a single supersite (""i"") for potent NTD-binding antibodies, the binding of many of these are likely affected. Using 20 potent (primaruly anti-RBD) antibodies, neutralization was measured by a focus reduction neutralization test (FRNT) and compared with  neutralization of Victoria (~wild type) and variants B.1.1.7 and B.1.351. Compared to Victoria neutralization by the mAbs was significantly impacted by P.1,  with 12/20 showing > 10-fold reduction in FRNT50 titer and a number showing complete knockout of activity. The results with P.1 showed a  greater impact compared to B.1.1.7 but were, as expected, similar to those with B.1.351."	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.P26S	c.C76T	p.P26S			21638	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	C	antibody epitope effects	Wang et al. (2021)	https://dx.doi.org/10.1101%2F2021.03.01.433466	'L18F', 'T20N', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y'	Amongst RBD-targeting Emergency Use Authorized monoclonal antibody treatments CB6, LY-CoV555 and REGN10933 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1, but REGN10987 activity remains strong. RBD-targeting monoclonal antibodies 2-15 and C121 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1. N terminal domain targeting monoclonal antibodies 5-7, 4-8, 4-18 and 2-17 have abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.P26S	c.C76T	p.P26S			21638	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	C	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.08x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.P26S	c.C76T	p.P26S			21638	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	C	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G', 'L18F', 'T20N', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	This variant combination (representing P.1 aka Gamma)  showed a 1.3x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.P26S	c.C76T	p.P26S			21638	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	C	convalescent plasma escape	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 	'L18F', 'T20N', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	B.1.1.248 variant constellation in 10 convalescent human sera ~1mo post infection had mild to moderate resistence against most samples, P	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.P26S	c.C76T	p.P26S			21638	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	C	convalescent plasma escape	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 	'L18F', 'T20N', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	B.1.1.7 variant constellation two-tailed Wilcoxon matched-pairs signed-rank test against 10 convalescent sera P	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.P26S	c.C76T	p.P26S			21638	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	C	convalescent plasma escape	Hoffman et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.036	'L18F', 'T20N', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	VSV pseudotype P.1 showed 4.8-fold decrease in NT50 vs wild type in sera from 9 ICU patients undergoing treatment in Germany (pre-variant infections).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.P26S	c.C76T	p.P26S			21638	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	C	convalescent plasma escape	Luftig et al. (2021)	https://doi.org/10.1056/nejmc2104036	'L18F', 'T20N', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	In sera from six patients collected 1 to 12 weeks post-infection with B.1, antibody titer in a microneutralization assay was on average 71.46 for P.1 virus. Compare to much stronger neutralization titers for B.1.1.7 (256) and wild type (456.1) in the same sera. 	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.P26S	c.C76T	p.P26S			21638	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	C	convalescent plasma escape	McCallum et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1	'L18F', 'T20N', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	In 13 plasma collected ~1mo after B.1.1.7 infection (nursing home in Ticino, Switzerland), neutralization  reduced to undetectable levels in many plasma for P.1 pseudotyped virus, as well as WT and other VOCs.  [paper does not detail the P.1 variants used, using the most popular as a stand in]	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.P26S	c.C76T	p.P26S			21638	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	C	convalescent plasma escape	Mendes-Correa et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.05.11.21256908v1	'L18F', 'T20N', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	Neutralizing antibodies that were generated following a mild infection with SARS-CoV-2 B.1.128 were effective in vitro,  and likely protective, against the SARS-CoV-2 P.1. variant in the majority of individuals based on 60 convalescent sera tested.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.P26S	c.C76T	p.P26S			21638	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	C	convalescent plasma escape	Tang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.19.436183v1	'L18F', 'T20N', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	Loss of neutralizing activity (PsVNA50 assay) using 6 hyperimmune immunoglobulin preparations from convalescent plasma was seen against P.1 (3.5-fold). Neutralization against 10 convalescent plasma was slightly poorer (3.9-fold).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.P26S	c.C76T	p.P26S			21638	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	C	convalescent plasma escape	Wang et al. (2021)	https://dx.doi.org/10.1101%2F2021.03.01.433466	'L18F', 'T20N', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y'	In convalescent sera one month or more post-infection in Spring 2020, an average 6.5x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.4x decrease against the full P.1 type vs WA-1 was observed, with  better full P.1 ID50 reciprocal value compared to the 10-mutation model.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.P26S	c.C76T	p.P26S			21638	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	C	pharmaceutical effectiveness	Hoffman et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.036	'L18F', 'T20N', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	VSV pseudotype P.1 entry mediated by the S proteins of the P.1 variant was completely resistant to blocking by REGN10989 and Bamlanivimab. Cell fusion proficiency was slight impaired. Entry driven by the S proteins of the B.1.351 was partially resistant against Casirivimab.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.P26S	c.C76T	p.P26S			21638	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	C	reinfection	Malta Romano et al. (2021)	https://doi.org/10.1590/s1678-9946202163036	'L18F', 'T20N', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I'	After a 128 day interval, a patient in Sao Paulo State, Brazil reinfected with P.1 (first episode likely predates P.1 emergence). Both cases were fairly mild (difficulty breathing, tiredness, dizziness and fatigue).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.P26S	c.C76T	p.P26S			21638	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	C	trafficking	Esclera et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.05.455290v1	'L18F', 'T20N', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I'	~6x cleavage of S2 relative to WA1 (D614G) wildtype by Gamma variant as measured by mass spectrometry of Vero-TMPRSS culture  [no mutations directly at furin cleavage site, but H655Y is upstream] Compare to 4.5x or less for variants of concern with  direct furin clevage site mutations.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.P26S	c.C76T	p.P26S			21638	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	C	trafficking	Hoffman et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.036	'L18F', 'T20N', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	VSV pseudotype P.1 showed slight decrease in cell entry relative to wild type in 262T and 263T-ACE2 (kidney) cell lines. Cell fusion proficiency was slight impaired.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.P26S	c.C76T	p.P26S			21638	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	C	transmissibility	Stefanelli et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.04.06.21254923v1	'L18F', 'T20N', 'D138Y', 'R190S', 'E484K', 'N501Y', 'D614G', 'H655Y'	The relative transmissibility of P.1 estimated at the national level (Italy) varied according to the assumed  degree of cross-protection granted by infection with other lineages and ranged from 1.12 (95%CI 1.03-1.23) in the  case of complete immune evasion by P.1 to 1.39 (95%CI 1.26-1.56) in the case of complete cross-protection. PG: variant list has been abbreviated due to mixed K417 bases in this lineage, potential miscalls of deletions	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.P26S	c.C76T	p.P26S			21638	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	C	vaccine neutralization efficacy	Alenquer et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1	'L18F', 'T20N', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	Using P.1 defining mutations for Spike, observed 4x average decrease in neutralization efficiency  (but still relevant titres) for sera from 10 BNT162b2 vaccinees 12 days after second dose, but only one  relevant titre 12 days after first dose. Compares unfavorably to wild type or B.1.1.7 titres.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.P26S	c.C76T	p.P26S			21638	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	C	vaccine neutralization efficacy	Andrade et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.14.439719v1	'L18F', 'T20N', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	In human sera 8 weeks post-vaccination with INO-4800, a ~2-fold reduction in P.1 neutralization was observed.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.P26S	c.C76T	p.P26S			21638	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	C	vaccine neutralization efficacy	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 	'L18F', 'T20N', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	The neutralizing activity of vaccine was slightly lower against B.1.1.248 variant constellation in sera tested from most of the 15 patients with  the BNT162b2 mRNA vaccine. (Fig. 4)	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.P26S	c.C76T	p.P26S			21638	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	C	vaccine neutralization efficacy	Choi et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1	'L18F', 'T20N', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	Neutralization efficiency (ID50) against P.1 reduced 3.2x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.P26S	c.C76T	p.P26S			21638	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	C	vaccine neutralization efficacy	Gallagher et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.03.442455v1	'L18F', 'T20N', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	ELISpot assays show T cell neutralization reduced by 16.6% in this B.1.1.248 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose, with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.P26S	c.C76T	p.P26S			21638	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	C	vaccine neutralization efficacy	Garcia-Beltran et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.013	'L18F', 'T20N', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	Pseudotyped P.1 virus has reduced neutralization activity vs wild type: 6.7x (30 sera Pfizer median 9 days post 2nd dose)  and 4.5x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.P26S	c.C76T	p.P26S			21638	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	C	vaccine neutralization efficacy	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'L18F', 'T20N', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	1.15x *increase* in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees)	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.P26S	c.C76T	p.P26S			21638	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	C	vaccine neutralization efficacy	Hitchlings et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.04.07.21255081v1	'L18F', 'T20N', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	Among 46,884 HCWs in Manaus, Brazil vaccinated with at least one dose of CoronaVac, a 0.50-fold reduction (adjusted vaccine  effectiveness, 49.6%: 95% CI, 11.3 - 71.4) in the odds of  symptomatic SARS-CoV-2 infection was observed during the period 14 days or more after receiving the first dose. Estimated vaccine effectiveness of at least one dose against any SARS-CoV-2 infection was 35.1% (95% CI, −6.6 - 60.5) in the same time period.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.P26S	c.C76T	p.P26S			21638	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	C	vaccine neutralization efficacy	Hoffman et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.036	'L18F', 'T20N', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	VSV pseudotype P.1 showed 5.12-fold reduction in neutralization efficiency vs wild type in 15 Pfizer BNT162b2 vaccinee sera 13-15 days post second dose. Cell fusion proficiency was slight impaired.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.P26S	c.C76T	p.P26S			21638	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	C	vaccine neutralization efficacy	Leier et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.04.25.21256049v1	'L18F', 'T20N', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	Neutralizing antibody titers increased in previously infected vaccinees relative to uninfected vaccinees  4.3-fold against P.1 (contrast with 3.4 fold against original SARS-CoV-2).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.P26S	c.C76T	p.P26S			21638	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	C	vaccine neutralization efficacy	Tarke et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.27.433180v1	'L18F', 'T20N', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	PBMCs of Pfizer/BioNTech BNT162b2 (n	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.P26S	c.C76T	p.P26S			21638	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	C	vaccine neutralization efficacy	Wang et al. (2021)	https://dx.doi.org/10.1101%2F2021.03.01.433466	'L18F', 'T20N', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y'	In 12 Moderna vaccinee sera 15 days post second dose (43 days since first vaccination), an average 2.8x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 4.8x decrease against the full P.1 type vs WA-1 was observed, though overall with  a higher ID50 reciprocal value. In 10 Pfizer vaccinee sera 7 days or more post second dose (28 days or more since first vaccination), an average 2.2x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.8x decrease against the full P.1 type vs WA-1 was observed, with  similar variant ID50 reciprocal value.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.P26S	c.C76T	p.P26S			21638	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	C	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.23x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.37x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.P26S	c.C76T	p.P26S			21638	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	C	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G', 'L18F', 'T20N', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	This variant combination (representing P.1 aka Gamma)  showed a 1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.27x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.P26S	c.C76T	p.P26S			21638	S	S	MISSENSE	11383	172.0	11387						0	T=11383	11383	T	C	virion structure	Wang et al. (2021)	https://dx.doi.org/10.1101%2F2021.03.01.433466	'L18F', 'T20N', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y'	CryoEM reveals the P.1 trimer to adopt exclusively a conformation in which one of the receptor-binding domains is in the “up” position.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.P309Q	c.C926A	p.P309Q			1191	orf1ab	ORF1ab	MISSENSE	2	2.0	11387			nsp2	produced by both pp1a and pp1ab	YP_009725298.1	1	A=1	1	A	C						False	P.1.7	P.1.7=False	VOC		11-Jan-2021	
p.P4715L	c.C14144T	p.P4715L			14408	orf1ab	ORF1ab	MISSENSE	11387	172.0	11387			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only	YP_009725307.1	0	T=11387	11387	T	C						False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.P681H	c.C2042A	p.P681H			23604	S	S	MISSENSE	2	2.0	11387						0	A=2	2	A	C	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.23x decrease in binding (KD) relative to D614G.	False	P.1.7	P.1.7=True	VOC		11-Jan-2021	
p.P681H	c.C2042A	p.P681H			23604	S	S	MISSENSE	2	2.0	11387						0	A=2	2	A	C	antibody epitope effects	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 		Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.	False	P.1.7	P.1.7=True	VOC		11-Jan-2021	
p.P681H	c.C2042A	p.P681H			23604	S	S	MISSENSE	2	2.0	11387						0	A=2	2	A	C	antibody epitope effects	Haynes et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.01.06.20248960v1		Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 7.8% to 1.2% (significantly poorer immune recognition) Together with other B1.1.7 lineage mutational changes (Spike: Y144del,N501Y, A570D Nucleoprotein: D3L, S235F) resulted in only 2 of 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen.	False	P.1.7	P.1.7=True	VOC		11-Jan-2021	
p.P681H	c.C2042A	p.P681H			23604	S	S	MISSENSE	2	2.0	11387						0	A=2	2	A	C	antibody epitope effects	Johnson et al. (2020)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7457603/ 		This variant is adjacent to the Spike protein furin cleavage site (cleavage of S into S1 and S2 subunits is required for viral membrane fusion and subsequent entry into host cells), a site shown to be highly immunogenic.	False	P.1.7	P.1.7=True	VOC		11-Jan-2021	
p.P681H	c.C2042A	p.P681H			23604	S	S	MISSENSE	2	2.0	11387						0	A=2	2	A	C	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.26x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	P.1.7	P.1.7=True	VOC		11-Jan-2021	
p.P681H	c.C2042A	p.P681H			23604	S	S	MISSENSE	2	2.0	11387						0	A=2	2	A	C	trafficking	Lubinski et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.06.438731v1		While the introduction of P681H in the SARS-CoV-2 B.1.1.7 variant may increase spike cleavage by furin-like proteases,  this does not significantly impact viral entry or cell-cell spread. We consider that other factors are at play to account  for the increased in transmission and disease severity attributed to this variant of concern (VOC).	False	P.1.7	P.1.7=True	VOC		11-Jan-2021	
p.P681H	c.C2042A	p.P681H			23604	S	S	MISSENSE	2	2.0	11387						0	A=2	2	A	C	trafficking	Maaroufi (2021)	https://www.researchgate.net/publication/348943694_The_mutation_P681H_in_the_B117_variant_of_SARS-CoV-2_probably_enhances_viral_entry_and_replication		This mutation in the first base of the furin clevage site maintains the RXXR recognition motif, and is presumed to enhance cleavage based on the removal of a proline-directed phosphotase recognition site at S680. In a homologuous site in Infectious  Bronchitis Virus (IBV, Gammacoronaviruses), abolition of S680 phosphorylation improves furin cleavage  (and presumably cell entry).	False	P.1.7	P.1.7=True	VOC		11-Jan-2021	
p.P681H	c.C2042A	p.P681H			23604	S	S	MISSENSE	2	2.0	11387						0	A=2	2	A	C	trafficking	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1		Lentiviral pseudotyped with this individual mutation from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing NO statistically significant infection rate change amongst the cells, suggesting that furin cleavage typically used for cell entry is not affected by this change one  amino acid upstream of the RXXR recognition pattern. 	False	P.1.7	P.1.7=True	VOC		11-Jan-2021	
p.P681H	c.C2042A	p.P681H			23604	S	S	MISSENSE	2	2.0	11387						0	A=2	2	A	C	vaccine neutralization efficacy	Zuckerman et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.03.25.21253908v1	'D614G'	No significant change in virus neutralzation by 18 Pfizer two dose vaccinee sera compared to B.1.1.7. [results without including the used mutation A27S likely generalizable, as this is not a lineage defining mutation]	False	P.1.7	P.1.7=True	VOC		11-Jan-2021	
p.P681H	c.C2042A	p.P681H			23604	S	S	MISSENSE	2	2.0	11387						0	A=2	2	A	C	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.11x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	P.1.7	P.1.7=True	VOC		11-Jan-2021	
p.P681H	c.C2042A	p.P681H			23604	S	S	MISSENSE	2	2.0	11387						0	A=2	2	A	C	virion structure	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1		The Ratio of S2 (processed Spike) to full length Spike is higher for this mutation,  due to a drop in the full length Spike measured, suggesting that this mutation compensates for decreased Spike production by improved proteolytic processing.	False	P.1.7	P.1.7=True	VOC		11-Jan-2021	
p.P777P	c.A2331G	p.P777P			2596	orf1ab	ORF1ab	SILENT	1	1.0	11387			nsp2	produced by both pp1a and pp1ab	YP_009725298.1	0	G=1	1	G	A						False	P.1.15	P.1.15=True	VOC		11-Jan-2021	
p.P80R	c.C239G	p.P80R			28512	N	N	MISSENSE	11387	172.0	11387						0	G=11387	11387	G	C						False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.Q5267H	c.G15801T	p.Q5267H			16065	orf1ab	ORF1ab	MISSENSE	2	2.0	11387			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only	YP_009725307.1	1	T=1	1	T	G						False	P.1.7	P.1.7=False	VOC		11-Jan-2021	
p.R190S	c.G570T	p.R190S			22132	S	S	MISSENSE	11356	172.0	11387						0	T=11356	11356	T	G	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.82x increase in binding (KD) relative to D614G.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.R190S	c.G570T	p.R190S			22132	S	S	MISSENSE	11356	172.0	11387						0	T=11356	11356	T	G	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G', 'L18F', 'T20N', 'P26S', 'D138Y', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing P.1 aka Gamma)  showed a 4.24x increase in binding (KD) relative to D614G.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.R190S	c.G570T	p.R190S			22132	S	S	MISSENSE	11356	172.0	11387						0	T=11356	11356	T	G	anthropozoonotic events	Montagutelli et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.18.436013v1	'L18F', 'T20N', 'P26S', 'D138Y', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	Unlike wild type or B.1.1.7, P.1 lineage virus was able to infect and replicate in common lab mouse strains, with high titer.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.R190S	c.G570T	p.R190S			22132	S	S	MISSENSE	11356	172.0	11387						0	T=11356	11356	T	G	antibody epitope effects	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 	'L18F', 'T20N', 'P26S', 'D138Y', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	B.1.1.248 variant constellation ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07. B.1.1.248 variant constellation ablates Class 3 N-terminal domain targeting antibody COV2-2676.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.R190S	c.G570T	p.R190S			22132	S	S	MISSENSE	11356	172.0	11387						0	T=11356	11356	T	G	antibody epitope effects	Dejnirattisai et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.055	'L18F', 'T20N', 'P26S', 'D138Y'	"The neutralization titer of NTD-binding mAb159 was 133-fold reduced on P.1 compared to Victoria (~wild type), with only 64% neutralization at 10 μg/mL.  Residues 20, 18, and 138 form a cluster underlying the 245–259 loop, which inserts into a groove between the light and heavy chains of Fab 159. In addition, the N-terminal residues preceding residue 18 interact with the antibody and may be perturbed.  Given that there is likely a single supersite (""i"") for potent NTD-binding antibodies, the binding of many of these are likely affected. Using 20 potent (primaruly anti-RBD) antibodies, neutralization was measured by a focus reduction neutralization test (FRNT) and compared with  neutralization of Victoria (~wild type) and variants B.1.1.7 and B.1.351. Compared to Victoria neutralization by the mAbs was significantly impacted by P.1,  with 12/20 showing > 10-fold reduction in FRNT50 titer and a number showing complete knockout of activity. The results with P.1 showed a  greater impact compared to B.1.1.7 but were, as expected, similar to those with B.1.351."	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.R190S	c.G570T	p.R190S			22132	S	S	MISSENSE	11356	172.0	11387						0	T=11356	11356	T	G	antibody epitope effects	Wang et al. (2021)	https://dx.doi.org/10.1101%2F2021.03.01.433466	'L18F', 'T20N', 'P26S', 'D138Y', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y'	Amongst RBD-targeting Emergency Use Authorized monoclonal antibody treatments CB6, LY-CoV555 and REGN10933 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1, but REGN10987 activity remains strong. RBD-targeting monoclonal antibodies 2-15 and C121 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1. N terminal domain targeting monoclonal antibodies 5-7, 4-8, 4-18 and 2-17 have abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.R190S	c.G570T	p.R190S			22132	S	S	MISSENSE	11356	172.0	11387						0	T=11356	11356	T	G	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.09x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.R190S	c.G570T	p.R190S			22132	S	S	MISSENSE	11356	172.0	11387						0	T=11356	11356	T	G	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G', 'L18F', 'T20N', 'P26S', 'D138Y', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	This variant combination (representing P.1 aka Gamma)  showed a 1.3x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.R190S	c.G570T	p.R190S			22132	S	S	MISSENSE	11356	172.0	11387						0	T=11356	11356	T	G	convalescent plasma escape	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 	'L18F', 'T20N', 'P26S', 'D138Y', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	B.1.1.248 variant constellation in 10 convalescent human sera ~1mo post infection had mild to moderate resistence against most samples, P	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.R190S	c.G570T	p.R190S			22132	S	S	MISSENSE	11356	172.0	11387						0	T=11356	11356	T	G	convalescent plasma escape	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 	'L18F', 'T20N', 'P26S', 'D138Y', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	B.1.1.7 variant constellation two-tailed Wilcoxon matched-pairs signed-rank test against 10 convalescent sera P	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.R190S	c.G570T	p.R190S			22132	S	S	MISSENSE	11356	172.0	11387						0	T=11356	11356	T	G	convalescent plasma escape	Hoffman et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.036	'L18F', 'T20N', 'P26S', 'D138Y', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	VSV pseudotype P.1 showed 4.8-fold decrease in NT50 vs wild type in sera from 9 ICU patients undergoing treatment in Germany (pre-variant infections).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.R190S	c.G570T	p.R190S			22132	S	S	MISSENSE	11356	172.0	11387						0	T=11356	11356	T	G	convalescent plasma escape	Luftig et al. (2021)	https://doi.org/10.1056/nejmc2104036	'L18F', 'T20N', 'P26S', 'D138Y', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	In sera from six patients collected 1 to 12 weeks post-infection with B.1, antibody titer in a microneutralization assay was on average 71.46 for P.1 virus. Compare to much stronger neutralization titers for B.1.1.7 (256) and wild type (456.1) in the same sera. 	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.R190S	c.G570T	p.R190S			22132	S	S	MISSENSE	11356	172.0	11387						0	T=11356	11356	T	G	convalescent plasma escape	McCallum et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1	'L18F', 'T20N', 'P26S', 'D138Y', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	In 13 plasma collected ~1mo after B.1.1.7 infection (nursing home in Ticino, Switzerland), neutralization  reduced to undetectable levels in many plasma for P.1 pseudotyped virus, as well as WT and other VOCs.  [paper does not detail the P.1 variants used, using the most popular as a stand in]	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.R190S	c.G570T	p.R190S			22132	S	S	MISSENSE	11356	172.0	11387						0	T=11356	11356	T	G	convalescent plasma escape	Mendes-Correa et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.05.11.21256908v1	'L18F', 'T20N', 'P26S', 'D138Y', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	Neutralizing antibodies that were generated following a mild infection with SARS-CoV-2 B.1.128 were effective in vitro,  and likely protective, against the SARS-CoV-2 P.1. variant in the majority of individuals based on 60 convalescent sera tested.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.R190S	c.G570T	p.R190S			22132	S	S	MISSENSE	11356	172.0	11387						0	T=11356	11356	T	G	convalescent plasma escape	Tang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.19.436183v1	'L18F', 'T20N', 'P26S', 'D138Y', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	Loss of neutralizing activity (PsVNA50 assay) using 6 hyperimmune immunoglobulin preparations from convalescent plasma was seen against P.1 (3.5-fold). Neutralization against 10 convalescent plasma was slightly poorer (3.9-fold).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.R190S	c.G570T	p.R190S			22132	S	S	MISSENSE	11356	172.0	11387						0	T=11356	11356	T	G	convalescent plasma escape	Wang et al. (2021)	https://dx.doi.org/10.1101%2F2021.03.01.433466	'L18F', 'T20N', 'P26S', 'D138Y', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y'	In convalescent sera one month or more post-infection in Spring 2020, an average 6.5x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.4x decrease against the full P.1 type vs WA-1 was observed, with  better full P.1 ID50 reciprocal value compared to the 10-mutation model.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.R190S	c.G570T	p.R190S			22132	S	S	MISSENSE	11356	172.0	11387						0	T=11356	11356	T	G	pharmaceutical effectiveness	Hoffman et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.036	'L18F', 'T20N', 'P26S', 'D138Y', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	VSV pseudotype P.1 entry mediated by the S proteins of the P.1 variant was completely resistant to blocking by REGN10989 and Bamlanivimab. Cell fusion proficiency was slight impaired. Entry driven by the S proteins of the B.1.351 was partially resistant against Casirivimab.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.R190S	c.G570T	p.R190S			22132	S	S	MISSENSE	11356	172.0	11387						0	T=11356	11356	T	G	reinfection	Malta Romano et al. (2021)	https://doi.org/10.1590/s1678-9946202163036	'L18F', 'T20N', 'P26S', 'D138Y', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I'	After a 128 day interval, a patient in Sao Paulo State, Brazil reinfected with P.1 (first episode likely predates P.1 emergence). Both cases were fairly mild (difficulty breathing, tiredness, dizziness and fatigue).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.R190S	c.G570T	p.R190S			22132	S	S	MISSENSE	11356	172.0	11387						0	T=11356	11356	T	G	trafficking	Esclera et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.05.455290v1	'L18F', 'T20N', 'P26S', 'D138Y', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I'	~6x cleavage of S2 relative to WA1 (D614G) wildtype by Gamma variant as measured by mass spectrometry of Vero-TMPRSS culture  [no mutations directly at furin cleavage site, but H655Y is upstream] Compare to 4.5x or less for variants of concern with  direct furin clevage site mutations.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.R190S	c.G570T	p.R190S			22132	S	S	MISSENSE	11356	172.0	11387						0	T=11356	11356	T	G	trafficking	Hoffman et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.036	'L18F', 'T20N', 'P26S', 'D138Y', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	VSV pseudotype P.1 showed slight decrease in cell entry relative to wild type in 262T and 263T-ACE2 (kidney) cell lines. Cell fusion proficiency was slight impaired.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.R190S	c.G570T	p.R190S			22132	S	S	MISSENSE	11356	172.0	11387						0	T=11356	11356	T	G	transmissibility	Stefanelli et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.04.06.21254923v1	'L18F', 'T20N', 'P26S', 'D138Y', 'E484K', 'N501Y', 'D614G', 'H655Y'	The relative transmissibility of P.1 estimated at the national level (Italy) varied according to the assumed  degree of cross-protection granted by infection with other lineages and ranged from 1.12 (95%CI 1.03-1.23) in the  case of complete immune evasion by P.1 to 1.39 (95%CI 1.26-1.56) in the case of complete cross-protection. PG: variant list has been abbreviated due to mixed K417 bases in this lineage, potential miscalls of deletions	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.R190S	c.G570T	p.R190S			22132	S	S	MISSENSE	11356	172.0	11387						0	T=11356	11356	T	G	vaccine neutralization efficacy	Alenquer et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1	'L18F', 'T20N', 'P26S', 'D138Y', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	Using P.1 defining mutations for Spike, observed 4x average decrease in neutralization efficiency  (but still relevant titres) for sera from 10 BNT162b2 vaccinees 12 days after second dose, but only one  relevant titre 12 days after first dose. Compares unfavorably to wild type or B.1.1.7 titres.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.R190S	c.G570T	p.R190S			22132	S	S	MISSENSE	11356	172.0	11387						0	T=11356	11356	T	G	vaccine neutralization efficacy	Andrade et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.14.439719v1	'L18F', 'T20N', 'P26S', 'D138Y', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	In human sera 8 weeks post-vaccination with INO-4800, a ~2-fold reduction in P.1 neutralization was observed.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.R190S	c.G570T	p.R190S			22132	S	S	MISSENSE	11356	172.0	11387						0	T=11356	11356	T	G	vaccine neutralization efficacy	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 	'L18F', 'T20N', 'P26S', 'D138Y', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	The neutralizing activity of vaccine was slightly lower against B.1.1.248 variant constellation in sera tested from most of the 15 patients with  the BNT162b2 mRNA vaccine. (Fig. 4)	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.R190S	c.G570T	p.R190S			22132	S	S	MISSENSE	11356	172.0	11387						0	T=11356	11356	T	G	vaccine neutralization efficacy	Choi et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1	'L18F', 'T20N', 'P26S', 'D138Y', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	Neutralization efficiency (ID50) against P.1 reduced 3.2x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.R190S	c.G570T	p.R190S			22132	S	S	MISSENSE	11356	172.0	11387						0	T=11356	11356	T	G	vaccine neutralization efficacy	Gallagher et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.03.442455v1	'L18F', 'T20N', 'P26S', 'D138Y', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	ELISpot assays show T cell neutralization reduced by 16.6% in this B.1.1.248 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose, with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.R190S	c.G570T	p.R190S			22132	S	S	MISSENSE	11356	172.0	11387						0	T=11356	11356	T	G	vaccine neutralization efficacy	Garcia-Beltran et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.013	'L18F', 'T20N', 'P26S', 'D138Y', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	Pseudotyped P.1 virus has reduced neutralization activity vs wild type: 6.7x (30 sera Pfizer median 9 days post 2nd dose)  and 4.5x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.R190S	c.G570T	p.R190S			22132	S	S	MISSENSE	11356	172.0	11387						0	T=11356	11356	T	G	vaccine neutralization efficacy	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'L18F', 'T20N', 'P26S', 'D138Y', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	1.15x *increase* in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees)	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.R190S	c.G570T	p.R190S			22132	S	S	MISSENSE	11356	172.0	11387						0	T=11356	11356	T	G	vaccine neutralization efficacy	Hitchlings et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.04.07.21255081v1	'L18F', 'T20N', 'P26S', 'D138Y', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	Among 46,884 HCWs in Manaus, Brazil vaccinated with at least one dose of CoronaVac, a 0.50-fold reduction (adjusted vaccine  effectiveness, 49.6%: 95% CI, 11.3 - 71.4) in the odds of  symptomatic SARS-CoV-2 infection was observed during the period 14 days or more after receiving the first dose. Estimated vaccine effectiveness of at least one dose against any SARS-CoV-2 infection was 35.1% (95% CI, −6.6 - 60.5) in the same time period.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.R190S	c.G570T	p.R190S			22132	S	S	MISSENSE	11356	172.0	11387						0	T=11356	11356	T	G	vaccine neutralization efficacy	Hoffman et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.036	'L18F', 'T20N', 'P26S', 'D138Y', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	VSV pseudotype P.1 showed 5.12-fold reduction in neutralization efficiency vs wild type in 15 Pfizer BNT162b2 vaccinee sera 13-15 days post second dose. Cell fusion proficiency was slight impaired.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.R190S	c.G570T	p.R190S			22132	S	S	MISSENSE	11356	172.0	11387						0	T=11356	11356	T	G	vaccine neutralization efficacy	Leier et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.04.25.21256049v1	'L18F', 'T20N', 'P26S', 'D138Y', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	Neutralizing antibody titers increased in previously infected vaccinees relative to uninfected vaccinees  4.3-fold against P.1 (contrast with 3.4 fold against original SARS-CoV-2).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.R190S	c.G570T	p.R190S			22132	S	S	MISSENSE	11356	172.0	11387						0	T=11356	11356	T	G	vaccine neutralization efficacy	Tarke et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.27.433180v1	'L18F', 'T20N', 'P26S', 'D138Y', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	PBMCs of Pfizer/BioNTech BNT162b2 (n	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.R190S	c.G570T	p.R190S			22132	S	S	MISSENSE	11356	172.0	11387						0	T=11356	11356	T	G	vaccine neutralization efficacy	Wang et al. (2021)	https://dx.doi.org/10.1101%2F2021.03.01.433466	'L18F', 'T20N', 'P26S', 'D138Y', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y'	In 12 Moderna vaccinee sera 15 days post second dose (43 days since first vaccination), an average 2.8x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 4.8x decrease against the full P.1 type vs WA-1 was observed, though overall with  a higher ID50 reciprocal value. In 10 Pfizer vaccinee sera 7 days or more post second dose (28 days or more since first vaccination), an average 2.2x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.8x decrease against the full P.1 type vs WA-1 was observed, with  similar variant ID50 reciprocal value.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.R190S	c.G570T	p.R190S			22132	S	S	MISSENSE	11356	172.0	11387						0	T=11356	11356	T	G	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.19x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.59x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.R190S	c.G570T	p.R190S			22132	S	S	MISSENSE	11356	172.0	11387						0	T=11356	11356	T	G	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G', 'L18F', 'T20N', 'P26S', 'D138Y', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	This variant combination (representing P.1 aka Gamma)  showed a 1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.27x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.R190S	c.G570T	p.R190S			22132	S	S	MISSENSE	11356	172.0	11387						0	T=11356	11356	T	G	virion structure	Spratt et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1		Estimated free energy change (ddG) for this variant is -0.69 kcal/mol (i.e. destabilizing relative to wild type) 	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.R190S	c.G570T	p.R190S			22132	S	S	MISSENSE	11356	172.0	11387						0	T=11356	11356	T	G	virion structure	Wang et al. (2021)	https://dx.doi.org/10.1101%2F2021.03.01.433466	'L18F', 'T20N', 'P26S', 'D138Y', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y'	CryoEM reveals the P.1 trimer to adopt exclusively a conformation in which one of the receptor-binding domains is in the “up” position.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.R246G	c.A736G	p.R246G			22298	S	S	MISSENSE	6	6.0	11387						2	G=4	4	G	A	monoclonal antibody serial passage escape	McCallum et al. (2021)	https://doi.org/10.1101/2021.01.14.426475 		Escape mutation against Spike N terminal domain antigenic supersite i mAbs S2M28, S2X28	False	P.1.12.1, P.1.12	P.1.12=False, P.1.12.1=True	VOC		11-Jan-2021	
p.R3368R	c.C10104T	p.R3368R			10369	orf1ab	ORF1ab	SILENT	2	2.0	11387			3C-like proteinase	nsp5A_3CLpro and nsp5B_3CLpro, main proteinase (Mpro), mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al., 2003), produced by both pp1a and pp1ab	YP_009725301.1	0	T=2	2	T	C						False	P.1.12.1	P.1.12.1=True	VOC		11-Jan-2021	
p.R4017K	c.G12050A	p.R4017K			12315	orf1ab	ORF1ab	MISSENSE	8	8.0	11387			nsp8	produced by both pp1a and pp1ab	YP_009725304.1	6	A=2	2	A	G						False	P.1.12	P.1.12=False	VOC		11-Jan-2021	
p.RG203KR	c.AGTAGGG604_610TCTAAAC	p.RG203KR			28877	N	N		11375	172.0	11387						0	TCTAAAC=11374	11374	TCTAAAC	AGTAGGG						False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.S1188L	c.C3563T	p.S1188L			3828	orf1ab	ORF1ab	MISSENSE	11387	172.0	11387			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	0	T=11387	11387	T	C						False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.S1252F	c.C3755T	p.S1252F			25317	S	S	MISSENSE	11211	0.0	11387						9967	T=1244	1244	T	C						False	P.1.14	P.1.14=False	VOC		11-Jan-2021	
p.S171L	c.C512T	p.S171L			25904	ORF3a	ORF3a	MISSENSE	4	4.0	11387						3	T=1	1	T	C						False	P.1.12	P.1.12=False	VOC		11-Jan-2021	
p.S253P	c.T757C	p.S253P			26149	ORF3a	ORF3a	MISSENSE	11386	172.0	11387						0	C=11360, CCCA=4, CCCG=22	11360,4,22	C,CCCA,CCCG	T						False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.S26L	c.C77T	p.S26L			25469	ORF3a	ORF3a	MISSENSE	26	26.0	11387						21	T=5	5	T	C						False	P.1.17	P.1.17=False	VOC		11-Jan-2021	
p.S2947N	c.G8840A	p.S2947N			9105	orf1ab	ORF1ab	MISSENSE	11214	0.0	11387			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab	YP_009725300.1	31	A=11183	11183	A	G						False	P.1.14	P.1.14=True	VOC		11-Jan-2021	
p.S3675del	c.11023_11031delTCTGGTTTT	p.S3675_F3677del	S3675_F3677del	'3676del', 'F3677del'	11287	orf1ab	ORF1ab		11385	172.0	11387			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab	YP_009725302.1	0	G=11385	11385	G	GTCTGGTTTT						False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.S549S	c.C1647T	p.S549S			1912	orf1ab	ORF1ab	SILENT	2	2.0	11387			nsp2	produced by both pp1a and pp1ab	YP_009725298.1	0	T=2	2	T	C						False	P.1.7	P.1.7=True	VOC		11-Jan-2021	
p.S74F	c.C221T	p.S74F			25613	ORF3a	ORF3a	MISSENSE	6	6.0	11387						2	T=4	4	T	C						False	P.1.12.1, P.1.12	P.1.12=False, P.1.12.1=True	VOC		11-Jan-2021	
p.T1027I	c.C3080T	p.T1027I			24642	S	S	MISSENSE	11346	172.0	11387						1	T=11345	11345	T	C	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.69x decrease in binding (KD) relative to D614G.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.T1027I	c.C3080T	p.T1027I			24642	S	S	MISSENSE	11346	172.0	11387						1	T=11345	11345	T	C	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G', 'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing P.1 aka Gamma)  showed a 4.24x increase in binding (KD) relative to D614G.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.T1027I	c.C3080T	p.T1027I			24642	S	S	MISSENSE	11346	172.0	11387						1	T=11345	11345	T	C	anthropozoonotic events	Montagutelli et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.18.436013v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'V1176F'	Unlike wild type or B.1.1.7, P.1 lineage virus was able to infect and replicate in common lab mouse strains, with high titer.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.T1027I	c.C3080T	p.T1027I			24642	S	S	MISSENSE	11346	172.0	11387						1	T=11345	11345	T	C	antibody epitope effects	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'V1176F'	B.1.1.248 variant constellation ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07. B.1.1.248 variant constellation ablates Class 3 N-terminal domain targeting antibody COV2-2676.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.T1027I	c.C3080T	p.T1027I			24642	S	S	MISSENSE	11346	172.0	11387						1	T=11345	11345	T	C	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.56x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.T1027I	c.C3080T	p.T1027I			24642	S	S	MISSENSE	11346	172.0	11387						1	T=11345	11345	T	C	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G', 'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y'	This variant combination (representing P.1 aka Gamma)  showed a 1.3x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.T1027I	c.C3080T	p.T1027I			24642	S	S	MISSENSE	11346	172.0	11387						1	T=11345	11345	T	C	convalescent plasma escape	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'V1176F'	B.1.1.248 variant constellation in 10 convalescent human sera ~1mo post infection had mild to moderate resistence against most samples, P	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.T1027I	c.C3080T	p.T1027I			24642	S	S	MISSENSE	11346	172.0	11387						1	T=11345	11345	T	C	convalescent plasma escape	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'V1176F'	B.1.1.7 variant constellation two-tailed Wilcoxon matched-pairs signed-rank test against 10 convalescent sera P	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.T1027I	c.C3080T	p.T1027I			24642	S	S	MISSENSE	11346	172.0	11387						1	T=11345	11345	T	C	convalescent plasma escape	Hoffman et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.036	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'V1176F'	VSV pseudotype P.1 showed 4.8-fold decrease in NT50 vs wild type in sera from 9 ICU patients undergoing treatment in Germany (pre-variant infections).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.T1027I	c.C3080T	p.T1027I			24642	S	S	MISSENSE	11346	172.0	11387						1	T=11345	11345	T	C	convalescent plasma escape	Luftig et al. (2021)	https://doi.org/10.1056/nejmc2104036	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'V1176F'	In sera from six patients collected 1 to 12 weeks post-infection with B.1, antibody titer in a microneutralization assay was on average 71.46 for P.1 virus. Compare to much stronger neutralization titers for B.1.1.7 (256) and wild type (456.1) in the same sera. 	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.T1027I	c.C3080T	p.T1027I			24642	S	S	MISSENSE	11346	172.0	11387						1	T=11345	11345	T	C	convalescent plasma escape	McCallum et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'V1176F'	In 13 plasma collected ~1mo after B.1.1.7 infection (nursing home in Ticino, Switzerland), neutralization  reduced to undetectable levels in many plasma for P.1 pseudotyped virus, as well as WT and other VOCs.  [paper does not detail the P.1 variants used, using the most popular as a stand in]	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.T1027I	c.C3080T	p.T1027I			24642	S	S	MISSENSE	11346	172.0	11387						1	T=11345	11345	T	C	convalescent plasma escape	Mendes-Correa et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.05.11.21256908v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'V1176F'	Neutralizing antibodies that were generated following a mild infection with SARS-CoV-2 B.1.128 were effective in vitro,  and likely protective, against the SARS-CoV-2 P.1. variant in the majority of individuals based on 60 convalescent sera tested.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.T1027I	c.C3080T	p.T1027I			24642	S	S	MISSENSE	11346	172.0	11387						1	T=11345	11345	T	C	convalescent plasma escape	Tang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.19.436183v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'V1176F'	Loss of neutralizing activity (PsVNA50 assay) using 6 hyperimmune immunoglobulin preparations from convalescent plasma was seen against P.1 (3.5-fold). Neutralization against 10 convalescent plasma was slightly poorer (3.9-fold).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.T1027I	c.C3080T	p.T1027I			24642	S	S	MISSENSE	11346	172.0	11387						1	T=11345	11345	T	C	pharmaceutical effectiveness	Hoffman et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.036	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'V1176F'	VSV pseudotype P.1 entry mediated by the S proteins of the P.1 variant was completely resistant to blocking by REGN10989 and Bamlanivimab. Cell fusion proficiency was slight impaired. Entry driven by the S proteins of the B.1.351 was partially resistant against Casirivimab.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.T1027I	c.C3080T	p.T1027I			24642	S	S	MISSENSE	11346	172.0	11387						1	T=11345	11345	T	C	reinfection	Malta Romano et al. (2021)	https://doi.org/10.1590/s1678-9946202163036	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y'	After a 128 day interval, a patient in Sao Paulo State, Brazil reinfected with P.1 (first episode likely predates P.1 emergence). Both cases were fairly mild (difficulty breathing, tiredness, dizziness and fatigue).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.T1027I	c.C3080T	p.T1027I			24642	S	S	MISSENSE	11346	172.0	11387						1	T=11345	11345	T	C	trafficking	Esclera et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.05.455290v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y'	~6x cleavage of S2 relative to WA1 (D614G) wildtype by Gamma variant as measured by mass spectrometry of Vero-TMPRSS culture  [no mutations directly at furin cleavage site, but H655Y is upstream] Compare to 4.5x or less for variants of concern with  direct furin clevage site mutations.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.T1027I	c.C3080T	p.T1027I			24642	S	S	MISSENSE	11346	172.0	11387						1	T=11345	11345	T	C	trafficking	Hoffman et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.036	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'V1176F'	VSV pseudotype P.1 showed slight decrease in cell entry relative to wild type in 262T and 263T-ACE2 (kidney) cell lines. Cell fusion proficiency was slight impaired.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.T1027I	c.C3080T	p.T1027I			24642	S	S	MISSENSE	11346	172.0	11387						1	T=11345	11345	T	C	vaccine neutralization efficacy	Alenquer et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y'	Using P.1 defining mutations for Spike, observed 4x average decrease in neutralization efficiency  (but still relevant titres) for sera from 10 BNT162b2 vaccinees 12 days after second dose, but only one  relevant titre 12 days after first dose. Compares unfavorably to wild type or B.1.1.7 titres.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.T1027I	c.C3080T	p.T1027I			24642	S	S	MISSENSE	11346	172.0	11387						1	T=11345	11345	T	C	vaccine neutralization efficacy	Andrade et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.14.439719v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y'	In human sera 8 weeks post-vaccination with INO-4800, a ~2-fold reduction in P.1 neutralization was observed.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.T1027I	c.C3080T	p.T1027I			24642	S	S	MISSENSE	11346	172.0	11387						1	T=11345	11345	T	C	vaccine neutralization efficacy	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'V1176F'	The neutralizing activity of vaccine was slightly lower against B.1.1.248 variant constellation in sera tested from most of the 15 patients with  the BNT162b2 mRNA vaccine. (Fig. 4)	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.T1027I	c.C3080T	p.T1027I			24642	S	S	MISSENSE	11346	172.0	11387						1	T=11345	11345	T	C	vaccine neutralization efficacy	Choi et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'V1176F'	Neutralization efficiency (ID50) against P.1 reduced 3.2x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.T1027I	c.C3080T	p.T1027I			24642	S	S	MISSENSE	11346	172.0	11387						1	T=11345	11345	T	C	vaccine neutralization efficacy	Gallagher et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.03.442455v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'V1176F'	ELISpot assays show T cell neutralization reduced by 16.6% in this B.1.1.248 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose, with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.T1027I	c.C3080T	p.T1027I			24642	S	S	MISSENSE	11346	172.0	11387						1	T=11345	11345	T	C	vaccine neutralization efficacy	Garcia-Beltran et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.013	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'V1176F'	Pseudotyped P.1 virus has reduced neutralization activity vs wild type: 6.7x (30 sera Pfizer median 9 days post 2nd dose)  and 4.5x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.T1027I	c.C3080T	p.T1027I			24642	S	S	MISSENSE	11346	172.0	11387						1	T=11345	11345	T	C	vaccine neutralization efficacy	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'V1176F'	1.15x *increase* in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees)	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.T1027I	c.C3080T	p.T1027I			24642	S	S	MISSENSE	11346	172.0	11387						1	T=11345	11345	T	C	vaccine neutralization efficacy	Hitchlings et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.04.07.21255081v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y'	Among 46,884 HCWs in Manaus, Brazil vaccinated with at least one dose of CoronaVac, a 0.50-fold reduction (adjusted vaccine  effectiveness, 49.6%: 95% CI, 11.3 - 71.4) in the odds of  symptomatic SARS-CoV-2 infection was observed during the period 14 days or more after receiving the first dose. Estimated vaccine effectiveness of at least one dose against any SARS-CoV-2 infection was 35.1% (95% CI, −6.6 - 60.5) in the same time period.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.T1027I	c.C3080T	p.T1027I			24642	S	S	MISSENSE	11346	172.0	11387						1	T=11345	11345	T	C	vaccine neutralization efficacy	Hoffman et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.036	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'V1176F'	VSV pseudotype P.1 showed 5.12-fold reduction in neutralization efficiency vs wild type in 15 Pfizer BNT162b2 vaccinee sera 13-15 days post second dose. Cell fusion proficiency was slight impaired.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.T1027I	c.C3080T	p.T1027I			24642	S	S	MISSENSE	11346	172.0	11387						1	T=11345	11345	T	C	vaccine neutralization efficacy	Leier et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.04.25.21256049v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'V1176F'	Neutralizing antibody titers increased in previously infected vaccinees relative to uninfected vaccinees  4.3-fold against P.1 (contrast with 3.4 fold against original SARS-CoV-2).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.T1027I	c.C3080T	p.T1027I			24642	S	S	MISSENSE	11346	172.0	11387						1	T=11345	11345	T	C	vaccine neutralization efficacy	Tarke et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.27.433180v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'V1176F'	PBMCs of Pfizer/BioNTech BNT162b2 (n	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.T1027I	c.C3080T	p.T1027I			24642	S	S	MISSENSE	11346	172.0	11387						1	T=11345	11345	T	C	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.32x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.22x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.T1027I	c.C3080T	p.T1027I			24642	S	S	MISSENSE	11346	172.0	11387						1	T=11345	11345	T	C	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G', 'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y'	This variant combination (representing P.1 aka Gamma)  showed a 1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.27x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.T1027I	c.C3080T	p.T1027I			24642	S	S	MISSENSE	11346	172.0	11387						1	T=11345	11345	T	C	virion structure	Spratt et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1		Estimated free energy change (ddG) for this variant is 1.51 kcal/mol (i.e. stabilizing relative to wild type) 	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.T151I	c.C452T	p.T151I			25844	ORF3a	ORF3a	MISSENSE	6	6.0	11387						2	T=4	4	T	C						False	P.1.12.1, P.1.12	P.1.12=False, P.1.12.1=True	VOC		11-Jan-2021	
p.T1854I	c.C5561T	p.T1854I			5826	orf1ab	ORF1ab	MISSENSE	2	2.0	11387			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	0	T=2	2	T	C						False	P.1.12.1	P.1.12.1=True	VOC		11-Jan-2021	
p.T20N	c.C59A	p.T20N			21621	S	S	MISSENSE	11379	172.0	11387						0	A=11379	11379	A	C	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.96x increase in binding (KD) relative to D614G.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.T20N	c.C59A	p.T20N			21621	S	S	MISSENSE	11379	172.0	11387						0	A=11379	11379	A	C	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G', 'L18F', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing P.1 aka Gamma)  showed a 4.24x increase in binding (KD) relative to D614G.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.T20N	c.C59A	p.T20N			21621	S	S	MISSENSE	11379	172.0	11387						0	A=11379	11379	A	C	anthropozoonotic events	Montagutelli et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.18.436013v1	'L18F', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	Unlike wild type or B.1.1.7, P.1 lineage virus was able to infect and replicate in common lab mouse strains, with high titer.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.T20N	c.C59A	p.T20N			21621	S	S	MISSENSE	11379	172.0	11387						0	A=11379	11379	A	C	antibody epitope effects	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 	'L18F', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	B.1.1.248 variant constellation ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07. B.1.1.248 variant constellation ablates Class 3 N-terminal domain targeting antibody COV2-2676.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.T20N	c.C59A	p.T20N			21621	S	S	MISSENSE	11379	172.0	11387						0	A=11379	11379	A	C	antibody epitope effects	Dejnirattisai et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.055	'L18F', 'P26S', 'D138Y', 'R190S'	"The neutralization titer of NTD-binding mAb159 was 133-fold reduced on P.1 compared to Victoria (~wild type), with only 64% neutralization at 10 μg/mL.  Residues 20, 18, and 138 form a cluster underlying the 245–259 loop, which inserts into a groove between the light and heavy chains of Fab 159. In addition, the N-terminal residues preceding residue 18 interact with the antibody and may be perturbed.  Given that there is likely a single supersite (""i"") for potent NTD-binding antibodies, the binding of many of these are likely affected. Using 20 potent (primaruly anti-RBD) antibodies, neutralization was measured by a focus reduction neutralization test (FRNT) and compared with  neutralization of Victoria (~wild type) and variants B.1.1.7 and B.1.351. Compared to Victoria neutralization by the mAbs was significantly impacted by P.1,  with 12/20 showing > 10-fold reduction in FRNT50 titer and a number showing complete knockout of activity. The results with P.1 showed a  greater impact compared to B.1.1.7 but were, as expected, similar to those with B.1.351."	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.T20N	c.C59A	p.T20N			21621	S	S	MISSENSE	11379	172.0	11387						0	A=11379	11379	A	C	antibody epitope effects	Wang et al. (2021)	https://dx.doi.org/10.1101%2F2021.03.01.433466	'L18F', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y'	Amongst RBD-targeting Emergency Use Authorized monoclonal antibody treatments CB6, LY-CoV555 and REGN10933 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1, but REGN10987 activity remains strong. RBD-targeting monoclonal antibodies 2-15 and C121 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1. N terminal domain targeting monoclonal antibodies 5-7, 4-8, 4-18 and 2-17 have abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.T20N	c.C59A	p.T20N			21621	S	S	MISSENSE	11379	172.0	11387						0	A=11379	11379	A	C	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.65x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.T20N	c.C59A	p.T20N			21621	S	S	MISSENSE	11379	172.0	11387						0	A=11379	11379	A	C	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G', 'L18F', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	This variant combination (representing P.1 aka Gamma)  showed a 1.3x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.T20N	c.C59A	p.T20N			21621	S	S	MISSENSE	11379	172.0	11387						0	A=11379	11379	A	C	convalescent plasma escape	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 	'L18F', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	B.1.1.248 variant constellation in 10 convalescent human sera ~1mo post infection had mild to moderate resistence against most samples, P	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.T20N	c.C59A	p.T20N			21621	S	S	MISSENSE	11379	172.0	11387						0	A=11379	11379	A	C	convalescent plasma escape	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 	'L18F', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	B.1.1.7 variant constellation two-tailed Wilcoxon matched-pairs signed-rank test against 10 convalescent sera P	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.T20N	c.C59A	p.T20N			21621	S	S	MISSENSE	11379	172.0	11387						0	A=11379	11379	A	C	convalescent plasma escape	Hoffman et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.036	'L18F', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	VSV pseudotype P.1 showed 4.8-fold decrease in NT50 vs wild type in sera from 9 ICU patients undergoing treatment in Germany (pre-variant infections).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.T20N	c.C59A	p.T20N			21621	S	S	MISSENSE	11379	172.0	11387						0	A=11379	11379	A	C	convalescent plasma escape	Luftig et al. (2021)	https://doi.org/10.1056/nejmc2104036	'L18F', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	In sera from six patients collected 1 to 12 weeks post-infection with B.1, antibody titer in a microneutralization assay was on average 71.46 for P.1 virus. Compare to much stronger neutralization titers for B.1.1.7 (256) and wild type (456.1) in the same sera. 	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.T20N	c.C59A	p.T20N			21621	S	S	MISSENSE	11379	172.0	11387						0	A=11379	11379	A	C	convalescent plasma escape	McCallum et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1	'L18F', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	In 13 plasma collected ~1mo after B.1.1.7 infection (nursing home in Ticino, Switzerland), neutralization  reduced to undetectable levels in many plasma for P.1 pseudotyped virus, as well as WT and other VOCs.  [paper does not detail the P.1 variants used, using the most popular as a stand in]	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.T20N	c.C59A	p.T20N			21621	S	S	MISSENSE	11379	172.0	11387						0	A=11379	11379	A	C	convalescent plasma escape	Mendes-Correa et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.05.11.21256908v1	'L18F', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	Neutralizing antibodies that were generated following a mild infection with SARS-CoV-2 B.1.128 were effective in vitro,  and likely protective, against the SARS-CoV-2 P.1. variant in the majority of individuals based on 60 convalescent sera tested.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.T20N	c.C59A	p.T20N			21621	S	S	MISSENSE	11379	172.0	11387						0	A=11379	11379	A	C	convalescent plasma escape	Tang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.19.436183v1	'L18F', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	Loss of neutralizing activity (PsVNA50 assay) using 6 hyperimmune immunoglobulin preparations from convalescent plasma was seen against P.1 (3.5-fold). Neutralization against 10 convalescent plasma was slightly poorer (3.9-fold).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.T20N	c.C59A	p.T20N			21621	S	S	MISSENSE	11379	172.0	11387						0	A=11379	11379	A	C	convalescent plasma escape	Wang et al. (2021)	https://dx.doi.org/10.1101%2F2021.03.01.433466	'L18F', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y'	In convalescent sera one month or more post-infection in Spring 2020, an average 6.5x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.4x decrease against the full P.1 type vs WA-1 was observed, with  better full P.1 ID50 reciprocal value compared to the 10-mutation model.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.T20N	c.C59A	p.T20N			21621	S	S	MISSENSE	11379	172.0	11387						0	A=11379	11379	A	C	pharmaceutical effectiveness	Hoffman et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.036	'L18F', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	VSV pseudotype P.1 entry mediated by the S proteins of the P.1 variant was completely resistant to blocking by REGN10989 and Bamlanivimab. Cell fusion proficiency was slight impaired. Entry driven by the S proteins of the B.1.351 was partially resistant against Casirivimab.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.T20N	c.C59A	p.T20N			21621	S	S	MISSENSE	11379	172.0	11387						0	A=11379	11379	A	C	reinfection	Malta Romano et al. (2021)	https://doi.org/10.1590/s1678-9946202163036	'L18F', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I'	After a 128 day interval, a patient in Sao Paulo State, Brazil reinfected with P.1 (first episode likely predates P.1 emergence). Both cases were fairly mild (difficulty breathing, tiredness, dizziness and fatigue).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.T20N	c.C59A	p.T20N			21621	S	S	MISSENSE	11379	172.0	11387						0	A=11379	11379	A	C	trafficking	Esclera et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.05.455290v1	'L18F', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I'	~6x cleavage of S2 relative to WA1 (D614G) wildtype by Gamma variant as measured by mass spectrometry of Vero-TMPRSS culture  [no mutations directly at furin cleavage site, but H655Y is upstream] Compare to 4.5x or less for variants of concern with  direct furin clevage site mutations.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.T20N	c.C59A	p.T20N			21621	S	S	MISSENSE	11379	172.0	11387						0	A=11379	11379	A	C	trafficking	Hoffman et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.036	'L18F', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	VSV pseudotype P.1 showed slight decrease in cell entry relative to wild type in 262T and 263T-ACE2 (kidney) cell lines. Cell fusion proficiency was slight impaired.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.T20N	c.C59A	p.T20N			21621	S	S	MISSENSE	11379	172.0	11387						0	A=11379	11379	A	C	transmissibility	Stefanelli et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.04.06.21254923v1	'L18F', 'P26S', 'D138Y', 'R190S', 'E484K', 'N501Y', 'D614G', 'H655Y'	The relative transmissibility of P.1 estimated at the national level (Italy) varied according to the assumed  degree of cross-protection granted by infection with other lineages and ranged from 1.12 (95%CI 1.03-1.23) in the  case of complete immune evasion by P.1 to 1.39 (95%CI 1.26-1.56) in the case of complete cross-protection. PG: variant list has been abbreviated due to mixed K417 bases in this lineage, potential miscalls of deletions	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.T20N	c.C59A	p.T20N			21621	S	S	MISSENSE	11379	172.0	11387						0	A=11379	11379	A	C	vaccine neutralization efficacy	Alenquer et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1	'L18F', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	Using P.1 defining mutations for Spike, observed 4x average decrease in neutralization efficiency  (but still relevant titres) for sera from 10 BNT162b2 vaccinees 12 days after second dose, but only one  relevant titre 12 days after first dose. Compares unfavorably to wild type or B.1.1.7 titres.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.T20N	c.C59A	p.T20N			21621	S	S	MISSENSE	11379	172.0	11387						0	A=11379	11379	A	C	vaccine neutralization efficacy	Andrade et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.14.439719v1	'L18F', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	In human sera 8 weeks post-vaccination with INO-4800, a ~2-fold reduction in P.1 neutralization was observed.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.T20N	c.C59A	p.T20N			21621	S	S	MISSENSE	11379	172.0	11387						0	A=11379	11379	A	C	vaccine neutralization efficacy	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 	'L18F', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	The neutralizing activity of vaccine was slightly lower against B.1.1.248 variant constellation in sera tested from most of the 15 patients with  the BNT162b2 mRNA vaccine. (Fig. 4)	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.T20N	c.C59A	p.T20N			21621	S	S	MISSENSE	11379	172.0	11387						0	A=11379	11379	A	C	vaccine neutralization efficacy	Choi et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1	'L18F', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	Neutralization efficiency (ID50) against P.1 reduced 3.2x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.T20N	c.C59A	p.T20N			21621	S	S	MISSENSE	11379	172.0	11387						0	A=11379	11379	A	C	vaccine neutralization efficacy	Gallagher et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.03.442455v1	'L18F', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	ELISpot assays show T cell neutralization reduced by 16.6% in this B.1.1.248 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose, with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.T20N	c.C59A	p.T20N			21621	S	S	MISSENSE	11379	172.0	11387						0	A=11379	11379	A	C	vaccine neutralization efficacy	Garcia-Beltran et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.013	'L18F', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	Pseudotyped P.1 virus has reduced neutralization activity vs wild type: 6.7x (30 sera Pfizer median 9 days post 2nd dose)  and 4.5x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.T20N	c.C59A	p.T20N			21621	S	S	MISSENSE	11379	172.0	11387						0	A=11379	11379	A	C	vaccine neutralization efficacy	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'L18F', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	1.15x *increase* in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees)	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.T20N	c.C59A	p.T20N			21621	S	S	MISSENSE	11379	172.0	11387						0	A=11379	11379	A	C	vaccine neutralization efficacy	Hitchlings et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.04.07.21255081v1	'L18F', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	Among 46,884 HCWs in Manaus, Brazil vaccinated with at least one dose of CoronaVac, a 0.50-fold reduction (adjusted vaccine  effectiveness, 49.6%: 95% CI, 11.3 - 71.4) in the odds of  symptomatic SARS-CoV-2 infection was observed during the period 14 days or more after receiving the first dose. Estimated vaccine effectiveness of at least one dose against any SARS-CoV-2 infection was 35.1% (95% CI, −6.6 - 60.5) in the same time period.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.T20N	c.C59A	p.T20N			21621	S	S	MISSENSE	11379	172.0	11387						0	A=11379	11379	A	C	vaccine neutralization efficacy	Hoffman et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.036	'L18F', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	VSV pseudotype P.1 showed 5.12-fold reduction in neutralization efficiency vs wild type in 15 Pfizer BNT162b2 vaccinee sera 13-15 days post second dose. Cell fusion proficiency was slight impaired.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.T20N	c.C59A	p.T20N			21621	S	S	MISSENSE	11379	172.0	11387						0	A=11379	11379	A	C	vaccine neutralization efficacy	Leier et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.04.25.21256049v1	'L18F', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I', 'V1176F'	Neutralizing antibody titers increased in previously infected vaccinees relative to uninfected vaccinees  4.3-fold against P.1 (contrast with 3.4 fold against original SARS-CoV-2).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.T20N	c.C59A	p.T20N			21621	S	S	MISSENSE	11379	172.0	11387						0	A=11379	11379	A	C	vaccine neutralization efficacy	Tarke et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.27.433180v1	'L18F', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I', 'V1176F'	PBMCs of Pfizer/BioNTech BNT162b2 (n	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.T20N	c.C59A	p.T20N			21621	S	S	MISSENSE	11379	172.0	11387						0	A=11379	11379	A	C	vaccine neutralization efficacy	Wang et al. (2021)	https://dx.doi.org/10.1101%2F2021.03.01.433466	'L18F', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y'	In 12 Moderna vaccinee sera 15 days post second dose (43 days since first vaccination), an average 2.8x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 4.8x decrease against the full P.1 type vs WA-1 was observed, though overall with  a higher ID50 reciprocal value. In 10 Pfizer vaccinee sera 7 days or more post second dose (28 days or more since first vaccination), an average 2.2x decrease in reciprocal ID50 value was observed  ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.8x decrease against the full P.1 type vs WA-1 was observed, with  similar variant ID50 reciprocal value.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.T20N	c.C59A	p.T20N			21621	S	S	MISSENSE	11379	172.0	11387						0	A=11379	11379	A	C	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.29x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.39x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.T20N	c.C59A	p.T20N			21621	S	S	MISSENSE	11379	172.0	11387						0	A=11379	11379	A	C	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G', 'L18F', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	This variant combination (representing P.1 aka Gamma)  showed a 1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.27x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.T20N	c.C59A	p.T20N			21621	S	S	MISSENSE	11379	172.0	11387						0	A=11379	11379	A	C	virion structure	Wang et al. (2021)	https://dx.doi.org/10.1101%2F2021.03.01.433466	'L18F', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y'	CryoEM reveals the P.1 trimer to adopt exclusively a conformation in which one of the receptor-binding domains is in the “up” position.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.T2183I	c.C6548T	p.T2183I			6813	orf1ab	ORF1ab	MISSENSE	2	2.0	11387			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	1	T=1	1	T	C						False	P.1.7	P.1.7=False	VOC		11-Jan-2021	
p.T284I	c.C851T	p.T284I			22413	S	S	MISSENSE	2	2.0	11387						0	T=2	2	T	C						False	P.1.12.1	P.1.12.1=True	VOC		11-Jan-2021	
p.T299I	c.C896T	p.T299I			22458	S	S	MISSENSE	2	2.0	11387						0	T=2	2	T	C						False	P.1.12.1	P.1.12.1=True	VOC		11-Jan-2021	
p.T3082A	c.A9244G	p.T3082A			9509	orf1ab	ORF1ab	MISSENSE	1	1.0	11387			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab	YP_009725300.1	0	G=1	1	G	A						False	P.1.15	P.1.15=True	VOC		11-Jan-2021	
p.T3288S	c.C9863G	p.T3288S			10128	orf1ab	ORF1ab	MISSENSE	4	4.0	11387			3C-like proteinase	nsp5A_3CLpro and nsp5B_3CLpro, main proteinase (Mpro), mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al., 2003), produced by both pp1a and pp1ab	YP_009725301.1	3	G=1	1	G	C						False	P.1.12	P.1.12=False	VOC		11-Jan-2021	
p.T4083M	c.C12248T	p.T4083M			12513	orf1ab	ORF1ab	MISSENSE	52	52.0	11387			nsp8	produced by both pp1a and pp1ab	YP_009725304.1	26	T=26	26	T	C						False	P.1.17	P.1.17=False	VOC		11-Jan-2021	
p.T4355I	c.C13064T	p.T4355I			13329	orf1ab	ORF1ab	MISSENSE	4	4.0	11387			nsp10	nsp10_CysHis, formerly known as growth-factor-like protein (GFL), produced by both pp1a and pp1ab	YP_009725306.1	1	T=3	3	T	C						False	P.1.10	P.1.10=False	VOC		11-Jan-2021	
p.T6144N	c.C18431A	p.T6144N			18695	orf1ab	ORF1ab	MISSENSE	2	2.0	11387			3'-to-5' exonuclease	nsp14A2_ExoN and nsp14B_NMT, produced by pp1ab only	YP_009725309.1	1	A=1	1	A	C						False	P.1.7	P.1.7=False	VOC		11-Jan-2021	
p.V1176F	c.G3526T	p.V1176F			25088	S	S	MISSENSE	11379	172.0	11387						2	T=11377	11377	T	G	anthropozoonotic events	Montagutelli et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.18.436013v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I'	Unlike wild type or B.1.1.7, P.1 lineage virus was able to infect and replicate in common lab mouse strains, with high titer.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.V1176F	c.G3526T	p.V1176F			25088	S	S	MISSENSE	11379	172.0	11387						2	T=11377	11377	T	G	antibody epitope effects	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I'	B.1.1.248 variant constellation ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07. B.1.1.248 variant constellation ablates Class 3 N-terminal domain targeting antibody COV2-2676.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.V1176F	c.G3526T	p.V1176F			25088	S	S	MISSENSE	11379	172.0	11387						2	T=11377	11377	T	G	convalescent plasma escape	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I'	B.1.1.248 variant constellation in 10 convalescent human sera ~1mo post infection had mild to moderate resistence against most samples, P	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.V1176F	c.G3526T	p.V1176F			25088	S	S	MISSENSE	11379	172.0	11387						2	T=11377	11377	T	G	convalescent plasma escape	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I'	B.1.1.7 variant constellation two-tailed Wilcoxon matched-pairs signed-rank test against 10 convalescent sera P	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.V1176F	c.G3526T	p.V1176F			25088	S	S	MISSENSE	11379	172.0	11387						2	T=11377	11377	T	G	convalescent plasma escape	Hoffman et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.036	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	VSV pseudotype P.1 showed 4.8-fold decrease in NT50 vs wild type in sera from 9 ICU patients undergoing treatment in Germany (pre-variant infections).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.V1176F	c.G3526T	p.V1176F			25088	S	S	MISSENSE	11379	172.0	11387						2	T=11377	11377	T	G	convalescent plasma escape	Luftig et al. (2021)	https://doi.org/10.1056/nejmc2104036	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	In sera from six patients collected 1 to 12 weeks post-infection with B.1, antibody titer in a microneutralization assay was on average 71.46 for P.1 virus. Compare to much stronger neutralization titers for B.1.1.7 (256) and wild type (456.1) in the same sera. 	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.V1176F	c.G3526T	p.V1176F			25088	S	S	MISSENSE	11379	172.0	11387						2	T=11377	11377	T	G	convalescent plasma escape	McCallum et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	In 13 plasma collected ~1mo after B.1.1.7 infection (nursing home in Ticino, Switzerland), neutralization  reduced to undetectable levels in many plasma for P.1 pseudotyped virus, as well as WT and other VOCs.  [paper does not detail the P.1 variants used, using the most popular as a stand in]	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.V1176F	c.G3526T	p.V1176F			25088	S	S	MISSENSE	11379	172.0	11387						2	T=11377	11377	T	G	convalescent plasma escape	Mendes-Correa et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.05.11.21256908v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	Neutralizing antibodies that were generated following a mild infection with SARS-CoV-2 B.1.128 were effective in vitro,  and likely protective, against the SARS-CoV-2 P.1. variant in the majority of individuals based on 60 convalescent sera tested.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.V1176F	c.G3526T	p.V1176F			25088	S	S	MISSENSE	11379	172.0	11387						2	T=11377	11377	T	G	convalescent plasma escape	Tang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.19.436183v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	Loss of neutralizing activity (PsVNA50 assay) using 6 hyperimmune immunoglobulin preparations from convalescent plasma was seen against P.1 (3.5-fold). Neutralization against 10 convalescent plasma was slightly poorer (3.9-fold).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.V1176F	c.G3526T	p.V1176F			25088	S	S	MISSENSE	11379	172.0	11387						2	T=11377	11377	T	G	pharmaceutical effectiveness	Hoffman et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.036	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	VSV pseudotype P.1 entry mediated by the S proteins of the P.1 variant was completely resistant to blocking by REGN10989 and Bamlanivimab. Cell fusion proficiency was slight impaired. Entry driven by the S proteins of the B.1.351 was partially resistant against Casirivimab.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.V1176F	c.G3526T	p.V1176F			25088	S	S	MISSENSE	11379	172.0	11387						2	T=11377	11377	T	G	trafficking	Hoffman et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.036	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	VSV pseudotype P.1 showed slight decrease in cell entry relative to wild type in 262T and 263T-ACE2 (kidney) cell lines. Cell fusion proficiency was slight impaired.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.V1176F	c.G3526T	p.V1176F			25088	S	S	MISSENSE	11379	172.0	11387						2	T=11377	11377	T	G	vaccine neutralization efficacy	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I'	The neutralizing activity of vaccine was slightly lower against B.1.1.248 variant constellation in sera tested from most of the 15 patients with  the BNT162b2 mRNA vaccine. (Fig. 4)	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.V1176F	c.G3526T	p.V1176F			25088	S	S	MISSENSE	11379	172.0	11387						2	T=11377	11377	T	G	vaccine neutralization efficacy	Choi et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	Neutralization efficiency (ID50) against P.1 reduced 3.2x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.V1176F	c.G3526T	p.V1176F			25088	S	S	MISSENSE	11379	172.0	11387						2	T=11377	11377	T	G	vaccine neutralization efficacy	Gallagher et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.03.442455v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I'	ELISpot assays show T cell neutralization reduced by 16.6% in this B.1.1.248 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose, with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.V1176F	c.G3526T	p.V1176F			25088	S	S	MISSENSE	11379	172.0	11387						2	T=11377	11377	T	G	vaccine neutralization efficacy	Garcia-Beltran et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.013	'E484K', 'D614G'	Pseudotyped P.2 virus has reduced neutralization activity vs wild type: 5.8x (30 sera Pfizer median 9 days post 2nd dose)  and 2.9x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.V1176F	c.G3526T	p.V1176F			25088	S	S	MISSENSE	11379	172.0	11387						2	T=11377	11377	T	G	vaccine neutralization efficacy	Garcia-Beltran et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.013	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I'	Pseudotyped P.1 virus has reduced neutralization activity vs wild type: 6.7x (30 sera Pfizer median 9 days post 2nd dose)  and 4.5x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.V1176F	c.G3526T	p.V1176F			25088	S	S	MISSENSE	11379	172.0	11387						2	T=11377	11377	T	G	vaccine neutralization efficacy	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	1.15x *increase* in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees)	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.V1176F	c.G3526T	p.V1176F			25088	S	S	MISSENSE	11379	172.0	11387						2	T=11377	11377	T	G	vaccine neutralization efficacy	Hoffman et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.036	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	VSV pseudotype P.1 showed 5.12-fold reduction in neutralization efficiency vs wild type in 15 Pfizer BNT162b2 vaccinee sera 13-15 days post second dose. Cell fusion proficiency was slight impaired.	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.V1176F	c.G3526T	p.V1176F			25088	S	S	MISSENSE	11379	172.0	11387						2	T=11377	11377	T	G	vaccine neutralization efficacy	Leier et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.04.25.21256049v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'D614G', 'H655Y', 'T1027I'	Neutralizing antibody titers increased in previously infected vaccinees relative to uninfected vaccinees  4.3-fold against P.1 (contrast with 3.4 fold against original SARS-CoV-2).	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.V1176F	c.G3526T	p.V1176F			25088	S	S	MISSENSE	11379	172.0	11387						2	T=11377	11377	T	G	vaccine neutralization efficacy	Tarke et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.27.433180v1	'L18F', 'T20N', 'P26S', 'D138Y', 'R190S', 'K417T', 'E484K', 'N501Y', 'H655Y', 'T1027I'	PBMCs of Pfizer/BioNTech BNT162b2 (n	False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.V2116V	c.A6348G	p.V2116V			6613	orf1ab	ORF1ab	SILENT	11387	172.0	11387			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	0	G=11387	11387	G	A						False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
p.V3377V	c.G10131T	p.V3377V			10396	orf1ab	ORF1ab	SILENT	4	4.0	11387			3C-like proteinase	nsp5A_3CLpro and nsp5B_3CLpro, main proteinase (Mpro), mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al., 2003), produced by both pp1a and pp1ab	YP_009725301.1	3	T=1	1	T	G						False	P.1.10	P.1.10=False	VOC		11-Jan-2021	
p.V3782F	c.G11344T	p.V3782F			11609	orf1ab	ORF1ab	MISSENSE	4	4.0	11387			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab	YP_009725302.1	2	T=2	2	T	G						False	P.1.7	P.1.7=False	VOC		11-Jan-2021	
p.V491V	c.G1473T	p.V491V			1738	orf1ab	ORF1ab	SILENT	4	4.0	11387			nsp2	produced by both pp1a and pp1ab	YP_009725298.1	2	T=2	2	T	G						False	P.1.10	P.1.10=False	VOC		11-Jan-2021	
p.V6050V	c.T18150A	p.V6050V			18414	orf1ab	ORF1ab	SILENT	2	2.0	11387			3'-to-5' exonuclease	nsp14A2_ExoN and nsp14B_NMT, produced by pp1ab only	YP_009725309.1	1	A=1	1	A	T						False	P.1.7	P.1.7=False	VOC		11-Jan-2021	
p.V89V	c.A267G	p.V89V			532	orf1ab	ORF1ab	SILENT	2	2.0	11387			leader protein	nsp1, produced by both pp1a and pp1ab	YP_009725297.1	1	G=1	1	G	A						False	P.1.7	P.1.7=False	VOC		11-Jan-2021	
p.V93F	c.G277T	p.V93F			27670	ORF7a	ORF7a	MISSENSE	11191	0.0	11387						9824	T=1367	1367	T	G						False	P.1.14	P.1.14=False	VOC		11-Jan-2021	
p.Y4171Y	c.C12513T	p.Y4171Y			12778	orf1ab	ORF1ab	SILENT	11387	308.0	11387			nsp9	ssRNA-binding protein, produced by both pp1a and pp1ab	YP_009725305.1	0	T=11387	11387	T	C						False	P.1.12.1, P.1.17, P.1.14, P.1.15, P.1, P.1.12, P.1.10, P.1.7	P.1.12=True, P.1.14=True, P.1.7=True, P.1.10=True, P.1=True, P.1.12.1=True, P.1.17=True, P.1.15=True	VOC		11-Jan-2021	
